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ABSTRACT 
Bacterial gastroenteritis affects millions, especially in the developing world. While the 
mechanisms by which enteric pathogens trigger inflammation have been studied 
extensively, how they evade immune recognition is less understood. We hypothesised 
that the structural components of common enteric pathogens, such as Clostridium 
difficile and Campylobacter jejuni, facilitate immune evasion by engaging inhibitory 
receptors on innate immune cells. 
In the present study we investigated how C. difficile peptidoglycan (PGN) engages with 
monocytic cells and identified NOD2 as a critical innate sensor in this interaction. PGN 
affected cell maturation and in addition it modulated monocytic immune responses to 
other bacterial motifs, as PGN-exposed cells became unresponsive to subsequent 
Lipopolysaccharide (LPS) stimulation. This data suggests a role for C. difficile PGN-
NOD2 axis in trained immunity. 
We have previously reported on a novel interaction between C. jejuni flagellin 
pseudaminic acid moieties and the Siglec-10 receptor, an interaction that specifically 
targets the dendritic cell IL-10 axis. Herein, we studied the downstream signalling 
events involved in this crosstalk in human macrophages. Utilizing wild-type and 
isogenic mutant C. jejuni, we identified a potential role for the epidermal growth factor 
receptor (EGFR), the scaffolding SHP-2 and PI3K-AKT/MAPK kinase pathways in 
modulating IL-10 expression. We report for the first time novel engagement between C. 
jejuni 11168H capsule, lipooligosachharide (LOS) and host Siglec-5 and Siglec-9 
receptors, pathways involved in bacterial adherence and phagocytosis.  
Collectively, this thesis provides evidence as to how common bacterial structures exert 
immunosuppressive effects, effects that may hold the balance between asymptomatic 
colonization and infection. 
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Chapter 1 
Introduction
1.1 Gastrointestinal structure and function 
The gastrointestinal (GI) tract includes all the digestive structures between the mouth 
and the anus. It is a complex and dynamic organ at the centre of an intricate interplay 
between a myriad of environmental stimuli and the host. Food ingested through the 
mouth passes through the pharynx and the esophagus and enters the stomach where 
it becomes digested. It then enters the small intestine, in the lower part of the GI tract, 
where it is broken down enzymatically in the duodenum followed by nutrient absorption 
in the jejunum and ileum. Water absorption takes place in the large intestine, also 
referred to as the colon, and rectum while the remaining waste material is expelled in 
the form of faeces. 
The small intestine is the most important organ for digestion as it is where nutrient 
absorption takes place. To maximise the surface area available for nutrient absorption 
the epithelium of the small intestine is covered in finger-like protrusions called villi 
(Figure 1.1A). Additionally, each villus contains fine projections on its apical surface 
known as microvilli. Underlying the epithelium is the lamina propria (LP), which has a 
rich vascular and lymphatic network to absorb the digestive products. The epithelium 
around the villi contains crypts, moat-like invaginations lined largely with younger 
epithelial cells involved primarily in enzyme secretion.  
The epithelium of the villi is made up of tall columnar absorptive cells called 
enterocytes, and goblet cells; the latter secrete mucin, for lubrication of the intestinal 
contents and protection of the epithelium (Figure 1.1B). The crypts contain Paneth cells, 
which have a defensive function, and various neuroendocrine cells involved in the 
production and secretion of hormones and neurotransmitters. Stem cells, found a few 
cells away from the  base of the crypts, divide continuously to replace enterocytes, 
goblet cells, Paneth cells and neuroendocrine cells. 
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Figure 1.1. Structure and cells of the small intestine. 
(Α) Tissue anatomy of the small intestine. Putative stem cells reside above the Paneth 
cells near the crypt bottom. Proliferating progenitor cells occupy the remainder of the 
crypt. Differentiated cells populate the villus, and include goblet cells, enterocytes and 
entero-endocrine cells. (B) Intestinal epithelial cells (IECs) form a biochemical and 
physical barrier that maintains segregation between luminal microbial communities and 
the mucosal immune system. The intestinal epithelial stem cell niche, containing 
epithelial, stromal and haematopoietic cells, controls the continuous renewal of the 
epithelial cell layer by crypt-resident stem cells. Differentiated IECs migrate up the 
crypt–villus axis, as indicated by the dashed arrows. Secretory goblet cells and Paneth 
cells secrete mucus and antimicrobial proteins (AMPs) to promote the exclusion of 
bacteria from the epithelial surface. Goblet cells mediate transport of luminal antigens 
and live bacteria across the epithelial barrier to DCs, and intestine-resident 
macrophages sample the lumen through transepithelial dendrites. [Adapted from ref. 
(1)] 
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1.1.1 Gastrointestinal immunity 
 The epithelium of the small intestine is in continuous contact with food antigens, 
commensal bacteria and potential pathogens (2). It is the organ tissue most exposed to 
the external environment with a surface area of 200m2 densely populated by large 
numbers of microorganisms. There is a marked gradient of the numbers of commensal 
bacteria going down the intestine, from the almost sterile jejunum, to the descending 
colon, which has a large resident population of microbiota, consisting of at least 1010-
1012 organisms per gram of luminal contents (3). Continuous exposure to commensal 
and/or symbiotic microorganisms and their metabolites, along with the presence of 
pathogens and the antigenic load provided by diet, means that the GI mucosal immune 
system encounters more antigen/day than the systemic immune system encounters in 
a life-time. Not surprisingly, there is a strong biological necessity for a multifaceted, 
integrated epithelial and immune cell-mediated regulatory system for the maintenance 
of a healthy gut (4). 
 
1.1.1.1 GI epithelial immunity 
Consequently, the gut epithelium relies on multiple defense mechanisms, including a 
mucus layer, epithelial antimicrobial immunity, cell integrity and turnover. A single layer 
of intestinal epithelial cells (IECs) provides the distinct anatomical barrier that 
segregates the underlying tissues from potentially harmful compounds (5). The 
epithelial cells of the small intestine are coated in a glycocalyx of mucins and other 
glycoproteins that can interact with and entrap bacteria in the mucus so that they are 
simply washed away. In addition, anti-microbial peptides such as defensins are 
secreted by Paneth cells, providing another level of innate protection. IECs also act as 
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microbial sensors by secreting chemoattractant factors that facilitate the recruitment of 
a range of host immune cells (5). 
 
1.1.1.2 GI mucosal immune system  
In order to prevent translocation of commensals and, when present pathogenic 
microorganisms across this barrier, the intestinal tract possesses an integrated, highly 
sophisticated immune system. Intestinal immune cells located beneath the epithelium 
of both the small and large intestine play important roles in regulating the mucosal 
barrier and the resident microbiota. The majority of intestinal immune cells are located 
immediately below the epithelial layer in the lamina propria, either scattered or 
organised in tissue-specific lymphoid structures, such as Peyer’s patches and 
mesenteric lymph nodes (MLN). The role of all these immunotypes is in the induction 
phase of intestinal immune responses, as they represent the sites where antigens are 
taken up and presented to B and T lymphocytes (6).  
 GI immunity is comprised of the innate and adaptive immune system. Innate cells 
include dendritic cells (DCs), monocytes, macrophages, neutrophils, and NK cells (7). 
Upon microbial sensing, these cells produce an appropriate inflammatory response, 
which includes the production of chemical mediators, pro- and anti-inflammatory 
cytokines and chemokines. The latter act as chemoattractants that prime innate 
immune cells, particularly neutrophils and inflammatory monocytes recruiting them to 
the site of infection (8). The adaptive immune system comprises immunoglobulin (Ig)-
secreting plasma cells, B cells, CD4+ and CD8+ αβ-T cells, regulatory T (Treg) cells 
and γδ-T cells. The latter, intra-epithelial effector lymphocytes are integrated in the 
epithelial lining and extra-intestinal outposts, such as the MLNs and provide the host 
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with potent, adaptive immunity (9). The majority of mucosal T cells have a ‘memory’ 
phenotype and some show effector function such as cytokine production and cytotoxic 
T lymphocyte activity; others appear to be hyporesponsive and may be regulatory in 
nature (10). 
 
1.1.1.3 Macrophages 
Historically, macrophages were defined as tissue-resident innate immune cells with 
scavenging and bactericidal functions. Resident macrophages are found throughout the 
body and can have different morphology and immune specificity depending on their 
tissue of origin (11). These include Kupffer cells in the liver, microglia in the central 
nervous system, alveolar macrophages in the lung and the resident macrophages of 
the GI tract. All epithelial and endothelial surfaces contain a significant population of 
macrophages, generally located underneath the basement membrane separating the 
surface layer from the rest of the epithelial tissue. In the intestine, macrophages 
represent the most abundant mononuclear cell population, found mainly in the lamina 
propria of the small and large intestine (12). 
Macrophages exhibit stellate morphology, and express a wide range of receptors, 
including those for the Fc portions of Ig, complement components and for microbial 
motifs known as microbe--associated molecular patterns (MAMPs). They also 
contribute to the non-specific uptake of particulate material which they degrade using 
enzymes such as non-specific esterase, lysosomal hydrolases and ecto-enzymes (7). 
When activated, tissue macrophages phagocytose and kill microorganisms, and 
secrete pro-inflammatory mediators. Amongst these are the chemokine interleukin-8 
(IL-8), and the cytokines tumor necrosis factor alpha (TNFα), interleukins (IL) such as 
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IL-1β and IL-6. The pro-inflammatory cytokines and chemokines released upon 
activation contribute to the recruitment and activation of other innate immune cells, 
such as neutrophils, as well as antigen-specific lymphocytes (8). Macrophages can 
also instruct the adaptive immune system further, as they phagocytose, degrade and 
process antigens for presentation to T cells on MHC molecules, and may even be able 
to prime naïve T cells in vivo (13). 
 
1.1.2 Gastrointestinal (GI) homeostasis 
The   GI mucosal immune system relies to a great degree on innate immune cells and 
their rapid effector functions for early sensing of both commensal and pathogens and 
the maintenance of tissue homeostasis. Signals from commensal bacteria can 
influence immune cell development and susceptibility to infectious or inflammatory 
diseases. According to studies, commensal-derived compounds offer a degree of 
sustained, tonic stimulation that potentiates the immune cell response and effective 
clearance of bacterial and viral pathogens, acting as a rheostat for the activation 
threshold of these cells during immune-surveillance. For example, mice are less likely 
to develop infection-induced colitis in the presence of bacterial peptidoglycan (14). In 
turn, innate immune cells act as key modulators of commensal flora composition and 
homeostasis; maintaining the equilibrium known as intestinal tolerance (1). 
 
1.1.2.1 Inflammatory Bowel Disease 
Inappropriate responses against innocuous food and commensal antigens can lead to 
inflammatory disorders such as coeliac disease and inflammatory bowel diseases 
(IBDs). The two main forms of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), 
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are chronic, relapsing inflammatory disorders that result in loss of intestinal architecture 
and tissue destruction. UC is restricted to the colon and involves a superficial 
inflammation, whereas CD can affect the entire GI tract and is characterised by 
transmural inflammation and the formation of macrophage-rich granulomas. Both forms 
of IBD involve a substantial infiltrate of neutrophils, monocytes, eosinophils and T cells 
into the intestine (9). 
 
1.1.2.2 Infection 
Enteropathogenic infections can also lead to disruption of GI homeostasis, which can 
manifest in a range of clinical symptoms: from watery, bloody diarrhoea to colitis. 
Infection by Campylobacter jejuni is considered to be the most prevalent cause of 
bacterial-mediated diarrhoeal disease worldwide. Campylobacter infection causes local 
acute inflammatory changes in both the small and large bowel (15). Bacterial adhesion 
and invasion of the intestinal epithelium is succeeded by initiation of the inflammatory 
processes and diarrhoeal development. A steady rise in reported cases over the years 
has been attributed to the extensive colonization of livestock as well as antibiotic 
resistance (European Food and Safety Association; EFSA). Clostridium difficile is 
another major causal agent of antibiotic-associated diarrhea and is a leading cause of 
hospital-acquired infections. C. difficile has been known to cause severe diarrhea and 
colitis, but the emergence of  newer, hypervirulent strains of C. difficile has further 
compounded the problem, and recently both number of cases and mortality associated 
with C. difficile infection (CDI) has markedly increased into a serious global health 
burden (16). Although CDI affects mostly individuals with compromised immunity, such 
as the elderly or patients on antibiotic therapy, cases are also emerging in the 
community and in animals used for food (17). 
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1.2 Innate immunity to bacterial motifs 
To survey and regulate the GI ecosystem effectively, innate immune cells need to 
distinguish between potentially pathogenic microbial components and harmless 
antigens. Conserved structures found in microbes but not in the mammalian host 
(MAMPs) are recognized by cellular sensors known as pattern-recognition receptors 
(PRRs) (18). The two major families of PRRs are the cell surface and endosomal Toll-
like receptors (TLRs) and the cytoplasmic nucleotide-binding domain, leucine-rich 
repeat (NLR) proteins. These receptors are highly expressed on professional antigen 
presenting cells (APCs) such as DCs and macrophages.  
 
1.2.1 Toll-like receptors 
Toll-like receptors (TLRs) were first identified in Drosophila (19) with a human ortholog 
discovered subsequently (20). TLRs are type-1 transmembrane proteins, comprised of 
a C-terminal leucine-rich repeat (LRR) domain that is ligand-binding, a single 
membrane spanning domain, and an N-terminal cytoplasmic Toll/IL-1R (TIR) domain 
that binds to adaptor molecules to trigger downstream signalling cascades (21). There 
are 11 TLRs known in mammals and each recognises MAMPs associated with a 
unique category of microbial antigens. Most TLRs are present on mononuclear immune 
cells, either on the cell surface or within endosomes (22). TLRs have also been 
detected on B and T cells (23),(24). TLR4 was the first to be discovered and 
recognises lipopolysaccharide (LPS), a structural component of Gram-negative 
bacteria (25). 
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Early studies identified peptidoglycan (PGN) as the TLR2 agonist (26), although this 
was soon disputed by evidence of the presence of TLR2-activating lipoteichoic acid 
(LTA) components in cell wall extracts (detailed in section 1.3.1.4.3) (27). Yet, further 
research employing a lipoprotein negative mutant of Staphylococcus aureus showed 
that surface lipoprotein rather than LTA or PGN activate TLR2 (28). Until recently, 
lipoproteins were thought to be the only bacterial wall ligands sensed by TLR2 at 
physiological levels (29). However, a recent study showed that Gram-positive bacterial 
lipoglycans, whose lipid anchor is made of a glycosylated diacylglycerol unit, are also 
recognised by TLR2 (30). Unlike other TLRs, which are functionally active as homo-
dimers, TLR2 can heterodimerise with TLR1 or TLR6 to distinguish between Gram-
negative tri-acylated lipoproteins and Gram-positive di-acylated lipoproteins 
respectively (31).  
TLR activation by MAMPs leads to the activation of multiple signalling cascades; 
mediated by a number of scaffolding proteins that contain TIR-containing adaptor 
molecules, such as myeloid differentiation primary response protein (MyD88), MyD88 
adaptor-like (Mal), TIR domain containing adaptor inducing INF-β (TRIF) and TRIF 
related adaptor molecule (TRAF). TLR2-driven signalling cascades result in the 
activation of MAPK, NF-κB and interferon regulatory factor (IRF) pathways which are 
central to the cell’s inflammatory response (32). TLR2 activation leads to the NF-κB-
dependent induction of IL-8 (26). It also drives IL-6 through MAPK signalling (33). 
Furthermore, TLR2 signalling activates autophagy, a key cellular process involved in 
processing of bacterial MAMPs, via ERK activation (34). Interestingly, while 
heterodimerisation of TLR2 with TRL1 or TLR6 expands the ligand spectrum it does not 
lead to differential signalling (31). PGN containing lipoproteins can induce maturation of 
blood cells by inducing the expression of CD14, TLR2 and TLR4 (35). Furthermore, the 
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TLR2 axis is seen as a priming factor for LPS signalling since it can modulate the LPS-
mediated cytokine response in human monocytes. The synergistic effect is mediated 
by IRAK4, a shared signalling mediator, leading to the enhanced secretion of pro-
inflammatory cytokines such as TNFα. Researchers are looking to exploit this property 
of TLR2 ligands in vaccine development as they are effective adjuvants (36).  
 
1.2.2 Nod-like receptors 
To date, 22 nucleotide oligomerisation domain (Nod)-like receptors (NLRs) have been 
identified in humans and 34 in mice, found primarily in immune and epithelial cells (37). 
NOD1 is widely expressed in cells of haematopoietic and non-haematopoietic origin. 
NOD2 expression is more restricted and the protein is mostly found in the 
haematopoietic lineage in myeloid and lymphoid cells. NOD1 and NOD2 were the first 
members of the NLR family to be discovered (38),(39) and the first NLRs to be 
identified as MAMP sensors. Despite being initially identified as receptors for bacterial 
LPS, further refinement and purification of bacterial cell preparations revealed that the 
NOD proteins recognise bacterial PGN (40). 
 
1.2.2.1 Structure 
Members of the NLR family are characterized by a tripartite domain structure, including 
a functionally differentiating domain distinct in each of the four subfamilies. The NOD1 
and NOD2 proteins consist of a central nucleotide-binding domain (NBD; also known 
as NOD domain) which contains NACHT, winged helix and superhelical subdomains 
involved in oligomerisation and activation (41). The carboxy-terminal leucine-rich 
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repeats (LRRs) are important for ligand-sensing, while the N-terminus caspase 
recruitment domain (CARD) constitutes the effector domain and dictates the 
interactions of the receptor with different downstream effector molecules (42). NOD1 is 
composed of a single CARD, whereas NOD2 contains two CARD domains in tandem. 
Ligand recognition is thought to lead to a conformational change that results in NBD-
mediated oligomerisation of the NOD proteins. Subsequently, NOD1 or NOD2 
oligomers recruit the downstream adaptor RICK through CARD-CARD interactions 
forming a large signalling assembly (39),(43),(44).  
 
1.2.2.2 NOD signalling 
Each of the NOD receptors recognises a distinct PGN moiety. NOD2 recognises MDP, 
the PGN-derived muropeptide a moiety common to the cell wall of all Gram-positive 
and Gram-negative bacteria (45),(40). NOD1 recognises DAP found in the PGN of 
Gram-negative and some Gram-positive bacteria (46). Despite their discovery over a 
decade ago, direct binding of these motifs to the NOD receptors was only recently 
demonstrated. The binding interaction between NOD1 and DAP was shown to require 
the LRR domain (47). In contrast, the interaction of NOD2 with MDP was mediated by 
the central NBD rather than the LRR domain (48).  
 Figure 1.2. Model for PGN recognition by NOD1 and NOD2.  
The NLR proteins NOD1 and NOD2 sense intracellular DAP and MDP, respectively, 
leading to recruitment of the adaptor proteins RICK and CARD9. Extracellular PAMPs 
are recognized by TLRs, which signals through MyD88, IRAK proteins, and TRAF 
members. The subsequent activation of NF-κB and MAP kinases results in the 
transcriptional upregulation of proinflammatory genes. [Adapted from ref. (49)] 
 
 In the absence of NOD ligand, the NACHT domain is inhibited through interaction of the 
C-terminal LRR fragment with the N-terminal CARD-NACHT fragment. Upon activation 
by DAP or MDP respectively, the NOD proteins undergo conformational changes 
allowing the NACHT domain to self-oligomerise (50). Subsequently, exposure of the 
CARD fragment recruits RICK (RIP2), a CARD-containing serine threonine kinase, via 
CARD/CARD interactions (51) (Figure 1.2). Activated RIP2 triggers two distinct 
downstream pathways; NF-κB and MAPK signalling. RIP2 activates IKK, either directly 
or by recruitment of the transformation growth factor β-activated kinase (TGF-β-
activated kinase 1 (TAKI), leading to the phosphorylation and subsequent degradation 
of IκB resulting in the release and nuclear translocation of NF-κB (39),(51), a master 
transcriptional regulator of inflammation. Rip2 also activates the p38 and Erk MAP 
kinases upon MDP stimulation, although this interaction is less well-characterized (52). 
These pathways culminate in the induction of proinflammatory cytokines, chemokines 
and host defence.  
In addition to this canonical signalling, downstream effectors of NOD2 have been 
implicated in regulation of the anti-inflammatory cytokine IL-10. IL-10 is a pleiotropic 
cytokine involved in immunoregulation and dampening of inflammation. RICK is 
required for NOD2-mediated IL-10 production (53), but is only part of an intricate 
signalling network. Furthermore, NOD1 and NOD2 activation also induces cross-talk 
between the signalling factor Notch and members of the phosphoinositide-3-kinase 
(PI3K) pathway which controls the expression of IL-10 (54),(55). Accordingly, CD - 
associated mutations in NOD2 lead to a reduction in IL-10 transcription (56). 
Remarkably, this was not due to a loss-of-function but rather active inhibition of the 
hnRNP-A1 transcriptional controller of IL-10 by the mutant NOD2 protein (57). Despite 
the extensive effort that has gone into deciphering the role of NODs in immune 
signalling, a great deal of controversy regarding their function remains to this day. It is 
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worth noting that mutations in NOD2 often leads to opposite functional outcomes in 
mice compared to humans (58) which has led to numerous conflicting reports (59). 
 
1.2.2.3 NOD - TLR crosstalk 
The NOD receptors share signalling pathways with TLR2, the cell surface receptor for 
PGN and TLR4, which binds to LPS. NODs act synergistically with TLR4 signalling to 
enhance the immune response to LPS (60),(61). A study found that PGN co-localises 
with both TLR2 and NOD2 to induce innate immune signalling in macrophages (62). 
The synergistic action between TLR2 and NOD2 is important in the production of not 
only pro- but also anti-inflammatory immunity in response to Gram-positive cell walls 
(53). NOD1 and NOD2 are thought to enhance the TLR-mediated response in 
monocytes, NK cells (63) and IECs (64). Crosstalk has also been reported for non-
canonical signalling, as TLR2 activation enhances NOD-mediated Notch/PI3K 
signalling (55). In T cells however, NOD2 acts as a negative regulator of TLR2-
mediated Th1 type responses and might explain how mutations in NOD2 lead to 
excessive inflammation (65). Since the complex cross-talk amongst these receptors is 
pivotal in the maintenance of a balanced pro-/anti-inflammatory axis, it is important that 
these interactions are studied in concert. 
1.2.2.4 Outcome of NOD activation 
NOD-mediated sensing of PGN has been implicated in activating the immune system 
in many species (66),(67),(68). Amongst the pro-inflammatory immune factors are 
TNFα, IL-6, CC-chemokine ligand (CCL2), IL-8 and antimicrobial factors such as 
defensins (69),(70). Besides mediating the inflammatory response, NOD2 activity has 
also been linked to IL-10 (71). Furthermore, NOD activation leads to the transcription of 
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type I interferon (IFN) genes that are more commonly associated with viral infection 
(72). Although the focus of this thesis is on bacterial-innate immune crosstalk, it is 
worth noting that NOD proteins are also important in adaptive immunity as they are 
involved in the priming of T-helper cells and drive T helper 2-type immunity (73). 
 
1.2.2.5 NODs in immune homeostasis 
 
1.2.2.5.1 Pathology 
NOD2 was identified as a susceptibility gene for CD, a chronic inflammatory disorder of 
the GI tract that affects mainly the terminal ileum, cecum, colon and perianal area. 
Disease pathogenesis is thought to arise from a loss-of-function mutation leading to 
deregulated crosstalk between resident microbiota and the mucosal immune system 
(74). On the other hand, gain-of-function mutations in the NBD region of NOD2 lead to 
auto-inflammatory diseases such as Blau syndrome and early onset sarcoidosis. More 
recently, defects in NOD2 PGN sensing has been linked to diet induced inflammation 
and insulin resistance (75). Despite the homology in protein structure and shared 
downstream signalling only gene variants of NOD2, but not NOD1, have been linked to 
disease.  
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1.2.2.5.2 Bacterial sensing 
Both NOD1 and NOD2 are cytoplasmic proteins that become recruited to the plasma 
membrane where they detect invading bacteria. The first study to show NOD activation 
by a microorganism was conducted using Shigella flexneri (76); an invasive 
enteropathogen, which is consistent with their role as intracellular sensors. Since then, 
murine studies have demonstrated that NOD1 or NOD2 deficiency does indeed 
increase susceptibility to bacterial infection. NOD1 has been linked with the immune 
response against C. difficile (77), Campylobacter jejuni (78), Listeria monocytogenes, 
Pseudomonas aeruginosa and Helicobacter pylori (59). The pathogenic bacteria 
recognised by NOD2 are Streptococcus pneumoniae, Mycobacterium tuberculosis, 
Staphylococcus aureus, L. monocytogenes, Salmonella serotype typhimurium, Bacillus 
anthracis and more (59). Although a pathogen may be recognised by only one of the 
two receptors, they both cooperate in the innate immune response to enteric 
pathogens. For example, In a study in knock-out mice infected with Salmonella, only 
mice lacking both NOD proteins exhibited increased bacterial burden in the mucosal 
tissue (79). 
 
1.2.2.5.3 Immune tolerance 
Despite continual exposure to high levels of resident microbiota the GI mucosal 
immune system is able to maintain a homeostatic environment. One mechanism 
contributing to this is the relative tolerance of intestinal resident macrophages to 
bacterial products, which are instructed to become tolerant on entering the intestine 
(80). Unlike peripheral macrophages, intestinal macrophages do not secrete cytokines 
on stimulation of PRRs or cytokine receptors, indicating that they are already tolerant to 
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these stimuli (81). However, this down-regulation is impaired in individuals with CD-
associated NOD2 polymorphisms (82), leading to the hypothesis that tonic stimulation 
with NOD ligands is essential for the maintenance of intestinal equilibrium. Accordingly, 
Hedl and Abraham have shown that chronic, as opposed to acute, NOD2 stimulation 
down-regulates pro-inflammatory cytokines on re-stimulation with MDP leading to 
development of “self-tolerance” in monocyte-derived macrophages (MDMs) (81). 
Furthermore, chronic NOD2 stimulation leads to a diminished inflammatory response to 
TLR2 and TLR4 ligands, termed “cross-tolerance” (83). This is effected through NOD2-
dependent epigenetic reprogramming of gene promoter regions (84). The mechanism 
involves the release of nitric oxide following NOD1 or NOD2 stimulation (55) and 
activation of Notch1-PI3K signalling (54) that drives the reprogramming of the 
macrophages. Interestingly, while macrophages become insensitive to TLR ligands 
they remain responsive to NOD1 and NOD2 stimulation and NOD-mediated signalling 
and gene expression are enhanced (85). 
 
1.2.2.5.4 GI homeostasis 
Stimulation of NOD1 and NOD2 by the microbiota is important for gut homeostasis. 
Microbial ligands enter the cytosol of IECs inducing low-level tonic signalling via NOD 
activation. This drives the release of antimicrobial factors that maintain the apical 
surface of the epithelium relatively sterile. PGN released from commensal bacteria 
offers protection from induced colitis in a mouse model in a NOD2-dependent manner 
(4). In 2009, Petnicki-Ocwieja et al., identified a potential new role for NOD2 in GI 
homeostasis by noting that a lack of NOD2 or RICK resulted in an increased load of 
certain commensal bacteria in the terminal ileum (86). CD patients with NOD2 
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polymorphisms exhibit defects in bacterial clearance from ileal crypts of the intestine 
(87). A few studies to date, point to bi-directional homeostatic regulation between 
NOD2 and commensal bacteria; a feedback loop in which gut-residing bacteria 
positively regulate NOD2 and its associated signalling molecules, which in turn 
negatively regulate the commensal flora (88). NOD2 also has a role in regulating the 
effector functions of GI mononuclear phagocytic populations by inducing 
chemoattractants that recruit these cells, which in turn promote bacterial clearance (89). 
 
1.2.2.6 Inflammasomes 
Other members of the NLR family are also involved in sensing MAMPs. NLRC4/Ipaf is 
activated by bacterial flagellin (90), mouse Nalp1b by lethal toxin produced by B. 
anthracis (91), NLRP3/cryopyrin is activated in response to a variety of microbial 
molecules (92), as well as endogenous ligands, such as uric acid crystals (93). Upon 
activation, these NLRs form the inflammasomes, large molecular assemblies 
responsible for processing pro-caspase-1 into the enzymatically active heterodimer 
caspase-1. Active caspase-1 cleaves the precursor pro-IL1β and pro-IL-18 into mature 
bioactive IL-1β and IL-18. NLRP3 and NLRC4 inflammasomes also require the adaptor 
protein ASC [apoptosis-associated speck-like protein containing a CARD) in order to 
activate caspase-1 and process IL-1β and IL-18. These events also result in pyroptosis, 
a specialised form of inflammatory cell death (distinct from apoptosis and necrosis) 
following bacterial infection. Induction of pyroptosis in macrophages and DCs initiates 
the release of pro-inflammatory cytokines, growth factors, endogenous danger-
associated molecular patterns (DAMPs)  and microbial antigens (94).  
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Currently, the contribution of NOD2 ligands to inflammasome activity is unclear. In 
2008, M. Karin and colleagues showed direct interaction of NOD2 to caspase-1 via a 
CARD-CARD interaction, without the requirement for ASC mediation (95). This is an 
unusual finding as no other study to date has shown inflammasome activation in the 
absence of ASC. Other studies implicate interaction of NOD2 with NALP1 leading to 
the formation of an inflammasome. This interaction leads to enhanced caspase-1 and 
NF-κB signalling. Another report has suggested an interaction between NOD2 and 
NALP3 (96), but this evidence has not been re-affirmed by subsequent studies (97). 
What also remains unclear is the action of the MDP PGN moiety, as it has been 
claimed to be a ligand for NALP1 (98) and NALP3 (99). 
 
1.2.3 Peptidoglycan recognition proteins (PGRPs) 
In addition to PGN moieties interacting with TLR2, NOD1 and NOD2, they can also be 
sensed by PGN recognition proteins, a class of PRRs that remain less well studied. 
Humans and mice express four secreted PGN recognition proteins (PGRPs) that bind 
directly to both Gram-positive and Gram-negative PGN (100). All PGRPs function in 
antimicrobial defence and can hydrolyse PGN, while most have diversified to carry out 
other host-defence functions. Insect and mammalian PGRPs defend host cells against 
infection through very different mechanisms. Mammalian PGRPs are directly 
bactericidal and can affect immune outcome. The potential role of this family of 
receptors in immunity to enteropathogen motifs was not investigated in the current 
study. 
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1.3 Gastrointestinal (GI) infections 
GI infections affect over 1.7 billion people globally, particularly in the developing world. 
Diarrheal disease is the second leading cause of death in children under five years of 
age, as well as the leading cause of malnutrition. The development of vaccines has 
only been successful for a limited number of diarrhoea-causing agents therefore new 
therapeutic approaches are needed. But for this we need to understand host-pathogen 
interactions first. To date research has focused on Salmonella, interestingly Salmonella 
cases have been steadily declining over the last decade (EFSA), research effort is also 
shifting towards other bacteria. Two enteropathogens that have gained significance in 
the last two decades are C. difficile and C. jejuni. This is due to the increased incidence 
in cases of Campylobacter and C. difficile infections (see Section 1.1.2.2).  
CDI is the leading identifiable cause of antibiotic-associated diarrhea. Remarkably, 
C.difficile is commensal in children and can often colonise them asymptomatically 
(101),  but can cause disease in adults. In the last decade, the global incidence of CDI 
has increased dramatically due to the emergence and spread of epidemic strains 
associated with more severe disease, increased mortality, higher relapse rates and 
increased resistance to antibiotics (102). In contrast, C. jejuni is commensal in chicken 
and a main cause of gastroenteritis worldwide with young children being more 
susceptible to infection. Campylobacter infection is the leading cause of bacterial-
mediated diarrhoeal disease, which is common in children under five (103). In Africa, a 
few studies have indicated that Campylobacteriosis is most common among children of 
young age (104). Among Campylobacter spp., C. jejuni is the most commonly isolated 
species from cases of gastroenteritis. Each of these two pathogens offers different 
challenges, given their different epidemiology, mode of infection and virulence factors. 
A better understanding of the host inflammation and immune mechanisms that 
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modulate the course of disease and control host susceptibility to these pathogens 
could lead to novel strategies for combating the challenges posed by these infections. 
This thesis addresses some fundamental host-pathogen interactions of C. difficile and 
C. jejuni with the GI tract. 
 
1.3.1 C. difficile-host interactions 
 
1.3.1.1 C. difficile taxonomy 
C. difficile belongs to the Clostridia genus of the Firmicutes phylum, a group of large 
prokaryotes that encompass Gram-positive, rod-shaped, anaerobic bacteria. Clostridia 
are Gram-positive bacteria that form endospores and therefore have an ecological 
advantage for survival under adverse conditions. Members of the Clostridia class 
belong to one of three orders: Clostridiales, Halanaerobiales and 
Thermoanerobacteriales (105). 
C. difficile is a member of the phylogenetic cluster XI of Clostridia, while other 
pathogenic species, such as Clostridium perfrigens and Clostridium tetani are 
members of Clostridium cluster I. It was initially identified in 1935 as part of the normal 
gut flora of neonates and named Bacillus difficilis due to its slow growth and the 
difficulty encountered in culturing the bacterium (106). In 1978, C. difficile was first 
identified as a pathogen and as a causative agent for antibiotic-associated diarrhea 
(107).   
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1.3.1.2 Commensal Clostridia species 
The intestinal microbiome is composed of four major microbial phyla (Firmicutes, 
Bacteroides, Proteobacteria and Actinobacteria), divided into three distinct groups: 
Bacteroides, Clostridium cluster XIVa (also known as the Clostridium coccoides group) 
and Clostridium cluster IV (also known as the Clostridium leptum group) (108). Strains 
that fall within clusters IV, XIVa and XVIII of Clostridia lack prominent toxins and 
virulence factors. Clostridia make up roughly 60% of the total bacteria in the adult gut 
microbiome. They colonise the colon during the first month of life and populate the 
intestinal mucosa. This position brings them in close contact with IECs where they can 
act as effectors of physiologic, metabolic and immunologic events either on their own 
or via interactions with other resident microbes (16). In particular, commensal Clostridia 
play an important role in the metabolic welfare of colonocytes by releasing butyrate as 
an end-product of fermentation (109). A recent study showed that the relative 
abundance of Clostridia was much lower in infants suffering from necrotising 
enterocolitis (110). Interestingly, Clostridia species were used in a study to manipulate 
the microbiome for therapeutic purposes (111). Oral administration of a combination of 
Clostridia strains attenuated disease in mice models of colitis by enhancing Treg 
proliferation and inducing anti-inflammatory molecules such as IL-10. Through their 
metabolic role, Clostridia are emerging as key probiotic effectors in the intestine and a 
promising source of novel therapeutic strategies. 
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1.3.1.3 C. difficile associated diseases (CDAD)  
 
1.3.1.3.1 Pathogenesis 
We have focused on C. difficile, as it is currently, in clinical terms, the most important 
clostridial species. C. difficile is a major nosocomial bacterial pathogen that can cause 
a range of GI conditions in humans, these vary from simple diarrhoea to severe 
pseudomembranous colitis (PMC), an inflammation of the large intestine that leads to 
severe diarrhoea (112). C. difficile was first identified as the causative agent of PMC in 
1977, thus defining its virulent capacity in susceptible individuals (113). In 2003, new 
hypervirulent strains appeared, first in Canada, and since then C. difficile infection 
(CDI) has spread globally (114). In the UK there are over 50,000 cases annually, with 
7,000 deaths, effectively a person dying every hour in UK hospitals. CDI rates have 
also increased in groups that prior to 2000 were considered to be at low-risk, i.e. those 
with no immediate exposure to antibiotics, in children and in patients with IBD. CDI is 
considered a trigger in the aetiology of IBD and studies suggest that C. difficile 
gastroenteritis (115) may not only provide a trigger for flare-ups but may also be 
associated with disease severity in both adult and paediatric IBD (116),(117). A study 
demonstrated that patients with IBD who had associated C. difficile had a four times 
greater mortality and higher rates of colectomy than those without underlying IBD (118). 
Apart from humans, the bacterium can also infect other animal species, such as pigs, 
horses and dogs (119). The major virulence factors responsible for C. difficile 
pathogenesis are three toxins designated TcdA, TcdB and CDT (120),(121), where to 
date scientific endeavour, including work from our lab (122),(123), has focused on 
dissecting their function with the aim of generating antitoxin therapy (124). C. difficile 
remains less well-studied compared to other Gram-positive bacteria mainly due to the 
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difficulties in culturing anaerobes. 
1.3.1.3.2 Asymptomatic colonisation 
Although considered a major nosocomial pathogen, the majority of individuals who 
encounter C. difficile during their lifetime do not become ill. The bug will either 
transiently pass through the GI tract or exist asymptomatically in a low percentage (~ 
4%) of healthy adults and up to 20% of hospitalised patients. Asymptomatic carriage is 
even more common in children (101), where C. diffiicile colonises 60 - 70% of 
newborns and infants up to 12-18 months of age when normal colonic microflora is 
established (125). C. difficile also colonises ~25% of children up to five years of age 
(126) in an asymptomatic fashion and this association, good or bad (102), has 
remained largely unexplored. This non-immunogenic cross-talk between C. diffiicile 
and the innate immune system has not been studied in detail. One study in a neonatal 
porcine model of CDI suggested that neonatal gut may not express the receptor for 
TcdA as an explanation for its disease-free association (127). However, this conclusion 
is unsatisfactory as C. difficile can secrete up to 3 toxins and specific lack of toxin 
receptor(s) in children has not been shown. One recent study indicates that C. difficile 
association in the neonate maybe asymptomatic but it is not silent, as the authors 
found an association between the presence of C. difficile and changes in the 
composition of the intestinal microbiota (128). 
 
1.3.1.4 C. difficile cell wall 
The Gram-positive cell envelope consists of a cytoplasmic membrane surrounded by a 
variety of glycan polymers and proteins. The cell wall, external to the membrane is a 
complex matrix of PGN and other polymers, including anionic polymers such as 
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teichoic acids and lipoteichoic acids polymers (129). The composition of the cell wall 
can vary significantly between species and is important in a variety of functions, such 
as host interaction, motility, invasion and microbe-microbe interactions. 
 
1.3.1.4.1 Surface layer proteins 
Many bacteria express a surface-exposed proteinaceous surface layer, termed the S-
layer, which is formed by the self-assembly of monomeric proteins into a regularly 
spaced, two-dimensional array and is visible by electron microscopy. S‑layers are 
found on both Gram-positive and Gram-negative bacteria and are some of the most 
abundant proteins in the cell; consisting of one or more (glyco)proteins, known as 
S‑layer proteins (SLPs), that undergo self-assembly to form a regularly spaced array on 
the surface of the cell (130). C. difficile is unusual in expressing two S-layer proteins 
(SLPs), which are of varying size in a number of strains: the high-molecular weight 
(HMW) SLP and the low-molecular weight (LMW) SLP, both of which are produced by 
proteolytic cleavage of the precursor S-layer protein SlpA (131). This variation affects 
recognition by antibodies, which presumably reflects pressure from the host immune 
response (132). S‑layer diversity in C. difficile is derived from a ~10 kb cassette that 
encodes SlpA, a protein translocase subunit (SecA2) and two cell wall proteins 
(CWPs), where recombinational switching occurs to generate antigenic diversity. 
As the major surface antigen of C. difficile, the S‐layer has the capacity to activate the 
immune system. The SlpA proteins (HMW and LMW SLPs) induce the release of IL-12, 
TNFα and IL10, but not the production of IL‐1β from human monocytes and induce the 
maturation of human monocyte‐derived DCs (133) Further work advanced these 
findings by showing that DC activation was dependent on Toll‐like receptor 4 (TLR4). A 
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recent study showed that SLPs isolated from C. difficile induced the production of pro-
inflammatory cytokines and chemokines in macrophages and increased macrophage 
migration and phagocytotic activity in vitro. Furthermore, treatment with SLPs led to the 
up-regulation of a number of cell surface markers important in pathogen recognition 
and antigen presentation (134). 
  
1.3.1.4.2 Lipoproteins 
Bacterial proteins of the Gram-positive or Gram-negative cell wall carry lipid 
modifications that facilitate anchorage. Lipoproteins of Gram-positive bacteria are 
processed by two key enzymes; the prolipoprotein diacylglyceryl transferase (Lgt) 
enzyme and the lipoprotein signal peptidase (Lsp) enzyme. The Lgt enzyme 
recognizes a so-called lipobox motif (LXXC) in the C-terminal region of the signal 
peptide of a premature lipoprotein and transfers a diacylglyceryl moiety to the cysteine 
residue of the lipobox. Subsequently, the Lsp enzyme cleaves the signal peptide 
resulting in a mature lipoprotein (Figure 1.3) (135). Deletion of the lgt gene is lethal to 
most Gram-negative bacteria (424). The acylation pattern depends on the existence of 
an N-acyl-transferase, which is mostly absent in Gram-positive bacteria and 
mycoplasma to result in the production of only diacylated LP. Gram-negative bacteria, 
on the other hand, synthesize mainly triacylated lipoproteins (136). Lipid modification of 
Gram-positive bacterial lipoproteins via Lgt has been described to be essential for 
innate immune activation (285, 320). 
Lipoprotein coding genes comprise 2.25% of the C. difficile genome (137). A total of 85 
lipoproteins have been identified through genomic sequencing, yet only very few have 
been isolated and studied in detail. Recently, the lipoprotein CD0873 was identified as 
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a putative adhesin and a CD0873 mutant showed significant reduction in adherence to 
IECs (138). Interestingly, immunization of mice with purified recombinant proteins from 
C. perfingens elicited protective immunity against challenge with the pathogen in a  
mouse model of infection (139). Lipoproteins have been shown to play a role in 
virulence in other bacteria, including Enterococcus faecalis and Bacillus anthracis 
(140).  
 
 
 
Figure 1.3. The peptide lipidation reaction. 
(i) Diacylglyceryl modification of pre-prolipoproteins by phosphatidylglycerol 
proLipoprotein diacylGlyceryl Transferase (Lgt) to form diacylglyceryl–prolipoproteins; 
(ii) cleavage of signal peptide from diacylglyceryl-prolipoproteins by Lipoprotein Signal 
Peptidase (LspA) to form apolipoproteins; and (iii) N-acylation of apolipoproteins by an 
apoLipoproteiin N-acyl Transferase (Lnt), resulting in mature lipoproteins. The third 
reaction only occurs in Gram-negative bacteria. [Adapted from ref. (424)] 
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1.3.1.4.3 Cell-wall glycopolymers 
Most Gram-positive bacteria incorporate carbohydrate-based polymers termed cell-wall 
glycopolymers (CWG) into their cell envelopes (141). These are typically either 
membrane bound to glycolipids, termed lipoteichoic acids (LTA) (142), or linked to the 
PGN cell wall, termed wall teichoic acids (WTA) (143). The structure of CWGs varies 
between species but are typically polymers of sugar monomers containing phosphate 
groups such as 1,3-glycerol phosphate (Gro-P) or 1,5 D-ribitol-phosphate (Rbo-P) 
(144). CWGs differ according to their type of sugar, net charge and decoration of the 
repeating units. 
C. difficile contains a rare, complex  LTA polymer known as type V LTA, which has a 
proposed structure of α-D-GlcNAc(1–3)-α-D-GlcNAc repeating units linked through 
phosphodiester bridges. The second N-acetylglucosamine (GlcNAc) residue is further 
decorated with D–glyceric acid, and the polymer is retained in the membrane via a β-1-
6-linked triglucosyl-diacylglycerol glycolipid anchor (145). Teichoic acids play a 
protective role, as a study found that d-alanylation of teichoic acids provides protection 
against antimicrobial peptides that may be essential for growth of C. difficile in the host. 
(146). The easy accessibility of CWGs in the cell wall makes these polymers interesting 
candidate targets for novel anti-infective strategies against emerging highly antibiotic-
resistant bacteria such as C. difficile, particularly for new diagnostics and vaccines 
(129).   
 
1.3.1.4.4 Peptidoglycan architecture 
 PGN is a major component of the Gram-positive bacterial cell wall, whereas it only 
makes up a thin layer in the periplasmic space of Gram-negative bacteria. PGN 
surrounds the entire cell, contributing to the backbone framework for attachment of 
surface proteins and other polymers (143). It is crucial for plasma membrane integrity 
and confers resistance to antibiotics and anti-bacterial enzymes. The PGN biosynthesis 
pathway is targeted by a number of antibiotics, including penicillin and vancomycin. 
Gram-positive PGN is formed of long linear glycan strands cross-linked by short 
peptides (Figure 1.3). Some Gram-positive pathogens modify their PGN to resist host 
PGN-degrading lytic enzymes such as lysozymes. Lysozyme cleaves the (1-4) linkage 
between MurNAc and GlcNAc in the PGN backbone. Lysozyme is a critical host 
defence peptide found in abundance in macrophages and neutrophils (150). The two 
main mechanisms of PGN modification conferring lysozyme resistance involve 
acetylation of PGN glycan strands. These can be either N-deacetylation of the GlcNAc 
residues or O-acetylation of the OH group at C-6 of the MurNAc residues, (151).
  
Figure 1.4. Peptidogylcan (PGN) structure and receptor binding motifs. 
The chemical structure of DAP-type PGN, common in Gram-negative bacteria, is 
shown in black. The red inset shows the changes in structure common in Gram-
positive bacteria, including the change of m-diaminopimelic acid (DAP) to L-Lysine, and 
D-glutamic acid to D-iso-glutamine. Pink: The cleavage sites of the amidase 
peptidoglycan recognition protein-2 (Pglyrp-2) and lysozyme are indicated with dashed 
lines. [Adapted from ref. (147)]  
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The genes responsible for these activities in Gram-positive bacteria are pgdA (PG N-
deacetylase) and oatA (O-acetyltransferase), respectively. Both additional acetylation 
and deacetylation can confer increased lysozyme resistance depending on the 
microorganism. Increased lysozyme resistance is an important virulence factor for 
numerous Gram-positive bacteria, including L monocytogenes and S. pneumoniae 
which are N-deacetylated and S. aureus which is O-acetylated (152). Further to 
lysozyme resistance, the modification has been linked to bacterial survival and 
attenuation of host immunity. Inactivation of pgdA in L. monocytogenes revealed that 
the mutant was rapidly destroyed within macrophage vacuoles, followed by the release 
of its cell-wall components such as muropeptides and lipoteichoic acid (LTA). This led 
to the induction of a significant IFN-β response mediated by the PRRs TLR2 and 
NOD(153). Therefore, PGN N-deacetylation can function as a double-protection 
mechanism for Listeria against  host innate defence by escaping the action of lysozyme 
and providing a mechanism to evade TRL2 and the NOD proteins.  
 
1.3.1.4.5 C. difficile peptidoglycan 
Until recently, little was known about the structure and biosynthesis of C. difficile PGN. 
Compared to other Clostridium species, such as C. perfringens, C. difficile exhibits 
lower susceptibility to β-lactams; i.e higher minimal inhibitory concentrations of β-
lactams are needed to inhibit PGN biosynthesis (154). It also displays a preserved 
susceptibility to the antibiotic vancomycin despite the presence of a vanG-like operon 
that codes for a vancomycin-resistance gene (155). The fine structure of the vegetative 
cell wall of C. difficile was recently characterised by Peltier et al. and was found to have 
an original structure with many unique elements (156). The authors found a high 
percentage (93%) of GlcNAc in the C. difficile PGN to be deacetylated which accounted 
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for its resistance to lysozyme. Despite being intrinsically highly deacetylated, exposure 
to lysozyme can lead to additional deacetylation due to upregulation of a putative PGN 
deacetylase (157). The sequence of the peptide polymers mainly follows  a pattern of 
L-Ala – L-Gln – A2pm – D-Ala, with an occasional addition of D-Ala as a 5th residue, or 
a substitution of D-Ala4 with a glycine residue. The same study found that 73% of C. 
difficile crosslinks involve L-D transpeptidation between A2pm3-A2pm3 of adjacent 
peptide polymers, with 27% of crosslinks involving D-Ala4-A2pm3. As discussed 
earlier, l,d-transpeptidases are insensitive to most β-lactams and contribute to C. 
difficile antibiotic resistance. As there is no pentaglycine cross-bridge C. difficile is not 
susceptible to the action of the antimicrobial agent lysostaphin (158). Furthermore, it is 
likely that any sortase substrates present will be covalently attached to the DAP cross-
bridge as in B. anthracis (159). Beyond the structural role of PGN, this crucial moiety 
may also contribute to C. difficile asymptomatic survival and/or pathogenesis in 
genetically susceptible individuals.  
 
1.3.1.5 Peptidoglycan (PGN) recognition 
Given that the resident microbiota are normally non-invasive, NOD activation may be 
triggered without a cell invasion event. One hypothesis states that commensal bacteria 
come into contact with IECs or laminal propria DCs after stochastic diffusion through 
the mucus layer. Another suggestion is that free PGN fragments are released in the gut 
lumen and become endocytosed by IECs (160). In a study using radiolabelled PGN in 
mice, PGN fragments were detected in the serum suggesting that they had 
translocated through both the mucus layer and the intestinal barrier (161).  
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During their growth or cell division, bacteria are continuously shedding PGN 
muropeptides from the cell wall via the process of PGN turnover. In Gram-negative 
bacteria, turnover is coupled to recycling of the muropeptides back into the cytoplasm 
to be used in biosynthesis, yet only 30-60% of these muropeptides are recycled. Gram-
positive organisms are not enclosed in a permeability barrier and the turnover products 
are released into the surrounding environment. Studies have validated the presence of 
NOD1 and NOD2 ligands in the supernatants of bacterial cultures from numerous 
strains (162). PGN turnover has not yet been studied in C. difficile, but in other species 
between 20% to 50% of total PGN is turned over in each generation (163). The process 
is catalysed by PGN hydrolases, enzymes that degrade bacterial muropeptides to 
generate smaller monomers or PGN fragments (164). So far, two PGN hydrolyses have 
been identified in C. difficile; the autolysin Acd (165) and the cell wall protein Cwp22 
(132). Acd is an N-acetylglucosaminidase hydrolysing the bond between GlcNAc and 
MurNAc.  
PGN can also be degraded by host hydrolytic enzymes known as hydrolyses. 
Hydrolases, such as lysozyme, are some of the most abundant antimicrobials present 
on the mucosal surface. The muramidase activity of lysozyme leads to hydrolysis of the 
β-1,4 glycosidic bond between the C-1 carbon of MurNAc and the C-4 carbon of 
GlcNAc residues of the PGN backbone (166). In addition, intraepithelial lymphocytes 
(IELs) express a PGN amidase, N-acetylmuramoyl-L-alanine amidase (also known as 
PGLYRP2), which can cleave PGN into large MDP-containing fragments (167). Finally, 
secreted pattern recognitions receptors for PGN -peptidoglycan recognition proteins 
(PGRPs) have been shown to bind and  hydrolyse bacterial PGN (168). The plurality of 
bacterial and host peptidoglycan-degrading enzymes would suggest that PGN 
fragments recognised by innate immune cells are variable and may elicit diverse 
responses. Identifying the structure and quantities of the NOD ligands being released is 
important for understanding how intestinal homeostasis is maintained.  
 
1.3.1.5.1 Cytosolic peptidoglycan (PGN) 
Although NODs have traditionally been seen as sensors of invading cytosolic bacteria, 
recent work suggests they are able to sense ligands released by extracellular 
pathogens. In the absence of direct cellular invasion by a pathogen, for example C. 
difficile, NOD signal transduction can take place by PGN entry to the cytosol; either by 
injection through bacterial secretion systems (169) or via delivery by outer membrane 
vesicles of Gram-negative bacteria (170),(171). Furthermore, two recent reports have 
found that epithelial cells and macrophages can take up PGN through endocytosis, 
demonstrating that NOD1 or NOD2 ligand uptake occurs through clathrin-mediated 
endocytosis (172),(173). Killing of internalised bacteria in the phagolysosomes is 
mediated by hydrolases amongst other factors, which are present in the granules of 
professional phagocytic cells (macrophages, neutrophils) and can cause bacterial cell 
lysis. Additionally, oligopeptide transporters, such as pH-sensing regulatory factor of 
peptide transporter-1 (PEPT1), can carry PGN fragments into the cytosol (173),(174). 
Finally, the transfer of PGN fragments can be mediated via gap junctions as 
demonstrated by the NOD1-dependent activation in cells located adjacent to infected 
cells (175). The presence of multiple mechanisms of PGN delivery suggests that NODs 
have a wider role in immunosurveilance of the gut microbiota than initially thought.
1.3.2 Campylobacter jejuni-host interactions 
 
1.3.2.1 Campylobacter jejuni-mediated disease pathogenesis 
Campylobacteriosis is the most frequent cause of food-borne gastroenteritis in the 
European Union with over 190,000 cases reported per year, although the actual 
number of cases is estimated at 9 million with the annual cost of infection estimated at 
2.4 billion euros (European Food Safety Authority; EFSA). In the UK the rates of 
bacterial-associated gastroenteritis caused by Campylobacter sp. are as high as 9.3 
cases per 1000 persons for community-acquired infections (176). Over 90% cases of 
human Campylobacter enteritis are caused by Campylobacter jejuni. Gastroenteritis is 
self-limiting in the majority of cases, lasting less than 1 week; although a small number 
of individuals develop post-infectious autoimmune pathologies. Despite the high 
incidence and economic burden presented by C. jejuni, its pathogenesis remains less 
well studied compared to other enteropathogens such as Salmonella typhimurium, 
Shigella sp., and Escherichia coli. 
 
1.3.2.2 Taxonomy 
C. jejuni belongs to the genus Campylobacter, order Campylobacteriales, which are 
members of the epsilon class of proteobacteria. It is a spiral, comma-shaped Gram-
negative bacterium that utilises abipolar flagella for motility. C. jejuni was first described 
in 1931 in cattle suffering from spontaneous diarrhoea and termed Vibrio jejuni by 
Jones and colleagues (177). The Campylobacter genus was first identified as being 
separate from Vibrio in 1963 after Sebald and Véron noted the distinct biochemical 
properties of Vibrio fetus and Vibrio bubulus from other Vibrio species (178). In 1973, 
further analysis of microaerobic/anaerobic bacteria in the Vibrio taxa led to the re-
classification of these bacteria into the Campylobacter taxon (179). Until 1973 
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Campylobacter sp. were primarily seen as veterinary pathogens, however in the 1970’s 
the importance of Campylobacter sp. in human gastroenteritis became apparent as 
new techniques allowed the culturing of these micro-aerophillic bacteria from patients 
presenting with diarrhoea (180). There are currently 25 species of Campylobacter that 
have been isolated from a diverse array of hosts, both colonised without apparent 
symptoms and from those presenting with enteritis. 
There are two subspecies of C. jejuni: C. jejuni subsp. jejuni (referred to as C. jejuni), 
which is the major cause of human Campylobacter enteritis (campylobacteriosis), and 
C. jejuni subsp. doylei. Subsp. doylei is the cause of very few cases of gastroenteritis in 
comparison to subsp. jejuni and the two subspecies differ considerably in distribution 
and incidence. The second most common cause of campylobacteriosis is C. coli, which 
is genetically the closest relative of C. jejuni and accounts for a small number of cases 
of human disease (181). While over the past decade the importance of other 
enteropathogens in human disease has become increasingly appreciated, the 
fastidious growth conditions of these Campylobacter sp. has resulted in 
underrepresentation of these organisms in clinical diagnosis (182). 
 
1.3.2.3 Clinical manifestations 
Acute gastroenteritis is the major clinical manifestation in humans infected with C. 
jejuni. Clinical symptoms include watery or bloody diarrhoea, often accompanied by 
abdominal cramps and fever (183). Incubation times of between 24-72h have been 
reported and symptoms often resolve within one week although they may persist for 
longer. In the majority of cases in the developed world, campylobacteriosis induces 
inflammatory diarrhoea, with polymorphonuclear (PMN) cells and erythrocytes present 
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in the stools (184). Symptoms are generally self-limiting, although 
immunocompromised patients, such as HIV patients and the elderly, are more likely to 
have extended gastroenteritis and develop bacteremia (185) which suggests host 
immunity plays a major role in limiting systemic spread. 
Clinical manifestations of C. jejuni infection differ in people from developing countries 
who, mainly due to their more frequent exposure to multiple C. jejuni strains, develop 
fewer symptoms (183). The protective immunity acquired by repeated exposure 
protects only from symptomatic disease but not colonisation (186). Gastroenteritis is 
more commonly seen in children and it is rare for adults to develop symptomatic 
disease which suggests that exposure to multiple strains in early childhood contributes 
to the development of protective immunity. On the other hand, visitors from countries 
with no pre-existing C. jejuni immunity develop the more serious symptoms of bloody 
diarrhoea when infected in developing countries (187). Finally, although no differences 
have been found in strains isolated from symptomatic and asymptomatic infection 
(188), full genome sequencing of C. jejuni may reveal new associations.  
 
1.3.2.3.1 Inflammatory Bowel Disease (IBD) 
Increased risk of developing IBD has been associated with both Campylobacter and 
Salmonella infection (189). However, the evidence remains contradictory with a more 
recent study demonstrating that increased sampling bias around the onset of IBD is 
responsible for the increased detection rates of Campylobacter and Salmonella in 
newly diagnosed IBD patients (190). 
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1.3.2.3.2 Guillain-Barré Syndrome  
Guillain-Barré Syndrome (GBS) is an autoimmune neuropathy resulting from the 
production of autoantibodies that cause de-myelination of nerve gangliosides in the 
peripheral nervous system. Symptoms often begin in the lower extremities, and can 
ascend through the body resulting in full neuromuscular paralysis, with one third of 
patients requiring ventilator-assisted breathing. The majority of GBS cases are 
preceded by gastroenteritis, and the discovery of molecular mimics between C. jejuni 
lipooligosaccharide (LOS) and nerve gangliosides led to the identification of C. jejuni 
infection as a major aetiological agent of acute motor axonal neuropathy (AMAN), a 
variant of GBS. Host factors are also important as GBS-associated C. jejuni strains 
have been isolated from patients suffering from uncomplicated enteritis (192). 
 
1.3.2.4 C. jejuni surface structures 
Like many other mucosal pathogens, the surface structures of C. jejuni are heavily 
glycosylated with approximately 8% of its genome encoding proteins implicated in 
surface carbohydrate structures (Figure 1.4) (193). C. jejuni encodes both N-linked and 
O-linked glycosylation pathways for the modification of surface and flagella proteins 
respectively. Genome sequencing of C. jejuni identified the pathogen’s ability to 
promote phase-variation of many genes involved in glycosylation (193). Long stretches 
of repeated C or G bases called ”homopolymerlc tracts” increase slip-strand mispairing 
which can result in genes being ”switched on” or "switched off”. The importance of 
these glycosylation systems in bacterial-driven pathogenesis is only now being 
appreciated. 
 
1.3.2.4.1 Lipooligosaccharide 
Lipopolysaccharide/lipooligosaccharide (LPS/LOS) forms an integral part of the outer 
membrane of Gram-negative bacteria. C. jejuni expresses LOS, which consists of a 
hydrophobic lipid A anchored to the outer membrane and an extracellular carbohydrate 
oligosaccharide (OS) that lacks the repeating carbohydrate O-antigen of LPS 
molecules. The lipid A anchor is essential for membrane integrity and complete 
mutation of C. jejuni LOS is lethal (194). Variation in OS length and composition is a 
key strategy employed by Gram-negative bacteria that allows them to evade and 
modulate host immunity. 
The sugar components of the disaccharide lipid A backbone can be 2,3-diamino-2,3-
dideoxy-D-glucose (GIcN3N) or a D-glucosamine (GlcN) moiety (196). The lipid A 
backbone is hexacylated with either palmitic (14 carbon) or myristic (16 carbon) acid 
(196). GIcN3N contains two amide-linked palmitic/myristic acid chains, in comparison 
GlcN contains one amide and one ester linked fatty acid chain. The two additional 
palmitic acid chains are attached to the palmitic and myristic acid of the sugar proximal 
to the OS, making the disaccharide asymmetrical. 
 Figure 1.5. C. jejuni surface structure features.  
(a) The flagellum is anchored into both the inner and outer membrane. Flagellin 
proteins, FlaA and FlaB are O-linked glycosylated with sialic acid-like structures. (b) 
The capsule is a highly branched polysaccharide structure. (c) Lipooligosaccharide 
(LOS) is an essential feature of the outer membrane (d) Periplasmic and outer 
membrane embedded proteins are modified by the N-linked glycosylation system. 
[Adapted from ref. (195)].  
(A
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The most common backbone composition is GlcN3N-GlcN, although both GlcN3N-
GlcN3N and GlcN-GlcN structures have been detected (197). GlcN3N sugars reduce 
both the ability of C. jejuni LOS to activate Toll-like receptor 4 (TLR4) and the sensitivity 
of live C. jejuni to cationic AMPs (198). The disaccharide backbone can be modified 
with the addition of both phosphate (P) and O-phosphorylethanolamine (PEA) on either 
or both sugars (196),(197). The gene responsible for the addition of PEA groups onto 
the lipid A, Cj02S6, is also responsible for the modification of the flagellar rod protein, 
FlgG, with PEA (199). The phosphorylation pattern and disaccharide composition of C. 
jejuni varies between strains and is also dependent on the growth phase (197). 
The C. jejuni OS consists of a mainly conserved inner core OS proximal to the lipid A 
backbone, and an outer core OS which varies significantly between strains suggesting 
the two OS cores are under differential selective pressure (Figure 1.5). The inner core 
OS contains two 3-deoxy-D-manno-oct-2-ulosonic acid (KDO) residues, two heptose 
(Hep) residues, with two branched glucose (Glu) residues on each heptose, and one 
PEA/P residue on the heptose proximal to the KDO (200). The outer core OS of 11168 
and other C. jejuni strains are composed of galactose (Gal), glucose, N-acetyl-D-
galactosamine (GaINAc), and N-acetylneuraminic acid (Neu5Ac; sialic acid) residues. 
The number of each sugar varies between strains and some strains lack sialic acid and 
GalNAc residues completely. The LOS biosynthesis locus in the C. jejuni genome is 
hypervariable and is composed of between 10 - 20 genes (201). To date 19 different 
LOS classes have been identified with varying levels of homology (202),(201). Classes 
A, B, C, M and R are responsible for the sialylation of LOS and sequencing has 
revealed minor genetic alterations within strains of the same LOS class as an 
additional mechanism which C. jejuni employs to vary the outer core OS (201). Strains 
 Figure 1.6. Structure of the core oligosaccharide of NCTC 11168 LOS.  
The carbohydrate structures analogous to the gangliosides GM1a and GM2 are 
bracketed. Kdo, 3-deoxy-α-D-manno-oct-2-ulopyranosonic acid; Hep, L-glycero-D-
mannoheptose; Glc, glucose; Gal, galactose; Neu5Ac, N-acetylneuraminic acid or sialic 
acid; GalNAc, N-acetyl-D-galactosamine.   
isolated from livestock show a greater propensity for LOS sialylation compared to non-
livestock sources. Interestingly, the number of sialic acids correlated with TLR4 
activation and release of TNFα in human monocytes (203), suggesting that LOS 
variation is critical in monocyte activation. 
The high degree of variability in the outer core OS structure suggests that it may be 
under differential selective pressure compared to the inner core. Indeed many 
structural features of the outer core OS are critical in host-interactions 
(204),(205),(206). An important consequence is the molecular mimicry observed 
between the OS outer core structure and host gangliosides and other glycans 
(207),(208). In addition to gangliosides, C. jejuni LOS can share structural features with 
P-blood group, paragloboside, lacto-N-biose and sialyl-lewis-c units (208). Presumably, 
mimicry of host glycans is a potential immune evasion strategy, as adaptive immune 
cells with specificities for these glycans will be deleted leading to increased peripheral 
tolerance. 
 
1.3.2.4.2 Flagella 
C. jejuni possess a single flagellum at either pole; a structure critical for motility as well 
as colonisation of their avian host (209). The flagellar filament is composed of proteins 
FlaA and FlaB. FIaA is a major structural component since mutation of the flaA gene 
results in a non-motile phenotype and severe truncation of the flagellum (210). On the 
other hand, the ΔflaB mutant bears full-length flagella and exhibits only partially 
impaired motility. The flagellar filament is embedded into both the inner and outer 
membrane via a basal body and hook complex composed of multiple structural 
proteins, which allow free rotation of the filament to facilitate motility. The flagellar 
filament of C. jejuni is a coiled-coiled structure composed of 7 protofilaments with a 
central lumen (211). Unlike many other well-known Gram-negative enteropathogens 
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(e.g. Salmonella, Yersinia sp.), C. jejuni lack a functional secretion apparatus (such as 
type III), instead C. jejuni secretes effector proteins, invasion antigens (Cia proteins) 
and FIaC through the flagella apparatus (212). This process requires the basal body 
and hook structure, and one of the FlaA or FIaB proto-filaments but not both. 
Flagellin proteins are O-linked glycosylated with sialic acid (SA) like structures making 
up nearly 10% of its total mass. O-linked glycosylation involves the addition of a sugar 
moiety to the hydroxyl group of a serine or threonine residue of a target protein 
although no target amino acid sequence has been identified. O-linked glycosylation of 
flagellin proteins is considered to be critical for the assembly of functional flagella (213). 
Rather than SA, C. jejuni flagellin contains pseudaminic acid (Pse) and legionaminic 
acid (Leg), both derivatives of SA like structures encoded by the Pse and Ptm 
biosynthesis pathways respectively (214),(215),(193). All C. jejuni strains studied to 
date express either Pse and its derivatives (e.g. strain 81-176) or derivatives of both 
Pse and Leg (e.g. strain 11168). In strain 11168 the flagellin glycosylation genetic 
cluster is composed of 50 genes, which encode Pse and Leg pathways (193). In 
contrast, strain 81-176 contains only the Pse synthesis pathway. Exposure of 
glycosylated residues on the external surfaces of the flagellum suggests that these 
modifications may play a role in interaction with the host (216). In fact, mutation of the 
Leg structures in strain 11168 dramatically decreases the ability of C. jejuni to colonise 
the chicken GI tract (213). As an immune evasion strategy, C. jejuni and other 
proteobacteria have evolved mutations in their flagella such that it no longer interacts 
with TLR5 (217). Instead, C. jejuni flagella activate the immunoinhibitory Siglec-10 
receptor via Pse structures on its surface to induce production of IL-10 (218). 
Therefore, flagella may play an important role in the interaction of C. jejuni with host 
immunity by contributing to bacterial survival. 
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1.3.2.4.3 Capsule 
The capsule consists of a high molecular weight polysaccharide component originally 
thought to be LPS but later identified as capsular polysaccharide (CPS) based on the 
genome sequence (219),(220). The CPS and not the LOS was also found to be the 
determinant in the heat-stable Penner serotyping scheme. Similar to the LOS, phase 
variable cps genes have been also been identified, implying that CPS may interact with 
the host. The genetic locus for C. jejuni 11168 CPS contains 38 genes. Those involved 
in CPS polymerisation and translocation are conserved between strains however the 
internal region encoding the CPS repeating units is highly variable in size. Indeed, CPS 
was found to play a role in dampening the pro-inflammatory cytokine responses in DCs 
as well as invasion of IECs (221),(222).  
 
1.3.2.4.4 N-linked glycosylated proteins 
N-linked glycosylation involves the attachment of a sugar moiety to the amide nitrogen 
of an asparagine residue. C. jejuni was the first microorganism found to employ an N-
linked glycosylation system (223). N-linked glycosylated proteins are highly conserved 
between strains (224), unlike other C. jejuni surface structures. A heptasaccharide 
composed of a single bacillosamine moiety attached to a linear chain of 5 GalNAc 
residues with one tertiary glucose residue forms the structure of all C. jejuni N-linked 
carbohydrates. N-linked glycosylation is thought to play a role in colonisation of the 
chicken gut, adherence and invasion of human lECs and modulation of DC immunity 
(225),(222),(226). 
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1.3.2.5 Innate Immunity to C. jejuni 
Understanding of C. jejuni pathogenesis lags behind that of other enteric pathogens in 
part due to the lack of a good small animal disease model. Chick models are used for 
C. jejuni colonisation studies however the pathology associated with human disease is 
not observed. WiId-type (WT) mice of multiple genetic backgrounds show limited 
colonisation of C. jejuni and pathology is even more infrequent (227),(228). Until 
recently, mice with genetically altered immune systems such as IL-10 knock-outs or 
mice depleted of lymphocytes were the most frequently used animal model systems 
(227),(71),(228). In 2011, a model replacing the enteric flora of WT mice with human 
flora has been described (229). These mice were colonised with C. jejuni and 
subsequently developed inflammatory responses. Larger animaI models, such as new-
borne piglets, are also used for pathogenesis studies however, high cost and limited 
genetic tools make them less desirable (230). 
 
1.3.2.5.1 Dendritic cells 
Human peripheral blood monocyte-derived DCs (mDCs) or bone marrow-derived DCs 
(BMDCs) are frequently used in in vitro co-culture assays. Both DC types model a more 
inflammatory mDC subset, which is more likely to be present during intestinal infection 
and inflammation. C. jejuni is readily phagocytosed and killed by human mDCs and 
BMDCs (231),(228). Other enteropathogens such as Salmonella enterica are able to 
survive within DCs which may account for the greater incidence of systemic disease 
(232) compared to campylobacteriosis. H. pylori, which is highly related to C. jejuni, 
can also replicate within BMDCs for a limited time (233). 
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1.3.2.5.2 Macrophages 
Macrophage-mediated immunity to pathogens such as C. jejuni is central to the 
outcome of infection. Studies frequently utilise the pre-monocytic THP-1 cell line which 
assumes a macrophage-like phenotype upon stimulation with phorbol-12-myristate 13-
acetate (PMA) (234). Unlike resident intestinal macrophages, TLR ligands elicit a pro-
inflammatory response in PMA-differentiated THP-1 cells (dTHP-1 cells). C. jejuni 
bacterial cell lysates induce caspase-dependent IL-1β secretion from dTHP-1 cells 
(235), as well as apoptosis via a caspase-independent pathway. According to some 
studies, C. jejuni can survive within monocytes/macrophages for up to 7 days, whereas 
it is readily killed by murine BM macrophages and dTHP-1 cells (236),(237),(218). This 
discrepancy may be attributed to the use of distinct cell types although it is not currently 
known how resident macrophages respond to C. jejuni. 
 
1.3.2.5.3 Neutrophils 
Neutrophils along with eosinophils, basophils, and mast cells make up the 
polymorphonuclear (PMN) cells or granulocytes. Neutrophils engulf and rapidly kill 
bacteria via the production of reactive oxygen species (ROS) in the phagolysosome. 
Neutrophils have the most potent phagocytic and bactericidal capability of all the 
phagocytes and are therefore central in the host response to infection. PMNs have 
been implicated in C. jejuni-mediated inflammatory pathology as their degree of 
infiltration of the GI mucosa correlates with the degree of inflammation (238). 
Neutrophil chemoattactants such as IL-8 are secreted by IECs in response to C. jejuni 
(239),(240). In general, neutrophils act to limit the systemic spread of C. jejuni although 
	  	  67 
as a result they contribute toxic ROS (241). Interestingly, GI colonisation in chicken is 
not associated with recruitment of avian neutrophils (heterophils) (242). 
 
1.3.2.5.4 Cytokine responses to C. jejuni infection 
C. jejuni-mediated infection induces a pro-inflammatory response from lECs as well as 
innate and adaptive immune cells. Chemokines such as IL-8, and monocyte 
chemoattractants CCL2 and CCL4 are secreted from C. jejuni-stimulated lECs 
(244),(237). Ex vivo co-culture experiments with human intestinal biopsies also show 
elevated levels of IL-8 (245). C. jejuni also stimulates pro-inflammatory cytokine 
induction in DCs and macrophages (231),(228). Increase in acute-phase response 
inducers TNFα and IL-6, as well as Th1 and Th17 polarising cytokines IL-12 and IL-23 
respectively has also been noted (246). Similar to IEC responses, no dramatic 
difference between human and chicken C. jejuni-stimulated macrophages/monocytes 
has been observed (247). Minimal levels of IL-1β have also been detected in ex vivo 
stimulated biopsies (246). Initial reports suggesting induction of the potent anti-
inflammatory cytokine IL-10 is flagellin-dependent were later confirmed by a study 
showing the involvement of Pse structures of the C. jejuni flagella in IL-10 induction 
(222),(218). 
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1.3.2.6 Immune recognition of C. jejuni 
 
1.3.2.6.1 Toll-like receptors 
C. jejuni activates human TLR1/2/6 and TLR4/MD2 receptors (247). C jejuni LOS is the 
ligand for TLR4/MD-2 (248) while di- and tri-acylated lipoproteins are predicted to bind 
TLR1/2 and TLR2/6. C. jejuni can successfully colonise MyD88-/- but not WT mice 
highlighting the role of TLR signalling in colonisation resistance (249). In chicken, C. 
jejuni is able to stimulate TLR2 and TLR4 homologs as well as the chicken TLR9 
ortholog, chTLR21 (247). However, activated chicken TLR4 is unable to induce type 1 
IFN response unlike human TLR4. Whether these discrepancies play a role in the 
different outcomes of C. jejuni infection in humans and chicken requires clarification. 
 
1.3.2.6.2 NOD receptors 
In IECs, C. jejuni activates NOD1 but not NOD2 to induce the secretion of human β-
defensin 2 (HBD2) and IL-6 (78) NOD1 activation also minimises intracellular C. jejuni 
numbers. C. jejuni can also activate NOD2 in a reporter cell line although the functional 
consequences of this remain unknown (78),(250). 
 
 
1.3.2.6.3 Glycan receptors 
Bacteria employ glycosylation of their surface structures to gain potential fitness 
advantages. These include survival in harsh and varying environments, assembly of 
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surface structures, adherence and invasion of target cells and subversion of host 
immunity (251). In contrast to protein, glycans are less immunogenic as they are not 
generally presented on MHC molecules to T cells, and are therefore mainly T-cell 
independent antigens. There is mounting evidence of the capacity of polysaccharides 
from commensal bacteria to influence the mucosal immune system. Polysaccharide A 
(PSA), a component of the CPS of the human commensal B. fragilis, activates TLR2 on 
mucosal CD4’ T cells inducing Treg differentiation by inducing IL-10, TGF-β and Fοxp3 
and further immunoinhibitory signalling (252). Bacterial glycan structures can bind to a 
wide variety of host receptors expressed on immune and non-immune cells. With 
respect to C. jejuni, these interactions have been shown to both enhance and dampen 
pro-inflammatory immune responses (226,248). 
 
1.3.2.6.4 Sialic-acid binding glycan receptors 
Sialic-acid binding immunoglobulin-like receptors (Siglecs) are a group of receptors 
largely expressed on the surface of haematopoietic cells. Siglecs are composed of a 
single trans-membrane domain, multiple extracellular lg domains that bind ligand, and 
a cytoplasmic intracellular inhibitory motif (ITIM) domain which exerts regulatory 
function (253). Some Siglecs contain an intracellular growth factor receptor binding 
protein-2 (Grb2) binding motif and ITlM-like motifs that do not conform to canonical 
ITIM sequences, however the functional consequences of these remains largely 
uncharacterised (254). There are two sub-categories of Siglec receptors based on 
sequence similarity. The first includes Sialoadhesin, CD22, SigIec-4 and -15; the 
second subset share sequence homology with CD33 and are termed the CD33-related 
Siglecs(253),(255). The CD33-related receptors are rapidly evolving, with variation in 
the numbers of receptors between species, even in higher order mammals. There are 
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currently 10 known human CD33-related Siglecs which are expressed in both innate 
and adaptive immune cells (256). Although humans display the most rapid rate of 
Siglec evolution, lower Siglec expression in human compared to chimpanzee T cells 
has been implicated in the heightened reactivity of human T cells to many stimuli (257). 
Additionally, lower expression is thought to contribute to the “over-reactivity” of the 
human immune system leading to diseases such as asthma and rheumatoid arthritis.  
Siglecs bind sialylated structures (most often sialylated glycans) via the terminal V-set 
Ig domain, and have varying specificities for the linkage of the sialic acid and the 
underlying glycan structure, which can be present on both host cells and microbes. 
Interestingly, recent reports have also highlighted the ability of Siglecs to bind to both 
host and pathogen non-sialylated ligands. Siglec-5 can bind the β-protein of group B 
Streptococcus (258), and SigIec-10 can bind vascular adhesion protein-1(259). 
However it is unlikely that these interactions occur via the sialic-acid binding pocket. 
Siglec engagement has been implicated in many cellular processes including 
endocytosis, apoptosis, cellular activation, and proliferation(253). The 
immunomodulatory capability of Siglecs is often via the modulation of TLR signalling 
(260) (Figure 1.6). Siglecs can bind to host cell surface sialic acid both via cis (on the 
same cell) and trans (different cell) interactions. Binding of Siglec-10 (murine SigIec-G) 
by the receptor CD24 leads to down-regulation of NF-κB signalling, protecting mice in a 
inducible liver necrosis model (261). This suggests that Siglecs play a role in limiting 
immune responses to DAMPs. This immune modulatory capability of Siglecs may have 
been exploited by pathogens during evolution since binding to these receptors 
potentially reduces immune activation and therefore increase chances of establishing 
infection. Many sialylated pathogens engage Siglecs, including C. jejuni(262),(263). 
Engagement of SigIec-9 by sialylated CPS and Siglec-5 by β-protein by Group B 
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Streptococcus reduces the oxidative burst of neutrophils and increases intracellular 
survival (264),(265). Engagement of murine SigIec-E by Trypanosome cruzi reduces 
DC IL-12 production which alters subsequent T-cell activation (266). C. jejuni strains 
that contain terminal α2,8-linked and α2,3-linked sialic-acid on their LOS bind to Siglec-
7 and sialoadhesin respectively (262),(263). The differential expression of these 
linkages drives alternative T cell responses, a factor which is hypothesised to impact 
on the development of GBS post C. jejuni infection (267). 
Multiple hypotheses have been proposed for the rapid evolution of CD33-related 
Siglecs. One hypothesis is the need to keep pace with the changing host slalome 
(253). As a high percentage of sialic-acid containing pathogens infect humans; this 
raises a second hypothesis that rapid evolution might allow Siglecs to act as potential 
PRRs aiding microbial detection. However, the evolution of paired Siglec receptors 
which share structural identity of the ligand binding domain - but lack the intracellular 
signalling domain – is thought to be a decoy strategy by the host to counteract the 
immune inhibition pathogens achieve on Siglec engagement, therefore supporting the 
first hypothesis (255). Their exact role in microbe recognition and immune evasion 
remains open. 
 
1.3.2.6.5 C-type lectin receptors (CLRs) 
Similar to Siglec receptors, CLRs are a group of receptors predominantly found on the 
surface of immune cells. CLRs contain a single trans-membrane domain, a C-type 
lectin-like domain involved in ligand binding, and often an intracellular signalling 
domain (268). Similar to Siglecs, engagement of CLRs often leads to dampening of 
TLR signalling, and has therefore been described as an immune evasion strategy by 
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certain pathogens. Mycobacterium tuberculosis and Candida albicans are able to 
induce IL-10 secretion by engaging the CLR DC-SIGN (Dendritic Cell-Specific 
Intercellular adhesion molecule-3-Grabbing Non-integrin), via prolonged NF-κB 
activation (269). C. jejuni can bind the CLR macrophage-binding galectin (MGL) 
through GalNAc residues on N-linked glycosylated surface proteins. Additionally, the 
LOS from certain strains bearing a terminal GalNAc residue can also bind MGL. The 
interaction with MGL was shown to reduce IL-6, indicating that certain C. jejuni surface 
structures may actively promote immune suppression (226). Furthermore, H. pylori 
interaction with DC-SIGN reduces cytokine induction which stunts Th1 responses 
affecting T-cell polarization (270).  
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Figure 1.7. Siglecs in the regulation of inhibitory signalling.  
(A) Activation of a TLR by a PAMP results in the generation of Siglec ligands through 
activation of phagocytic mechanisms that regulate ligand availability. The generation of 
a Siglec ligand results in inhibitory signalling being brought into play. (B) Activation of a 
TLR by a PAMP results in the induction of Siglec expression, which in turn brings 
inhibitory signalling into play. [Adapted from ref (398)].   
A 
B
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1.3.2.7 Immune Signalling 
 
1.3.2.7.1 Nuclear factor Kappa-Light-Chain Enhancer of Activated B Cells 
In vitro inhibitor studies have revealed a critical role for NF-κB signalling in the 
induction of inflammatory cytokines both in C. jejuni-stimulated IECs and DCs 
(71),(218). In a gnobiotic IL-I0-/- NF-κB reporter murine model, pathology was 
associated with NF-κB activation in LP mononuclear cells and induction of IL-12p40 
and TNFα (71). However, the use of NF-κB inhibitors did not ameliorate C. jejuni-
mediated pathology suggesting this signalling pathway alone is not responsible for the 
inflammatory nature of campylobacteriosis in this model. 
 
1.3.2.7.2 Mitogen-activated protein kinases (MAPKs) 
MAPKs are a family of serine/threonine kinases with multifaceted roles in cellular 
biology, including cellular proliferation and survival, transcriptional control, cellular 
movement, as well as induction of inflammatory responses after microbe recognition. 
MAPKs are activated by upstream MAPK kinases, which in turn become activated by 
MAPK kinase kinases (MAP3K) (Figure 1.7). Once activated MAPKs regulate a 
number of different transcription factors involved in immune function. Regulation of 
activation is tightly controlled, for example MAPKs can regulate their own activation by 
negative feedback mechanisms involving activation of one of three classes of protein 
phosphatases (271). 
The MAPK cascade is composed of three major groups of kinases: extracellular signal-
regulated kinases (ERKs) comprising ERK1 and ERK2; JuN N-terminal kinases (JNKs) 
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comprising JNK1 and JNK2; and p38 (272). Each group exerts cell-specific effects on 
various cellular processes. p38 and JNK are linked to pro-inflammatory responses. p38 
was first identified as the target of pyridinyl imidazole, a group of compounds capable 
of inhibiting monocyte TNFα and IL-1 secretion (273). ERK has been linked to pro-
inflammatory responses in DCs (274) but it can also influence IL-10 and TGF-β 
expression, and the development of T-cell immunity (275). MAPKs activate 
transcription factors that differentially regulate inflammatory gene expression. For 
example TLR-mediated ERK-dependent activation of AP-1 is essential for IL-23 p19 
gene expression, although this pathway does not elevate lL-12/IL-23 p40 expression 
(276). 
The profile of transcription factor activation by these pathways tailors a specific immune 
response. TAK1 is an important MAP3K, downstream of many PRRs including TLRs, 
and is capable of activating all three MAPK members. In addition, TAK1 can activate 
NF-κB directly through the ubiquitination and degradation of inhibitory IKK molecules 
(277). ERK and p38 signalling consolidates in the activation of mitogen and stress 
activated protein kinase (MSK) 1 and 2 which in turn activate transcription factors that 
bind the IL-10 promoter. The transcription factors cAMP-responsive-element-binding 
protein (CREB) and activating transcription factor 1 (ATF1) become activated by MSKs 
in LPS-stimulated mouse macrophages (278). In addition to gene regulation, MAPKs 
can also participate in microbe uptake. Syk is a tyrosine kinase downstream of many 
CLRs and is involved in multiple immune functions including cytoskeletal 
rearrangement for phagocytosis. ERK-mediated Syk activation has been linked to the 
phagocytosis of Francisella tularensis by macrophages (279). 
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Figure 1.8. The MAPK signalling cascade.  
The top tier shows the MAP3Ks, the second tier shows the MKKs, and the third tier 
comprises the MAPKs (ERK, JNK, p38) that regulate various genes through 
phosphorylation of transcription factors (e.g. c-Jun, ATF2) and other kinases 
(MAPKAPK2/MK2). The primary, but overlapping, responses include cell growth and 
differentiation (ERK), matrix regulation (JNK), and inflammatory cytokine production 
(p38). [Adapted from ref. (272)]  
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C. jejuni induces ERK and p38 activation in IECs leading to IL-8 production (249). In 
DCs, hyper-induction of ERK and p38 in the presence of C. jejuni flagella leads to 
enhanced IL-10 expression(218). Therefore, MAPK signalling is emerging as an 
important target in C. jejuni-induced pathogenesis. 
 
1.3.2.7.3 Interferon-regulatory transcription factors (IRFs) 
Interferon-regulatory transcription factors (lRFs) are a family of transcription 
factors involved in the regulation of type 1 interferon genes. IRF3 is downstream of 
TRIF-mediated signalling. C. jejuni induces lRF3 phosphorylation via TLR activation 
leading to the upregulation of IFN-β secretion (228). Although type 1 interferons are 
more commonly associated with viral infections, there is increasing evidence that IFN-β 
may enhance anti-bacterial activity through a positive feedback mechanism (280). 
1.3.2.7.4 Phosphoinositide-3-Kinase (PI3K) 
Phosphoinositide 3-kinase (PI3K)-dependent signalling is involved in a diverse array of 
cellular functions including growth, proliferation, survival, and motility. More recently, 
PI3K has been implicated in the dampening of pro-inflammatory NF-κB signalling in 
response to LPS (281). In a gnobiotic IL-10-/- murine model of infection, inhibition of 
mammalian target of rapamycin complex-1 (mTORC1), a downstream effector of PI3K 
activation, inhibits colitis in mice (282). Contrary to the LPS reports, mTORC1 inhibition 
decreases NF-κB activation although it does not ameliorate disease (71). Blocking 
mTORC1 inhibits production of IL-1β and IL-17, a potent neutrophil chemoattractant, 
leading to a decrease in neutrophil infiltration. In the same model, mTORC1 was shown 
to mediate C. jejuni-induced colitis by regulating NF-κB and pro inflammatory signalling 
(282). In addition, IL-10 production is regulated by the PI3K pathway which 
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antagonises the activation of glycogen synthase kinase 3 (GSK3), a negative regulator 
of IL-10 (283). Currently, the contribution of this pathway to the C. jejuni-induced IL-10 
response remains unknown. 
 
1.4 Hypothesis and Aims 
 
Although our understanding of bacterial-gut immunity is improving, mechanisms 
involved in asympotomatic colonisation versus disease remains limited. To improve our 
understanding of these microbial-host interactions we hypothesised that the structural 
components of common enteric pathogens, such as C. difficile and C. jejuni, facilitate 
immune evasion by engaging inhibitory receptors on innate immune cells. 
In this study we set out to investigate the immunogenic properties of the peptidoglycan 
moiety from C. difficile and the receptors and signalling mechanisms associated with 
those. We also wanted to study the role of bacterial moieties, such as the flagellum and 
LOS, in the immune evasion strategy employed by C. jejuni. Firstly, to better 
understand the way in which C. jejuni induces production of the anti-inflammatory IL-10 
cytokine in human APCs via its flagellum. Secondly, to investigate potential interactions 
between Siglec receptors and C. jejuni and how they may affect the immune response 
to the pathogen.  
	  	  79 
 
 
 
Chapter 2 
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2.1 Peptidoglycan isolation and sonication  
Peptidoglycan (PGN) from WT and an lgt C. difficile 630 isogenic mutant strain was 
extracted by Dr. Johan Peltier as detailed in Peltier et al. (2011) (156). Insoluble PGN 
was suspended in 3 ml sterile water at 5 mg/ml in a 5-ml glass tube and sonicated for 
30mins (3x 10mins cycles with breaks for cooling in between cycles) in an ice-water 
bath with a 1/8 inch microprobe (70-80W output on a Vibra-Cell VCX400, Sonics 
sonicator). The solution was sterilised by heating at 90°C for 30mins and stored in 
solution at 4°C. Sterility was assessed by plating a drop of PGN on a nutrient agar 
plate and incubating at 37°C for 24h. 
 
2.2 Bacterial strains and culture 
2.2.1 C. jejuni 
C. jejuni strains were routinely cultured on blood agar (BA) plates supplemented with 
Campylobacter selective supplement (Oxoid, Hampshire, UK) and 7% (v/v) horse blood 
(TCS Microbiology) under microaerobic conditions at 37°C for 48 hours. The 
hypermotile strain 11168H is a variant of NCTC11168 WT (193); 81-176 is a milk-borne 
outbreak isolate (221). 11168H flagellin (flaA) and capsule (kpsM) isogenic mutants 
and an 81-176 flaA isogenic mutant were obtained from the London School of Hygiene 
and Tropical Medicine Campylobacter Resource Facility 
(http://crf.lshtm.ac.uk/index.htm). 
2.2.1.1 FITC-labelled C. jejuni  
1 x 109 CFU/mL were mixed 1:1 with saturated Fluorescein isothiocyanate (FITC; 
Sigma) and incubated in the dark at room-temperature (RT) for 30mins with gentle 
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agitation. After incubation bacteria were washed three times before resuspension in 
phosphate buffered saline (PBS).  
2.2.1.2 Heat-inactivated C. jejuni 
C. jejuni cultures were harvested, washed and the optical density (OD)  at 600nm was 
adjusted to 0.2 in PBS containing 2 mM MgCl2. Samples were heat inactivated in a 
water bath at 56°C for 45mins. 
 
2.2.1.3 C. jejuni flagella isolation and coupling to beads 
Following growth at 37°C for 48 h, bacteria were harvested and resuspended in PBS. A 
volume of cells equivalent to an OD600 of 20 was resuspended in 1 ml PBS. Cells 
were vortexed vigorously at RT for 30mins to physically dissociate the flagella. The 
suspension was centrifuged at 20,000×g for 10mins at 4°C, the supernatant was 
collected and centrifuged a second time to remove all cellular debris. The resulting 
supernatant was spun at 4,000 g for 13mins in a spin column of 10,000 MWCO 
(molecular weight cut off). For coupling of flagella to beads, 0.5 ml of 2.5% suspension 
of Red Carboxyl-modified Latex fluorescent beads (2 µm; Sigma) were mixed with 200 
µg of purified flagella in 0.4 mg/ml 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) (ThermoScientific, MA, USA), 0.6 mg/ml N-hydroxysulfosuccinimide (NHS) 
(LifeTechnologies, California, USA) solution in 10% morpholino) ethanesulfonic acid 
(MES) buffer (LifeTechnologies) at RT for 2 h according to the manufacturer's protocol. 
Flagella-coupled beads were washed, resuspended in PBS and stored at 4˚C. To 
determine the purity of isolated flagella as well as coating efficiency, coated beads 
were eluted in sodium dodecyl sulfate (SDS) sample buffer and electrophoresed on a 
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polyacrylamide gel. Post electrophoresis, the gel was stained with Coomassie Blue for 
protein detection. 
 
2.2.2 Salmonella Typhimurium  
Bacteria were grown on agar plates (Sigma Aldrich) and kept at 4°C for a maximum of 
two weeks. For long-term storage single colonies were transferred to glycerol stocks 
and stored at −80°C. Prior to the infection, a single colony was grown in 10ml of 
Lysogeny Broth (LB) (Sigma Aldrich) in a 15ml Falcon tube at 37°C.  
 
2.3 Cell line culture 
2.3.1 Cell culture reagents 
All plastic including 6, 12, 24, 96 well plates, 25cm2, 75cm2 tissue culture flasks, 
pipettes and polypropylene coated eppendorf tubes were purchased from Fisher 
Scientific, Leicestershire, UK. Cell culture reagents were purchased from Invitrogen, 
Paisley, UK. 
 
2.3.2 Cell lines 
Chinese hamster ovary (CHO) cells were cultured in complete Ham F12 media, 
supplemented with 10% heat inactivated FCS, 1% Penicillin/Streptomycin (Pen/Strep) 
and Non-Essential Amino Acids (NEAA). Cell monolayers were grown in 75cm2 flasks 
at 37°C, 5% CO2. Confluent cultures were washed with 1x PBS to remove serum, and 
incubated with trypsin/EDTA for a few minutes until complete detachment of the 
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monolayer. Cells were passaged at a 1:10 ratio in compete media. For long term 
storage cells were stored in freezing media (10% DMSO, 40% FCS, in DMEM). 
Human embryonic kidney (HEK293) cells were cultured in DMEM +Glutamax, 
supplemented with 10% FCS, 1% Pen/Strep. Cell monolayers were grown in 75cm2 or 
175cm2 culture flasks at 37°C, 5% CO2. Confluent cultures were washed with 1x PBS 
to remove serum and detached as above. Cells were passaged at a 1:10 ratio in 
compete media. 
Tohoku Hospital Patient-1 (THP-1) cells were cultured in RPMI-1640 + 1% L-Glutamine, 
supplemented with 10% FCS and 1% Pen/Strep. Cells were grown in 25cm2 or 75cm2 
upright culture flasks at 37°C, 5% CO2. Every 3 to 4 days - at approximately 80% 
confluency - cells where collected by centrifugation at 1,500 rpm for 5mins at RT and 
passaged at a 1:10 ratio using complete media. For dTHP-1 differentiation, cells were 
treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA) for 24 h followed by 24h 
incubation in media alone prior to commencement of co-culture studies, 
 
2.3.3 Co-culture studies 
For bacteria – cell co-culture, C. jejuni cultures were harvested, washed and OD600 
adjusted to 1 (=~3x109 cells). 1 x 106/mL PMA-differentiated THP-1 cells (referred as 
dTHP-1 cells hereafter) were cultured in RPMI containing 2 mM L-glutamine and 0.05% 
fetal calf serum (FCS), a day prior to infection with C. jejuni at an multiplicity of infection 
(MOI) 100. After inoculation, cells and bacteria were spun (1500 rpm, 5mins) to 
promote bacterial-cell association. Similar methodology was used for other bacteria. 
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2.4 Primary cell culture 
2.4.1 Isolation of peripheral blood-derived monocytes  
Blood from healthy donors (with appropriate consent) was collected in heparin-coated 
Falcon tubes and mixed 1:1 with RPMI-1640 media and then layered in falcon tubes 
containing Lymphoprep medium on a 3:1 ratio. Following centrifugation at 2,200 rpm 
for 25mins, peripheral blood mononuclear cells (PBMCs) were collected using a 
Pasteur pipette. The cells were washed twice in RPMI media, followed by a wash in 
MACS buffer (PBS + 2% FBS + 1 mM EDTA) and finally resuspended in 400μl of 
MACS buffer. For positive selection of monocytes, CD14 MACS MicroBeads were 
added, mixed thoroughly and incubated at 4°C for 45mins. Cells were then washed in 
excess MACS buffer and ran through a MACS LS Column attached to a MidiMACS 
Separator from Miltenyi Biotech (Bergisch Gladbach, Germany). The column was 
washed three times and then removed from the separator. CD14 positive monocytes 
were collected in a new collection tube by pipetting 5ml of MACS buffer into the column 
and applying a plunger. Alternatively, isolated PBMCs were cultured for 2h prior to 
selection of adherent monocytes. The cells were counted and platted in 6-well culture 
dishes in RPMI media supplemented with 10%FCS, 1% Pen/Strep.  
 
2.4.2 In vitro differentiation of PBMCs into M1- and M2-macrophages 
PBMC-derived monocytes were cultured in complete RPMI with 20ng/ml human GM-
CSF or human M-CSF (Sigma-Aldrich, St. Louis, MO) to induce M1- or M2-type 
macrophage differentiation respectively for 5 days. Fresh differentiation media was 
added at day 3 and cells rested in complete RPMI for another 2 days. 
 
	  85	  
2.5 Silencing of NOD expression by siRNA 
PBMCs were transfected with scramble siRNA (sc-108066), human NOD1 siRNA (sc-
37279) or human NOD2 siRNA (sc-43973) (Santa Cruz Biotechnology) using the 
Amaxa Nucleofector (Lonza). Briefly, PBMCs (1×106) were resuspended in 100μl of 
nucleofector solution followed by the addition of 8μg/mL of scramble, NOD1 or NOD2 
siRNA, incubated at RT for 3mins, and nucleofected according to the manufacturer’s 
instructions. PBMCs were then seeded on 12-well plates containing 1ml of RPMI 
supplemented with 10% autologous serum and incubated for 2 h at 37°C and 5% CO2. 
M-CSF or GM-CSF were omitted so as not to influence the transcriptional profile further. 
After 2 h, adherent cells were washed and repleted with warm RPMI containing 20% 
autologous serum for 72 h. Transfected cells were used for subsequent experiments,  
 
2.6 Lentiviral production 
2.6.1 Plasmids 
The eGFP pCMV plasmid was provided by Dr Holly Stephenson, IIIP program, Institute 
of Child Health. The NF-κB-luciferase SV40 plasmid was a kind gift from Dr David 
Escors, Infection and Immunity, University College London. Human WT NOD1-FLAG 
and human WT NOD2-FLAG pCMV vector plasmids were a kind gift from Dr Stephen E 
Girardin, University of Toronto, Canada. pRL Renilla luciferase reporter plasmid was 
purchased from Promega. Human Siglec-5 and human Siglec-9 pCMV6 cDNA clones 
were purchased from Origene, Rockville, USA. 
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2.6.2 Bacterial transformation 
Competent E. coli DH5α bacteria were mixed with 500ng of plasmid DNA and 
incubated on ice for 30mins. Application of heat shock at 42°C for 45 sec, followed by a 
further 2mins on ice was done to promote DNA uptake. Transformed bacteria were 
allowed to recover by incubation at 37°C in 100μl of sterile LB broth for 1 h. Cultures 
were streaked on an agar plate with appropriate antibiotic (Table 2.1) and incubated 
overnight at 37°C to enable single colony growth.  
 
Table 2.1 Plasmids and antibiotics used in transformation 
Plasmid Antibiotic Antibiotic Conc. (/ml) 
NF-κB Ampicillin 100μg/ml 
NOD1 Ampicillin 100μg/ml 
NOD2 Kanamycin 50μg/ml 
 
2.6.3 Isolation and purification of plasmid DNA 
QIAprep spin midi-prep kits (Qiagen, California, USA) were used and plasmid DNA was 
isolated according to the manufacturer’s instructions. DNA was eluted in 50μl distilled 
water. 
2.6.4 Transformation of packaging cell line 
The transfection mixture comprised of 7μg vector expressing construct (pHR_SIN), 
3.5μg pMD.G2 (envelope genes helper vector) and 3.5μg pCMV-dR8.74 (gag/pol 
packaging genes helper vector) added to 1ml Opti-MEM media (Gibco) per flask. This 
was filter-sterilised (0.22μm filter) and added to 2ml Opti-MEM with 60μl Fugene 6 
Transfection Reagent (Promega). The transfection mixture was incubated at RT for 
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15mins. 3ml were then added to a 175cm2 flask seeded with 2x106 HEK293 cells in 
DMEM 24h in advance. 
2.6.5 Virus harvesting and titration 
HEK293 culture media was collected every 24h for three days, filtered and 
ultracentrifuged at 23,000 rpm for 2 h. The virus pellet was resuspended in 100μl PBS 
and aliquots stored at −80°C. 
2.7 Cell transduction 
2.7.1 Lentivector transduction of NF-κB reporter plasmid  
THP-1 cells were transduced with lentiviruses (MOI 10) containing an NF-κB-luciferase 
reporter plasmid in the presence of 5 μg/mL protamine sulphate (Sigma Aldrich) and 
cultured for an additional 2 days. 1 x 105 transduced THP-1 cells (100μL RPMI, 10% 
FCS) were differentiated in the presence of 10ng/ml PMA for 24 h followed by 24h in 
media alone. dTHP-1 cells were stimulated with iE-DAP, MDP or PGN for the indicated 
times. Cells were equilibrated to RT, 100 μL Bright-Glo (Promega, Madison, WI, USA) 
reagent was added for 2mins before quantification of luciferase activity using a 
FluoSTAR Optima, (BMG Labtech, Germany) microplate reader.  
 
2.7.2 NF-κB luciferase reporter assay 
Dual NF-κB luciferase assay was carried out using Dual-Luciferase Reporter Assay 
System (Promega) according to the manufactures protocol. Briefly, cells were seeded 
in 24-well tissue culture plates one day before to ~70% confluence. Transfection mixes 
were prepared with 75ng NF-κΒ-luciferase plasmid, 30ng NOD1 or NOD2 plasmid and 
50ng Renilla luciferase vector (the latter for normalization of transfection efficiency). All 
mixes were normalized to 300ng DNA per well in 60μl using an empty pcDNA3 
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expression vector.   Polyethylenimine was added at 3μl per 1μg DNA ratio and the mix 
incubated at RT for 20mins before adding 0.7ml of DMEM. After 2 h, more media was 
added to a total volume of 3ml. 12 h after transfection, fresh media containing NOD 
ligands were added. After 8 h, media was aspirated, 100μl of lysis buffer was added 
and plates rotated gently for 15mins. The lysate was transferred onto white CELLSTAR 
microplates (Greiner Bio-One, Germany) and luciferase activity analysed using a 
FluoSTAR Optima, (BMG Labtech, Germany) microplate reader. 
2.8 Bacterial infection assays 
2.8.1 Gentamicin Protection Assay  
2 x 105 dTHP-1 cells (RPMI/ 2 mM L-glutamine/ 10% FCS) were infected with WT and 
ΔFlaA C. jejuni 11168 MOI 100 for 4 h at 37ºC Post-infection, cells were washed twice 
with sterile PBS, followed by addition of RPMI containing 150 μg/mL gentamicin and 
incubation for a further 2 h to kill extracellular bacteria. Following washing, cells were 
lysed in 0.5 mL 0.1% Triton-X 100 (Sigma) in PBS for 5mins prior to serial dilution and 
plating. Colony forming units (CFU) were quantified. 
 
2.8.2 Siglec-CHO adhesion assay 
Human Siglec-5 or Siglec-9 clone plasmid (Origene) was ligated into an expression 
pDUAL lentivector plasmid; viral propagation was conducted in a HEK293T packaging 
cell-line as described above. CHO cells were transduced (MOI 10 or 100) and 
expression assessed by flow cytometry. 1x106 cells/mL were resuspended in F12 
media containing 0.5% FCS. 300 μL of the re-suspension was co-cultured with FITC-
labelled C. jejuni (MOI 100, 2 h, 4ºC to inhibit phagocytosis) in sterile polystyrene tubes 
with gentle rotation. For competition binding, cells were pretreated with 100ng C. jejuni
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lipooligosacchride (LOS) for 1.5 h prior to co-culture with bacteria. After washing, cells 
were fixed in 4% paraformaldehyde (PFA). Bacterial adherence was assessed by flow 
cytometry using a FACSCalibur (BD Biosciences). 
 
2.8.3 Siglec-10 overexpressing THP-1 cells 
THP-1 cells were transduced as above. 2.5 x 105 /ml dTHP-1 cells (monocytic THP-1 
cells differentiated in the presence of 50ng/ml PMA for 24h followed by 24h in media 
alone) were infected with C. jejuni strains at an MOI of 100. Cytokines were assessed 
24h post-infection by ELISA (eBioscience).  
 
2.9 Polymerase Chain Reaction 
2.9.1 RNA extraction and cDNA synthesis 
Cells pellets were lysed in Trizol Reagent (Invitrogen) (1ml per 1x106 cells). 
Chloroform (200μl) was added and samples were left to stand for 5mins at RT, then 
centrifuged at 12,000 rpm at 4oC for 15mins. The aqueous phase of the separated 
mixture, containing the RNA, was collected and ice-cold isopropanol was added at a 
1:1 ratio. The solution was left to stand for 10mins at RT, next RNA was pelleted by 
centrifugation at 12,000 rpm for 10mins at 4ºC. The pellet was washed twice in 75% 
ethanol, air-dried and re-suspended in 27μl nuclease-free water. Double-stranded 
DNA contamination in the samples was removed by using the Ambion TURBO DNA-
free Kit (Invitrogen) according to the manufacturer’s instructions. RNA concentration 
was measured by a Nanodrop reader (Thermo Scientific). RNA (2μg per reaction) 
was incubated at 65ºC for 5mins with oligo (dT1) and random (hexamer) primers 
(1μg per reaction) in PCR tubes and then chilled on ice for 2mins. For the reverse 
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transcription reaction, the following were added to each PCR tube: 4μl Bioscript Red 
buffer (5x), 10mM dNTPs, 1.5μl nuclease-free water, 0.5μl Bioscript enzyme in 10μl 
total volume and the reaction was carried out in a MyiQ Thermocycler (Biorad) with 
the following settings: 
 
  
   
Step Temperature (ºC) Time 
Primer extension 25 10mins 
Reverse transcription 42 1hour 
Inactivation 75 10mins 
 
2.9.2 Semiquantitative-PCR 
Primers were reconstituted in MilliQ water 100pmol final concentration and stored at 
−20ºC. Working solutions of 5 pmol/μl concentration were prepared and stored at 4ºC. 
For each reaction 5μl cDNA was mixed with 25μl Biomix Red 2x [1.5μM Mg2+], 500nM 
primer mix and 15μl MilliQ water. Polymerase Chain Reaction (PCR) was carried out in 
a MyiQ Thermocycler (Biorad) as follows: initial denaturation 95ºC for 10 min (1 cycle); 
denaturation 95ºC for 30 sec, annealing 60ºC for 1 min, extension 72ºC for 45 sec (35 
cycles), final extension 72ºC for 10mins. Samples were analysed by electrophoresis in 
a 2% agarose gel using Hyperladder IV (Bioline). Primers utilised: NOD1 fwd 
TCCAAAGCCAAACAGAAACTC, NOD1 rev CAGCATCCAGATGAACGTG, NOD2 fwd 
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CATGTGCTGCTACGTGTTCTC, NOD2 rev CCTGCCACAATTGAAGAGGTG, β-actin 
fwd CGCCCAGACTTCTGCATGG, β-actin rev GGATGACCTGACTCACAAACT. 
 
2.9.3 Quantitative Real Time-PCR (QRT-PCR) 
QRT-PCR reaction master mixes contained 10 μL SYBR Green (Invitrogen) and 5 pmol 
of forward and reverse primer. PCR was performed in duplicate in a Rotor-Gene 6000 
machine (Qiagen) as follows: initial denaturation 95ºC for 10mins (1 cycle); 
denaturation 95ºC for 15 sec, annealing 58ºC for 30 sec, extension 72ºC for 30 sec (40 
cycles). Rotor-Gene (Qiagen) software was used for data analysis. Primers utilized: IL-
10 fwd GGTTGCCAAGCCTTATCGGA, IL-10 rev ACCTGCTCCACTGCCTTGCT, 
Polr2a fwd CGCCCAGACTTCTGCATGG, Polr2a rev 
GGATGACCTGACTCACAAACTG. 
 
2.10 Protein analysis 
2.10.1 Enzyme-linked immunosorbent assay 
eBioscience Ready-Set-Go Elisa Kits were used according to the manufacturer’s 
instructions and the procedure carried out in Maxisorp ELISA plates (NUNC). Samples 
were analysed in duplicate and the results obtained using a 96-well microplate reader 
(Bio-Rad). GraphPad Prism 5 and Microsoft Excel 2010 were used for graphical 
representation and statistics. 
2.10.2 Recombinant Siglec Elisa 
Live C. jejuni were harvested in PBS and OD600 adjusted to 0.2. 100μL of each 
bacterial strain was plated in triplicate in 96-well Maxisorp ELISA plates (NUNC Inc., 
the Netherlands). Plates were left open overnight at 37°C to allow bacterial adherence, 
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then washed three times in PBS/Tween (0.05%) and blocked in 1.5% milk powder for 2 
h at RT. Recombinant Siglec-5-Fc or Siglec-9-Fc chimera (R&D Systems) were pre-
complexed with peroxidase-conjugated anti-human IgG Ab (1:3000; Sigma) in 0.05% 
normal goat serum for 1 h with rotation. After washing, 100μL precomplexed Siglec-5-
Fc or Siglec-9-Fc was added per well, the plates were incubated for 2 h at RT, washed 
four times PBS/Tween (0.05%) and developed using 100μL tetramethylbenzidine 
substrate (Biolegend) per well. After an appropriate incubation time (approx. 5 min), the 
reaction was stopped by adding 100μL of 2M H2SO4 per well and signal intensity 
measured spectrophotometrically at 450nm in a 96-well microplate reader (Bio-Rad, 
the Netherlands).  
2.10.3 Western Blotting 
Cells were lysed in ice-cold lysis buffer (300μl per 1x106 cells) for 10mins. Protein 
concentration was assessed by a Bradford assay using Bradford Reagent (Sigma 
Aldrich). The manufacturer’s protocol was modified for a 96-well plate assay and 
sample fluorescence measured using a 96-well microplate reader (Bio-Rad). After 
adjustment of protein concentration, an equal volume of 2x loading buffer was added 
and lysates were heated at 95°C for 3mins. Lysates were vortexed briefly and 
centrifuged to pellet debris. Cell lysates were separated on 10 − 12% gels.  
Resolving gel buffer (4x) was prepared by dissolving 181.5 g of Trizma base in 850 mL 
of H2O (pH 8.8) and Stacking gel buffer (4x) by dissolving 60.5 g of Trizma base in 850 
mL of H2O (pH 6.8) (for details, see Table 2.2). 30μl of each sample was loaded per 
well along with SeeBlue Plus2 Pre-Stained Standard ladder (Invitrogen). Gels were run 
at 120V for 1.5 h in the appropriate buffer (see Table 2.3). Blots were transferred onto 
Hyperbond-C membrane at 200mA for 70mins with the apparatus on ice to avoid 
overheating and efficient transfer. Peroxidase activity was detected using Amersham 
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ECL Western Blotting Advance Detection Kit (GE Healthcare). Membranes were 
blocked using 5% skimmed milk in 1x PBS for 1h at RT. Primary antibodies (Table 2.4) 
were used at 1:1000 dilution in 5% milk with 0.1% Tween 20 in PBS. HRP conjugated 
secondary antibodies were used at 1:1000 (anti-mouse) and 1:2000 (anti-rabbit) 
dilution.  
Membrane was washed 3x with 0.1% Tween 20-PBS for 5mins each, the blot was 
incubated with secondary antibody (Polyclonal rabbit anti-goat Ig/HRP; Dako, 
Denmark; 1:2000) overnight at 4°C on a shaker. Blots were washed 3x with 0.1% 
Tween 20-PBS for 10mins. Toxins were detected using an enhanced 
chemiluminescence (ECL) reaction (Amersham ECL Western blotting detection reagent, 
GE Healthcare) followed by autoradiography film (Film CL-Xposure, Thermo Scientific, 
Loughborough, UK). The membranes were developed with an automated X-ray film 
developer (Autorad).  
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Table 2.2 Agarose gel for Western Blotting 
Reagent Resolving Gel (12%) Stacking gel (4%) 
H2O 3.75 ml 6 ml 
Acrylamide 30% 6 ml 1.5 ml 
Resolving buffer 3.75 ml  
Stacking buffer  2.5 ml 
Glycerol 1.5 ml  
*APS 50μl 50μl 
**T.E.M.E.D 10μl 10μl 
*APS = Ammonium Persulphate 
**T.E.M.E.D = Tetramethylethylenediamine  
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Table 2.3 Buffers used in Western blotting 
Buffer Contents 
Blocking buffer 5% skimmed milk in PBS + 0.1% Tween 
Loading buffer 
Laemmli buffer: 125mM Tris HCl, 4% SDS, 20% 
glycerol, 10% 2-mercaptoethanol, 0.004% 
bromophenol blue. 
Stripping buffer Re-blot Plus Strong (Millipore) 
Running buffer (10x) 
Trizma Base (30.3g) + Glycine, 98% (144.1g) + 
SDS (10g) made up to 1L in H2O 
Transfer Buffer (10x) 
Trizma Base (30.3g) + Glycine, 98% (144.1g) made 
up to 1L in H2O 
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  Table 2.4 Antibodies used in immunohistochemistry 
Primary antibody Clone Manufacturer 
CD14 M5E2 Biolegend 
CD68 Y1/82a Biolegend 
ASC aa2-27 LSBio 
NOD1 ab22143 Abcam 
NOD2 2D9 eBioscience 
ERK1/2 137/F5 Cell Signalling 
ERK1/2 (total) 9102 Cell Signalling 
JNK 9552 Cell Signalling 
p38 D13E1 Cell Signalling 
EGF-R pY1173 Alexa eBioscience 
SHP-2 pY542 Alexa eBioscience 
β-actin AC-15 Invitrogen 
Siglec-5 194128 R&D Systems 
Siglec-9 191240 R&D Systems 
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2.10.4 Phopho-array analysis 
Protein phosphorylation analysis was carried out using the Human Phospho-
Immunoreceptor Array and the Human Phospho-Kinase Array kits (R&D Systems) 
according to the manufacturer’s instructions. Pixel density analysis was performed 
using Gimp software.  
 
2.10.5 Immunofluorescence  
 A 13-mm round glass coverslip was aseptically transferred into a well of a 24-well 
tissue culture plate. Approximately 1 x 104 cells were plated onto each coverslip. After 
incubation with media containing the appropriate stimuli, media was removed and the 
cells rinsed once in 1ml of PBS. Cells were fixed for 15mins in 4% PFA at RT prior to 
performing three 5mins washes with PBS with mild shaking. The coverslips were 
incubated with combined permeabilizing and blocking solution (3% BSA, 10% FBS and 
0.2% Triton-x100 in PBS) for 1.5h at RT. Coverslips containing permeabilized and 
blocked cells were transferred to a light-protected chamber where solution of primary 
antibodies (see Table 2.4) was added to each (50 μl per coverslip) and incubated for 3-
3.5h at RT or overnight at 4°C. Subsequently coverslips were transferred to a new 24-
well tissue culture plate containing PBS to be washed as above. 50μl of secondary 
antibody solution was added to each coverslip and incubated for 1h at RT, followed by 
another washing step. Coverslips were allowed to air dry before being applied upside 
down facing a drop of Vectashield® mounting agent on a microscope glass slide. 
Round coverslips were sealed around the edge using a nail varnish solution. Slides 
were analysed using a Zeiss Axiovert 135 microscope or a Zeiss LSM 710 (Carl Zeiss, 
Germany) inverted confocal microscope. Microscopy images were analysed using 
ImageJ (NIH, USA).  
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2.10.6 Flow-cytometry 
0.5-1x106 cells were aliquoted into each assay tube by volume. Each tube was washed 
twice in 2 ml FACS buffer. Cells were resuspended in 100 μl FACS buffer (PBS + 0.5% 
BSA) and non-specific binding blocked by incubation for 10mins at RT. For intracellular 
staining, cells were permeabilized by adding 1ml ice-cold 90% methanol slowly while 
gently vortexing. After washing, cells were fixed in 4% PFA for 10mins at RT and 
washed again twice. Samples were incubated with fluorochrome-conjugated primary 
antibody at the recommended dilution for 1 h at RT, followed by washing in 2ml FACS 
buffer. Cells were resuspended in PBS and analyzed on a FACSCalibur (BD 
Biosciences). Flow cytometry data were analysed in FlowJo version 7.  
 
2.10.7 Caspase-1 assay 
Caspase-1 activity was measured with a Green FLICA Caspase-1 Assay Kit 
(Immunochemistry Technologies, Minnesota, USA) according to the instructions 
provided by the manufacturer. Fluorescent signal was measured in a FACSCalibur (BD 
Biosciences).  
 
2.11 Statistical analysis 
Data were analysed using GraphPad Prism version 5 (San Diego, USA). Statistical 
significance was calculated by the paired Student’s t test. Non parametric t-test (Mann-
Whitney) was performed to compare groups in non-parametric data. Grouped analysis 
was performed by two-way ANOVA and Bonferroni post-test to compare replicate 
means by row and compare each column to all the other columns. Data considered 
significant only if probability was p<0.05.  
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Chapter 3 
Pattern recognition receptor-
mediated sensing of  
C. difficile peptidoglycan 
 100 
3.1 Introduction 
Peptidoglycan (PGN) is the major component of the Gram-positive as well as a minor 
component of the Gram-negative bacterial cell wall; crucial for maintaining the 
structural integrity of the cell membrane, as well as conferring resistance to antibiotics 
(148). Emerging evidence suggests that the role of PGN is multifaceted. It not only is 
an important structural entity but it is also a crucial participant in host-pathogen 
interactions that determine host health and disease status. This paradigm has emerged 
with the discovery of immune cell receptors that sense PGN-derived motifs(150). 
Conserved microbial structures, such as PGN, referred to as MAMPs are recognized 
by cellular PRRs that are present on professional APCs such as DCs and 
macrophages. The two major families of PRRs are the cell surface and endosomal 
TLRs and the cytoplasmic NLRs (18). Early studies identified TLR2, a member of the 
TLR family of PRRs, as the receptor for PGN (25). However, further investigations 
employing a lipoprotein negative isogenic mutant of Staphylococcus aureus revealed 
that it is the surface lipoproteins in the Gram-positive cell wall, and not the lipotechoic 
acid or PGN, that activate TLR2 (28),(29). Studies suggesting that lipoproteins from 
Gram-positive bacteria are indeed TLR2 ligands (284), and key activators of innate 
immunity have been described (285),(286). 
The clostridia genus comprises ~40% of the human microbiome and as yet its 
interactions with the gastrointestinal (GI) mucosal immune system are not understood. 
A member of this genus, Clostridium difficile is an emerging enteropathogen and the 
leading cause of nosocomial and community-acquired infections in the elderly 
worldwide. To date, the majority of studies investigating C. difficile-host interactions 
have focused on the role of bacterial toxins on C. difficile associated gastroenteritis and 
diseases. At present very little is known of how C. difficle PAMPs interact with the 
innate immune system (138). Herein, PGN moieties from wild-type (WT) C. difficle 630 
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and its lipoprotein negative (Δlgt) mutant strain were employed to investigate their 
potential interactions with the human host. As TLR signalling is central to the innate 
immune response, we hypothesised that TLR activation by C. difficile lipoproteins may 
contribute to the immune outcome in response to this infection.  
The only receptors for bacterial PGN identified to date are the cytoplasmic NOD 
receptors of the NLR family. Each receptor recognises a distinct PGN moiety; NOD2 
recognises muramyl dipeptide (MDP), a PGN-derived muropeptide moiety common to 
the cell wall of all Gram-positive and Gram-negative bacteria (40), while NOD1 
recognises diaminopoimelic acid (DAP), a component of Gram-negative and some 
Gram-positive bacteria (287),(46). NOD1 was recently shown to mediate C. difficile 
recognition, as well as the immune response to the pathogen in a mouse model (77), 
where NOD1-/- mice exhibited increased inflammation and lethality in response to  C. 
difficiile infection. However, the study did not identify the specific bacterial ligands 
involved in this interaction. In 2011, the molecular structure of the vegetative cell wall 
was characterised by Peltier et al. (156). The authors found C. difficile PGN to possess 
a DAP residue at the third amino acid position of the peptide polymer cross-linking the 
sugar backbone. Although DAP is commonly found in Gram-negative PGN where 
Gram-positive bacteria contain a lysine residue, DAP-type PGN has been reported on 
other Gram-positive bacilli (288),(289). This unique characteristic may hold the key to C. 
difficile recognition by NOD1 and the consequent immune response. NOD activation by 
PGN motifs drives the induction of NF-κΒ, a key transcriptional regulator of 
inflammatory (pro- and anti) signalling, resulting in chemokine (e.g. IL-8) and cytokine 
(e.g. TNFα and IL-10) secretion (290).  
 In addition to the NOD family, MDP has been shown to activate two other NLR 
proteins: NALP1 and NALP3, although evidence remains limited. Upon activation, 
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these NLRs can lead to the formation of ‘Inflammasome’ complexes, large molecular 
assemblies that promote the maturation of IL-1β and IL-18 via caspase-1 activation 
and also trigger pyroptosis, a form of inflammatory cell-death (291). NALP3 
inflammasome activation has been reported in response to MDP (99),(292) and 
lipoproteins from S. aureus (293). Another study reported that MDP-activated NOD2 
interacts with and activates caspase-1, a component of the NALP-1 inflammasome (95). 
Activation of the Inflammasome by C. difficile toxins is now well-established (294),(122). 
At present the potential role of other C. difficile bacterial components, including PGN 
and lipoproteins in mediating inflammasome activation has not been investigated. 
 
In this chapter we aimed to:  
1. To investigate the effect of C. difficile cell wall lipoproteins on TLR2 activation. 
2. To establish the potential role of the NOD receptors in C. difficile PGN recognition. 
3. To study C. difficile PGN-mediated effects on macrophage signalling pathways.   
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3.2 Results 
3.2.1 C. difficile PGN-associated lipoproteins activate TLR2 
For every part of this study both cell lines and primary cells were employed sequentially. 
Initially, the epithelial cell line HEK293, which is often utilised in PRR signalling studies 
as it lacks native expression of these receptors, followed by a cell line model of human 
macrophages as well as primary macrophages from healthy donors. The PGN moieties 
from WT C. difficile 630 strain and its lgt isogenic mutant were isolated and kindly 
provided by Dr J. Peltier (Imperial College, London). Post-extraction, freeze-drying 
lyophilisation led to PGN aggregation which required ultrasonication for re-suspension. 
Ultrasonication aimed to promote breakdown of insoluble PGN into releasing soluble 
fragments of high molecular weight. Soluble fragments must contain ligands for PRRs 
such as TLRs and NLRs. Firstly, it was important to establish the effect of sonication on 
PRR stimulation. Transfected HEK293 cells stably expressing TLR2, the receptor for 
bacterial PGN polymers were employed in this series of experiments. PGN was 
sonicated according to the most widely adopted methodology (295). PGN from the 
Gram-positive bacterium S. aureus was studied in parallel. S. aureus PGN has been 
studied extensively and is commercially available as an insoluble preparation. It is also 
a known trigger for TLR2-mediated HEK293 cell activation and therefore was 
considered an appropriate control (296),(28). TLR2 activation was assessed by 
measuring IL-8 chemokine, one of the main epithelial chemokine mediators, in the 
supernatants. C. difficile and S. aureus PGN preparations were sonicated for 15 and 
30mins respectively prior to co-culture with untransfected and TLR2-transfected 
HEK293 cells. 24h post-stimulation, IL-8 protein was measured in supernatants by 
ELISA (Figure 3.1). Unsonicated PGN mediated an IL-8 response of ~ 250 and 
450pg/ml respectively. Sonication had a marked effect on TLR2  
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Figure 3.1. Sonication increases peptigoglycan-mediated TLR2 activation.  
C. difficile peptidoglycan (PGN) polymer was sonicated for 15 and 30mins. TLR2-
transfected HEK293 cells were stimulated with untreated and treated PGN (1mg/ml). 
24h post-stimulatiion, IL-8 was measured in the supernatant by ELISA. Values 
represent mean ± SEM from three independent experiments performed in duplicate. 
Statistical analysis by paired t-test (***P<0.001). 
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engagement as a statistically significant increase in IL-8 was observed in response to 
C. difficile PGN 30mins post-sonication (P<0.01). These experiments highlighted the 
requirement for PGN sonication prior to co-cultures. Based on this data, PGN 
preparations were routinely sonicated for 30mins prior to usage. 
Next, we wanted to establish dose and time-dependent effects of PGN on host 
responses. Untransfected and TLR2-transfected HEK293 cells were stimulated with 
sonicated PGN at varying dosage at 6 and 24h. A dose-dependent increase in IL-8 
protein was recorded in response to C. difficile PGN. At 6h, results were comparable 
between PGN from both species. Secreted IL-8 could be detected as early as 6h in 
response to 0.1μg/ml of PGN, with a dose-dependent increase in cells treated with 
1μg/ml (Figure 3.2A). An increase in concentration from 1 to 10μg/ml showed a modest 
increase, most likely indicating near saturation of TLR2 signalling. The 1μg/ml dose 
was therefore considered to be most appropriate for further studies in HEK293 cells. IL-
8 levels increased further 24h post-stimulation (Figure 3.2B). It was interesting to note 
that C. difficile PGN was a significantly more potent inducer of IL-8 in comparison to S. 
aureus PGN (P<0.02). 
The capacity of C. difficile PGN to activate TLR2, as others have demonstrated for 
PGN from other bacteria was examined next. At the same time, we wanted to test the 
purity of our preparation for the presence of other TLR-activating contaminants. A 
range of TLR-transfected HEK293 cells were treated with our PGN preparations. As 
expected, only TLR2 and TLR2/6 (HEK293 cells became activated (Figure 3.3B and C), 
showing statistically significant increase in in IL-8 secretion both after 6h (TLR2; 
P=0.0004, TLR2/6; P=0.0011) and 24h (TLR2; P=0.0013, TLR2/6; P=0.0027). In 
contrast, WT, TLR4- and TLR5-transfected HEK293 cells were unresponsive to WT C. 
difficile PGN (Figure 3.3A, D and E) indicating the absence of ligands for these  
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 Figure 3.2. Dose- and time-dependent effects of C. difficile PGN on TLR2 
activation.  
TLR2-, CD14-transfected HEK293 cells were stimulated with PGN from C. difficile or S. 
aureus at increasing concentrations (0.1, 1 and 10μg/ml) for (A) 6h and (B) 24h. 
Stimulation with 10ng/ml lipopolysaccharide (LPS) from E. coli served as a negative 
control. IL-8 was measured in the supernatant by ELISA. Values represent mean ± 
SEM from three independent experiments performed in duplicate. Statistical analysis 
by paired t-test (**P<0.01). 
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Figure 3.3. C. difficile PGN activates TLR2 and TLR2/6.  
(A) WT and (B-E) TLR-specific HEK293 cells were treated with 1μg/ml C. difficile WT 
PGN for 6 and 24h. 10ng/ml E. coli LPS, 1μg/ml S.aureus PGN or 1μg/ml Salmonella 
typhimurim flagellin stimulation served as positive controls as indicated. IL-8 was 
measured in the supernatant by ELISA. Values represent mean ± SEM from three 
independent experiments analysed in duplicate. 
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Figure 3.3. C. difficile PGN activates TLR2 and TLR2/6 (cont.).  
(A) WT and (B-E) TLR-specific HEK293 cells were treated with 1μg/ml C. difficile WT 
or C. difficile lgt PGN for 6 and 24h. 10ng/ml E. coli LPS, 1μg/ml S.aureus PGN or 
1μg/ml Salmonella typhimurim flagellin stimulation served as positive controls as 
indicated. IL-8 was measured in the supernatant by ELISA. Values represent mean ± 
SEM from three independent experiments analysed in duplicate. 
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receptors. The TLR2/6 HEK293 cells express a heterodimeric receptor composed of 
TLR2 and TLR6 monomers that is nevertheless able to recognise TLR2 ligands and as 
a result activate the same downstream signalling effectors(31). 
Next, we looked at the effect of C. difficile PGN treatment on the key signalling 
mediator downstream of TLRs; the NF-κB transcription factor. For studies in PGN-
mediated signalling, the widely used monocytic THP-1 cell line was used. The cell line 
was established from a patient with acute monocytic leukaemia in Japan(297). 
Previous studies in THP-1 cells have shown expression of functional TLRs and 
responsiveness to PGN(290). However, these cells occupy an early time point along 
the monocytic cell lineage; meaning a host of receptors involved in immune 
surveillance are expressed either at low levels or not at all. To create a better model of 
mature APCs, the cells are treated with PMA in order to induce differentiation into a 
macrophage-like phenotype (differentiated THP-1; dTHP-1) (234). To confirm the 
adoption of a macrophage-like phenotype following PMA treatment, cells were 
immunostained for the monocytic marker CD14 and the macrophage marker 
CD86(298). Analysis of dTHP-1 cells by flow-cytometry showed down-regulation of 
CD14, while CD86 was up-regulated (Figure 3.4), which is consistent with the 
maturation of primary monocytes towards the macrophage lineage(299) and, therefore, 
provides an appropriate model for our studies. A reporter cell line for NF-κB 
transcription activity was constructed using the THP-1 cell line. THP-1 cells were stably 
transduced with a plasmid carrying the NF-κB response element that drives the 
transcription of the luciferase reporter gene and intracellular luciferase levels quantified 
using a substrate of the enzyme. Again, PGN from S. aureus, known to activate NF-κB 
amongst other transcription factors(290), was used as positive control. Treatment of 
dTHP-1 cells with PGN led to a dose-dependent increase in NF-κB-mediated 
transcription (Figure 3.5). This was similar in cells treated with both PGN preparations  
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Figure 3.4. Phorbol 12-myristate 13-acetate (PMA)-treatment induces 
differentiation of monocytic -1 cells to macrophage-like phenotype.  
Monocytic THP-1 cells were treated with 10ng/ml phorbol 12-myristate 13-acetate 
(PMA) for 24h followed by culture in complete RPMI for 24h. 48h after treatment, THP-
1 (black line) and PMA-treated dTHP-1 (solid grey line) cells were stained with 
conjugated antibodies against the CD14 monocytic and the CD68 macrophage marker 
or isotype control (dotted line) and analysed by flow cytometry. Histograms are 
representative of three independent experiments performed in duplicate. 
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 Figure 3.5. C. difficile PGN induces NF-κB activation.  
Differentiated THP-1 cells (dTHP-1 cells) were transduced with NF-κB-firefly luciferase 
reporter and stimulated with 1 and 10μg/ml C. difficile or S. aureus PGN for (A) 6 and 
(B) 24h. Stimulation with 10ng/ml LPS from E. coli served as a positive control. 
Luciferase activity was determined by spectrophotometry (450 nm) (Values represent 
mean ± SEM from three independent experiments performed in duplicate). 
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for 6h (Figure 3.5A), but higher in those treated with C. difficile PGN after 24h (Figure 
3.5B). As discussed earlier, TLR2 and NF-κB activation is mediated by lipoproteins 
found in cell wall heteropolymers rather than PGN (30). To establish whether 
lipoproteins in our preparation were the inducers of TLR2-mediated IL-8 secretion, a 
PGN preparation from the Δlgt C. difficile mutant lacking the lipoproteins was used. 
Treatment with WT but not lgt C. difficile PGN led to a TLR2 and TLR2/6-mediated IL-8 
response (Figure 3.6), conclusively showing that lipoproteins are the TLR2 ligands 
present in C. difficile PGN. NF-κB induction was investigated using the NF-κB reporter 
cell line described earlier and was found to be significantly lower in lgt compared to WT 
C. difficile PGN-treated cells 4h post-stimulation (P=0.0195) (Figure 3.7). Between 6 
and 24h post-stimulation no difference was noted between WT and lgt PGN indicating 
the effect of lgt–mediated signalling is an early event.  
 
3.2.2 NOD-mediated recognition of C. difficile PGN 
The evidence of TLR2-independent NF-κB activation led us to hypothesise that C. 
difficile PGN is recognized by other PRRs with the NOD proteins being the strongest 
candidates. To investigate the sensing of C. difficile PGN by these receptors, HEK293 
cells were transiently transfected with plasmids expressing NOD1 or NOD2 together 
with an NF-κB-firefly luciferase and renilla luciferase reporter plasmid. HEK293 cells 
were cultured in transfection media for 4h, before being stimulated with 10μg/ml PGN 
for 16h. As a positive control, NOD1- and NOD2-transfected cells were treated with 
10μg/ml iE-DAP or MDP respectively. At the end of the experiment, the cells were 
gently lysed by passive shaking and cell lysates transferred to a 96-well plate. Using an 
optic luminometer with injection capability, the substrates for firefly and renilla 
luciferase were introduced in the samples in succession. The light released from each  
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 Figure 3.6. C. difficile cell wall lipoproteins activate TLR2.  
(A) WT, (B) TLR2- and (C) TLR2/6-specific HEK293 cells were treated with 1μg/ml C. 
difficile WT or C. difficile lgt PGN for 6 and 24h. IL-8 was measured in the supernatant 
by ELISA. Values represent mean ± SEM from three independent experiments 
analysed in duplicate. Statistical analysis by paired t-test (**P<0.005, ***P<0.001). 
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Figure 3.7. C. difficile lipoprotein- and PGN-mediated NF-κB activation. 
dTHP-1 cells were transduced with NF-κB-firefly luciferase reporter and stimulated with 
1μg/ml C. difficile WT or C. difficile lgt PGN. Cells were lysed and luciferase activity 
was determined at the indicated time intervals by spectrophotometry (450 nm). Values 
represent mean ± SEM from three independent experiments performed in duplicate. 
Statistical analysis by paired t-test (*P<0.05). 
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 catalytic reaction was measured and experimental results normalised using the renilla 
luciferase O.D readings, according to the manufacturer’s protocol. In HEK293 cells 
transduced with an empty vector plasmid only baseline luciferase levels were detected 
after PGN treatment (Figure 3.8). Interestingly, both NOD1 and NOD2 were able to 
mediate NF-κB activation in the presence of C. difficile PGN, with induction levels 
reaching statistical significance for both receptors (NOD1; P<0.0001, NOD2; P=0.0004). 
NF-κΒ activation was markedly higher in cells treated with the NOD ligands iE-DAP 
and MDP, affirming the experimental results. 
Again, macrophage-like dTHP-1 cells were employed to further study PGN sensing as 
they have been shown to express NOD proteins in relatively high levels (300). To 
confirm this in our cell line, the impact of PMA treatment on the NOD1/NOD2 transcript 
and protein levels was analysed by quantitative real-time PCR and Western blotting 
respectively. Gene transcription (Figure 3.9A) and protein expression (Figure 3.9B) of 
both receptors was up-regulated in dTHP-1 cells, in agreement with previous reports 
(301).  
To further investigate the role of NOD1 or NOD2 in the immune response to PGN, 
siRNA technology was used to silence the expression of the two receptors. Primary 
monocyte-derived macrophages (MDMs) were used in this study as they are known to 
express both receptors (299) and are able to mount a cytokine response to PGN (302). 
Freshly isolated PBMCs were transfected by electroporation with constructs for 
scrambled, NOD1- or NOD2-specific siRNA and plated in tissue culture dishes. A 
separate cell population was transfected with GFP to monitor transfection efficiency. 
Monocytes were selected by adhesion and differentiated into MDMs in 20% autologous 
serum for 72h. Over 60% of monocytes were GFP-positive after 24h as assessed by 
flow cytometry (Figure 3.10A). Cell enumeration by trypan blue staining   
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Figure 3.8. C. difficile PGN triggers NOD1- and NOD2-mediated NF-κB activation.  
HEK293 cells were transfected for 24h with vector, hNOD1 or hNOD2 plasmid, 
together with NF-κB-firefly luciferase and renilla luciferase reporter plasmid. After 24h, 
cells were stimulated with 10μg/ml C. diffiicile PGN. 10μg/ml g-D-glutamyl-meso-
diaminopimelic acid (iE-DAP) or muramyl dipeptide (MDP) stimulation served as a 
positive control. Luciferase activity was measured 16h after stimulation and firefly 
luciferase normalized to renilla luciferase levels. Data shown as fold change of firefly 
from renilla luciferase activity expressed as means ± SEM of three independent 
experiments performed in triplicate. Statistical analysis by paired t-test (***P <0.001). 
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Figure 3.9. PMA-treatment leads to up-regulation of NOD1 and NOD2 in dTHP-1 
cells.  
THP-1 cells were treated with 10ng/ml PMA for 24h followed by culture in complete 
RPMI for 24h. 48h after treatment, NOD1 and NOD2 (A) gene transcription was 
analysed by quantitative RT-PCR (values represent mean ± SEM from three 
independent experiments) and (B) protein expression analysed by Western blot 
(representative blot from two independent experiments is shown). 
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Figure 3.10. Knockdown of NOD1 and NOD2 expression in human monocyte-
derived macrophages (MDMs) by siRNA methodology.  
1x106 monocyte-derived macrophages (MDMs) were transfected with either a GFP, 
scrambled siRNA, NOD1 or NOD2 siRNA plasmid using an Amaxa nucleofector and 
plated in RPMI with 10% autologous serum for 72h. (A) Transfection efficiency was 
assessed by enumeration of GFP-positive cells by flow cytometry from three separate 
donors. (B) Cell death was assessed 72h post transfection to ensure equal numbers of 
cells by trypan blue staining (cumulative data shown as mean ± SEM). (C) After 72h, 
MDMs were lysed and NOD1 and NOD2 protein levels analysed by Western blot 
(representative blot from three different donors). Data shown are representative of 
three independent experiments. 
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72h post nucleofection demonstrated equal cell numbers amongst transfected MDMs, 
(Figure 3.10B). At 72h, NOD1/NOD2 knockdown was confirmed at the protein level by 
Western blotting (Figure 3.10C). Next, NOD1/NOD2 siRNA transfected cells were 
stimulated with 10μg/ml MDP or iE-DAP respectively to verify loss of function. 
Stimulation of NOD1 siRNA-transfected MDMs with iE-DAP led to a significant 
decrease in the TNFα response compared to cells transfected with scrambled siRNA 
(Figure 3.11). Likewise, MDMs transfected with NOD2 siRNA were almost completely 
unresponsive to MDP stimulation. Collectively, these data demonstrate the loss of 
NOD1 or NOD2 expression and functionality in transfected MDMs. Finally, cells were 
stimulated with 10μg/ml PGN for 24h and secreted TNFα measured by ELISA. No 
difference in TNFα secretion was observed between PGN-treated untransfected and 
scramble siRNA-transfected MDMs (Figure 3.12). Stimulation of either NOD1 or NOD2 
knock down cells had a significant impact on cytokine expression (NOD1; P<0.03) 
(NOD2; P=0.074). Our data suggest that both NOD receptors are involved in mediating 
the cytokine response to C. difficile PGN. 
 
3.2.3 C. difficile PGN-induced signalling in human macrophages 
Post NF-κΒ-mediated signalling, activation of the inflammasome is a second 
component of a two-step process that leads to the secretion of a key pro-inflammatory 
cytokine IL-1β (291). Various danger and stress signals, including PGN-derived MDP 
motifs have been shown to trigger inflammasome activation in murine model systems 
(99). PGN-NOD2 mediated inflammasome activation in human innate immune cells 
has not been characterised. We postulated that C. difficile PGN may act as an 
inflammasome activator. Caspase-1 activation was assessed by intracellular staining 
for active caspase-1 using a fluorescent tag inhibitor. dTHP-1 cells treated with 1μg/ml  
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 Figure 3.11. MDM TNFα protein expression in the presence of NOD1 and NOD2 
siRNA.  
2.5 x105 scrambled or NOD1/NOD2 siRNA-trasfected MDMs were stimulated with 
10μg/ml iE-DAP or MDP. 24h post-stimulation, TNFα in the supernatant was quantified 
by ELISA. Values represent mean ± SEM from six individual donors. Statistical analysis 
by paired t-test (**P<0.01).  
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Figure 3.12. NOD1 and NOD2 mediate the C. difficile PGN-induced TNFα 
response in human MDMs.  
Untransfected and scrambled, NOD1 and NOD2 siRNA-transfected MDMs were 
stimulated with 10μg/ml C. diffiicile lgt PGN for 24h and TNFα cytokine was measured 
in the supernatant by ELISA. Values represent mean ± SEM from seven individual 
donors measured in duplicate. Statistical analysis by paired t-test (*P<0.05, **P<0.01, 
n.s P=0.069). 
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PGN or MDP for 4h were not fluorescently labelled as assessed by flow cytometry, 
indicating no active caspase-1 was present (Figure 3.13A). Activated caspase-1 was 
only observed in cells treated with LPS and ATP, which is a very well characterised 
inflammasome activator (303). NALP-1 and NALP-3 inflammasome activation was 
assessed by quantifying polymerisation of the ubiquitous inflammasome component 
ASC and caspase-1. Following treatment with 1μg/ml WT or lgt PGN, 1μg/ml MDP or 
LPS and ATP served as a positive control. 4h post-stimulation, dTHP-1 cells were 
immunostained with an antibody against ASC. In activated cells, diffused ASC should 
rapidly relocate into a punctate speck that can be easily visualised under a laser 
microscope (Figure 3.13B). By quantifying specks we concluded that treatment with C. 
difficile PGN did not lead to inflammasome activation (Figure 3.13C). MDP alone was 
only able to activate a very low number of the cells, whereas cells stimulated with LPS 
and ATP had a significant incidence (>30%) of ASC specks. 
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Figure 3.13. C. difficile PGN does not activate the inflammasome.  
dTHP-1 cells were stimulated with 1μg/ml C. diffiicile WT or C. difficile lgt PGN, MDP or 
10ng/ml E. coli LPS and  ATP (30nM). (A) 4h post-stimulation, active caspase-1 was 
detected using the Flica assay and analysed by flow cytometry. Representative 
histogram from two independent experiments is shown. 
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 Figure 3.13. C. difficile PGN does not activate the inflammasome (cont.).  
dTHP-1 cells were stimulated with 1μg/ml C. diffiicile WT or C. difficile lgt PGN, MDP or 
10ng/ml E. coli LPS and  ATP (30nM). (B) 4h post-stimulation, oligomerised ASC was 
detected in TDM monolayers grown on coverslips using a fluorocrome-conjugated anti-
ASC antibody and visualised by laser microscopy (Pictures taken at 10x, 20x, 40x and 
100x magnification). (C) Number of ASC “specks” from ten fields chosen at random 
presented as percentage of total cells. Values are means ± SEM from two independent 
experiments. Statistical analysis by Mann-Whitney test (***P<0.001). 
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3.3 Discussion 
Ultasonication is routinely used to disperse aggregates that form during PGN isolation 
(295). The strong shearing forces employed are capable of breaking covalent bonds, 
causing the release of PGN fragments and altering the composition of the preparation 
into a mix of intact PGN and smaller soluble polymers. The observed dose-dependent 
increase in TLR2 activation following sonication of PGN (Figure 3.1) can be attributed 
to the detachment of such complexes from the PGN. Interestingly, while both C. difficile 
and S. aureus PGN induced comparable TLR2 activation at 6h, the former was a far 
more potent inducer of IL-8 at 24h (Figure 3.2). IL-8 induction was nearly maximal at a 
1μg/ml dose of C. difficile, while the dose-dependent increase in TLR2 activation by S. 
aureus was similar to that reported elsewhere (28). Since we demonstrated that 
lipoproteins anchored to the PGN are responsible for TLR2 activation (Figure 3.6), this 
difference may be due to the lipoprotein content of the two PGNs; nearly 50 
lipoproteins are predicted by the genome sequence of S. aureus (304) compared to 85 
for C. difficile (138). Differences also likely exist in the processing of PGN and release 
of its various moieties within the cell. These stem from modifications in the sugar 
backbone of PGN, mainly N-deacetylation or O-acetylation, which affect its resistance 
to-degrading enzymes, such as lysozyme, and are important for bacterial survival. 
Peltier et al. (156) found that 93% of GlcNAc in the C. difficile PGN is deacetylated, 
conferring the pathogen resistance to lysozyme. Increased lysozyme resistance is an 
important virulence factor for numerous Gram-positive bacteria, including Listeria 
monocytogenes and Streptococcus pneumoniae which are N-deacetylated whilst S. 
aureus which is O-acetylated (305). Resistance to lysozyme-induced degradation is 
likely to lead to delayed release of TLR2 activating ligands from C. difficile.  
In dTHP-1 cells, PGN from C. difficile was able to induce NF-κB activation at levels 
comparable to those of S. aureus PGN (Figure 3.5). Although 10μg/ml of PGN was 
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able to drive NF-κB activation equal to that of LPS stimulation, empirically, LPS would 
be expected to induce more NF-κΒ as it is the foremost inflammatory trigger. This may 
imply that our reporter construct signalling has reached saturation and therefore, 
quantitative comparisons are not wholly appropriate in this experimental system. 
Nevertheless, both WT and lgt C. difficile PGN were capable of NF-κB induction in 
dTHP-1 cells (Figure 3.7). The lack of TLR2 signalling in lgt PGN-treated cells would 
account for some loss in NF-κB activation and the time frame of NF-κB activation 
would indicate PGN recognition occurs later than TLR2-medated lipoprotein signalling. 
This is most likely due to the requirement for PGN internalisation and hydrolysis prior to 
its recognition by NOD1 and NOD2 (286). Nevertheless, lgt C. difficile PGN was also 
able to induce NOD-dependent NF-κΒ induction in non-phagocytic HEK293 cells 
(Figure 3.8). It is worth noting that our PGN preparation was free of TLR4 or TLR5 
agonists (Figure 3.3) whose presence has been reported in commercially available 
PGN preparations (306) and would lead to immune cell activation. 
Another unique feature of C. difficile PGN is the presence of DAP moieties, commonly 
found in Gram-negative organisms, with the exception of Gram-positive bacilli (289). C. 
difficile contains both DAP and MDP motifs which are the respective ligands of NOD1 
and NOD2. As anticipated, both NOD1 and NOD2 were able to recognise C. difficile 
and induce NF-κB activation in NLR-transfected cells (Figure 3.8). MDP sensing by 
NOD2 has been well-documented (40,307) in both Gram-positive and Gram-negative 
pathogenic bacteria, such as Streptococcus pneumonia (101), Mycobacterium 
tuberculosis (308), S. aureus (79), Salmonella serotype typhimurium (79) and Bacillus 
anthracis (95). The role of NOD1 in PGN recognition was first reported by Inohara et al. 
(46) studying the PGN of Bacillus subtilis, followed by reports on the PGN of B. 
anthracis (286) and Listeria monocytogenes (309). In the case of non-invasive 
pathogens, such as Helicobacter pylori, NOD1 can recognise PGN delivered to the 
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cytosol (169). The moderate levels of NF-κB induction may indicate the requirement for 
PGN degradation by lysozyme, or ex-vivo treatment with hydrolases, for the generation 
of NOD ligands as others have reported (172). The role of NOD1 in immune sensing of 
C. difficile was established in a recent study where NOD1- but not NOD2-deficient mice 
exhibit a compromised immune response to C. difficile infection (77), however the 
specific ligands were not identified.  
The presence of DAP-type PGN on all Clostridia bacilli strongly indicates that they too 
may possess NOD1-stimulating activity. Therefore, the importance of NOD-mediated 
recognition stretches beyond the innate response to C. difficile, since NOD1 regulates 
the Clostridiales population in the gut and NOD1-mediated detection is essential for the 
development of adaptive immunity and the maintenance of intestinal homeostasis (310). 
Also, NOD1-mediated sensing of PGN from the microbiota in mice, but not NOD2- or 
TLR4-mediated signalling, is important for the systemic priming of the innate immune 
response against pathogens (311). The frequency of several bacterial genera of 
Clostridia (312) NOD2 activation by commensals  (including Clostridia), plays multiple 
roles in  the maintenance of intestinal immune equilibrium. Moieties released from 
commensal bacteria can offer protection from induced colitis in mouse models in a 
NOD2-dependent manner (313). Petnicki-Ocwieja et al. (86) noted that lack of NOD2 
resulted in an increased load of certain commensal bacteria in the terminal ileum and 
defects in bacterial clearance from ileal crypts of the intestine has been reported in 
Crohn’s disease patients with NOD2 polymorphisms (314). 
Similar to NF-κB activation, the pro-inflammatory cytokine response to PGN was 
mediated by both NOD1 and NOD2 in primary macrophages (Figure 3.12). A decrease 
in the TNFα response was observed following knockdown of both NOD proteins, but 
only became statistically significant in NOD2-knockdown cells. This discrepancy can be 
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attributed to factors that lie both in experimental limitations and the complex interplay of 
NOD signalling. Receptor over-expression in HEK293 cells is a widely adopted method 
for ligand-receptor studies, however, excessive NOD protein expression may lower 
their activation threshold (315), (Personal communication). While the use of HEK293 
cells offers a reductive model for signalling studies, it cannot account for the plurality of 
functions of receptors such as these. Since a certain degree of redundancy exists 
between the NODs (85); it is possible that NOD2 signalling has compensated for the 
lack of NOD1 activity. And despite both proteins sharing downstream effectors that 
control TNFα expression, only a mutation in NOD2 has been linked to the development 
of disease (41). However, the literature remains conflicting over the outcomes of NOD 
activation in part due to the differences between human and mouse models (316). 
Identifying those parts of the PGN polymer involved in NOD1 and NOD2 activation and 
establishing their individual binding affinity, as others have done for the of E. coli (317), 
would shed more light on the role of each receptor. 
To this day, no reports of PGN-induced inflammasome activation exist. Not surprisingly, 
PGN from C. difficile did not activate the inflammasome (Figure 3.13). Despite the 
existence of limited evidence of inflammasome activation by MDP alone, the majority of 
the literature does not support that notion and neither did our work. Similarly for 
lipoproteins, although in study demonstrating inflammasome activation by the 
lipoproteins of S. aureus, secreted lipoproteins rather than those attached to the PGN 
scaffold were used and that may explain the different outcome (293). 
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Chapter 4 
Innate immune response to 
Clostridium difficile PGN 
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4.1 Introduction 
In Chapter 3, we described the interaction of C. difficile PGN with the NOD receptors 
and its effect on NF-κB signaling, which controls the expression of key secreted pro-
inflammatory mediators of innate immunity. We therefore wanted to investigate the 
immunogenic properties of C. difficile PGN, similar to studies of PGN from B. anthracis 
(318) and S. aureus (62). We set out to analyse the cytokine response to WT and lgt C. 
difficile PGN and identify their source amongst peripheral blood cells. Besides inducing 
an acute response from immune cells, bacterial compounds can inform their functional 
fate and instruct their maturation. MDP moieties of PGN have been shown to act 
cooperatively with low doses of LPS to induce the maturation of DCs (69). We 
hypothesised that the PGN of C. difficile may exhibit similar properties and proceeded 
to analyse the expression of co-stimulatory molecules and receptors in primary 
monocytes and macrophages.  
With the intestinal environment being littered with MAMPs, including PGN, intestinal 
immune cells are constantly presented with a concoction of antigens. Following the 
discovery of TLRs and NLRs, a lot of effort has gone into identifying how these two 
receptor families orchestrate host defence. Numerous studies have shown that NOD1, 
NOD2 and TLR signalling pathways intersect at multiple levels in cellular systems (319). 
Using ligands to co-activate NODs and TLRs simultaneously or sequentially, 
researchers have discovered that NOD-mediated signalling can modulate TLR-induced 
cytokine production and cell maturation. NOD2 activation acts synergistically to 
enhance the TNFα response to TLR2 and TLR4 ligands (69). And vice versa, 
lipoprotein-mediated activation of TLR2 can boost the effects of NOD2 stimulation by 
PGN (320). This synergistic action is important for the production of both pro- and anti-
inflammatory cytokines. In a recent study, NOD2 was shown to directly interact with a 
transcriptional controller of the IL-10 promoter (95). Furthermore, a joint role for TLRs 
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and NOD2 in triggering production of IL-10 has been described (53). Since NOD-
mediated modulation of TLR signalling can greatly affect the outcome of infection, we 
set out to investigate how the monocytic immune response to various pathogen-derived 
ligands is affected in the presence of C. difficile PGN, 
Beyond the acute response, stimulation with bacterial compounds can alter the 
functional fate of innate immune cells. This is done through the desensitisation or 
enhancement of the immune response of naive cells via the processes of tolerance or 
trained immunity respectively. LPS-induced tolerance has been known for decades and 
describes the diminished cytokine response to LPS upon secondary stimulation (321). 
More recently, the role of NOD2 in the development of LPS tolerance by monocyte-
derived macrophages (MDMs) was described (81). Trained immunity, on the other 
hand, refers to an enhanced cytokine response after a second encounter with a 
pathogen. This enhancement offers a protective effect to monocytes and macrophages 
that are thought to exhibit memory characteristics. Amongst the bacterial ligands 
known to enhance the cytokine response of MDMs were MDP and iE-DAP (322). As no 
reports exist on the effect of chronic PGN stimulation, we examined the effect of 
prolonged C. difficile PGN treatment on the macrophage response to LPS. 
In this chapter we aimed to: 
1. Characterise the immune cell phenotype and secreted mediators of the innate 
immune response to C. difficile PGN. 
2. Investigate the cross-talk between C. difficile PGN- and TLR-induced signaling.  
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4.2 Results  
4.2.1 Cytokine response to C. difficile PGN 
NOD receptors are known to mediate the cytokine response to PGN moieties in APCs 
(see Chapter 3). Here, the ability of C. difficile PGN to trigger the production of 
cytokines in peripheral blood mononuclear cells (PBMCs) was investigated. While 
PBMCs may not closely mirror mucosal immune cells (323), they are an accessible 
source of TLR- and NLR-expressing cells. Freshly isolated PBMCs were treated with 
1μg/ml PGN from C. difficile or S. aureus and the production of secreted chemokines 
and cytokines assessed. The two main pro-inflammatory mediators of the monocytic 
response to S. aureus PGN were analysed: IL-8 and TNFα (324). Both are 
predominantly mediated by TLR2 activation (26),(325). Treatment with C. difficile PGN 
induced significant levels of secreted IL-8 (P=0.086), ~ 6900pg/ml after 6h and 
9800pg/ml after 24h (Figure 4.1). Comparatively, PGN from S. aureus induced lower 
levels of IL-8 (~ 4000pg/ml); however the difference was not statistically significant. 
TNFα production only became significant after 24h of treatment (P=0.0014) reaching ~ 
9000pg/ml. Neither PGN was able to elicit significant levels of IL-1β, while only PGN 
from S. aureus induced secretion of IL-10. 
We then wanted to identify the source of this cytokine response. Collected PBMCs 
were sorted into CD14-/lymphocytic and CD14+/monocytic fractions. Neutrophils from 
whole blood were also included in the study. The cells were stimulated with PGN at 0.1 
and 1μg/ml for 24h before assessing IL-8 and TNFα levels in the supernatant. As 
Figure 4.2 shows, stimulation with 0.1μg/ml induced only low levels of IL-8 in PBMCs 
(~ 800pg/ml) (Figure 4.2A). The majority of IL-8 was produced by monocytes  (~ 
9000pg/ml) (Figure 4.2B), while modest amounts were secreted by neutrophils (~ 
1200pg/ml) (Figure 4.2D) and only low amounts by the CD14- fraction (granulocytes, T- 
 133 
 
Figure 4.1. C. difficile PGN elicits a cytokine response in peripheral blood 
mononuclear cells (PBMCs).  
5×105 peripheral blood mononuclear cells (PBMCs) were stimulated with 1μg/ml C. 
difficile or S. aureus PGN for 6 and 24h. (A) IL-8 chemokine and (B) TNFα, (C) IL-1β 
and IL-10 cytokine levels were measured in the supernatant by ELISA. Values 
represent mean ± SEM from six individuals analysed in duplicate. Statistical analysis 
by paired t-test (**P<0.01).  
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Figure 4.1. C. difficile PGN elicits a cytokine response in peripheral blood 
mononuclear cells (PBMCs) (continued).  
5×105 peripheral blood mononuclear cells (PBMCs) were stimulated with 1μg/ml C. 
difficile or S. aureus PGN for 6 and 24h. (A) IL-8 chemokine and (B) TNFa, (C) IL-1β 
and IL-10 cytokine levels were measured in the supernatant by ELISA. Values 
represent mean ± SEM from six individuals analysed in duplicate. Statistical analysis 
by paired t-test (**P<0.01).  
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Figure 4.2. CD14+ monocytes are the major source of C. difficile PGN-mediated 
IL-8 response.  
(A) PBMCs, (B) CD14+ monocytic or (C) CD14- PBMC fractions and (D) neutrophils 
were stimulated with 0.1 and 1μg/ml C. difficile WT or C. difficile lgt PGN. 24h post-
stimulation, IL-8 was measured in the supernatant by ELISA. Values represent mean ± 
SEM from six individuals analysed in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<0.01, ***P<0.001).  
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Figure 4.2. CD14+ monocytes are the major source of C. difficile PGN-mediated 
IL-8 response (continued).  
(A) PBMCs, (B) CD14+ monocytic or (C) CD14- PBMC fractions and (D) neutrophils 
were stimulated with 0.1 and 1μg/ml C. difficile WT or C. difficile lgt PGN. 24h post-
stimulation, IL-8 was measured in the supernatant by ELISA. Values represent mean ± 
SEM from six individuals analysed in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<0.01, ***P<0.001).  
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cells) (Figure 4.2C). To distinguish the contribution of PGN-associated lipoproteins from 
that of PGN, cells were also treated with 0.1 and 1μg/ml lgt C. difficile PGN. At a 
concentration of 0.1μg/ml the immune response was weak and no significant difference 
was observed between WT and lgt PGN-induced IL-8 or TNFα. Treatment with 1μg/ml 
lgt C. difficile PGN induced lower levels of IL-8 across all cell fractions in comparison to 
WT PGN (Figure 4.2). The difference between the two PGN preparations was more 
pronounced in CD14+/monocytes where WT PGN induced ~ 9000pg/ml and lgt PGN ~ 
3000pg/ml (Figure 4.2B).  
Stimulation of PBMCs with 0.1 and 1μg/ml PGN led to the secretion of ~ 400 and 
4900pg/ml TNFα respectively (Figure 4.3Α), with monocytes being the main source of 
the cytokine and producing  ~ 7500pg/ml (Figure 4.3B). In contrast to IL-8, there was 
greater contribution from the CD14- fraction (~ 1200pg/ml) (Figure 4.3C) and none from 
neutrophils (Figure 4.3D). While PBMCs secreted less TNFα when treated with lgt 
compared to WT C. difficile PGN (~ 3200 and 4900pg/ml respectively), the difference 
was not statistically significant (Figure 4.3A). However, when CD14+/monocytes and 
CD14-/lymphocytes were analysed, the difference between the two treatments was 
significant (P=0.0124) (Figure 4.3B). No significant difference in TNFα induction was 
detected in the remaining cell fractions (Figure 4.3C and D). Finally, PGN from C. 
difficile was able to induce both IL-6 and IL-10 in monocytes with median ~ 640 and 
520pg/ml respectively, but only low levels of IL-12 (Figure 4.4). Treatment with 1μg/ml 
lipoprotein-negative lgt PGN led to a significant reduction in IL-6 production (P=0.024). 
Notably, IL-10 levels were comparable between cells treated with WT and lgt C. difficile 
PGN as no statistically significant difference was detected. Taking into account their 
central role in cytokine-mediated immunity to PGN, monocytes were used to conduct 
further experiments. 
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Figure 4.3. CD14+ monocytes are the major source of C. difficile PGN-mediated 
TNFα response.  
(A) PBMCs, (B) CD14+ monocytic or (C) CD14- PBMC fractions and (D) neutrophils 
were stimulated with 0.1 and 1μg/ml C. difficile WT or C. difficile lgt PGN. 24h post-
stimulation, TNFα was measured in the supernatant by ELISA. Values represent mean 
± SEM from six individuals analysed in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<0.01, ***P<0.001).  
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 Figure 4.3. CD14+ monocytes are the major source of C. difficile PGN-mediated 
TNFα response (continued).  
(A) PBMCs, (B) CD14+ monocytic or (C) CD14- PBMC fractions and (D) neutrophils 
were stimulated with 0.1 and 1μg/ml C. difficile WT or C. difficile lgt PGN. 24h post-
stimulation, TNFα was measured in the supernatant by ELISA. Values represent mean 
± SEM from six individuals analysed in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<0.01, ***P<0.001).  
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Figure 4.4. Cytokine response to C. difficile PGN in human monocytes.  
CD14+ monocytes were stimulated with 0.1 and 1μg/ml C. difficile WT or C. difficile lgt 
PGN. 24h post-stimulation, IL-6, IL-10 and IL-12 cytokines were measured in the 
supernatant by ELISA. Values represent mean ± SEM from four individuals analysed in 
duplicate. Statistical analysis by paired t-test (*P<0.05, **P<0.01, ***P<0.001). 
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4.2.2 Synergistic role of C. difficile PGN-mediated NOD activation in TLR 
signalling 
Cytokine production is only one aspect of the multifaceted immune response to 
bacterial antigens. Simultaneously, innate immune cells up-regulate the expression of 
PRRs in order to enhance their surveillance capabilities. Surface molecules involved in 
cross-activation of other immune cells also become up-regulated as monocytes 
differentiate to mature APCs. Wanting to assess the capacity of C. difficile PGN to 
induce the maturation of naïve immune cells, we analysed the expression of the MHC 
Class II receptor HLA-DR, which becomes up-regulated in monocytes undergoing 
differentiation. We also examined the co-stimulatory molecules CD80 and CD86, found 
in mature macrophages and CD40, another co-stimulatory protein found on APCs. 
Treatment with PGN from WT C. difficile led to significant up-regulation of CD86 
(P=0.03), but had no effect on any of the other molecules (Figure 4.5). The increase in 
CD86 expression was lipoprotein-mediated, since treatment with lgt PGN did not lead 
to significant change in marker expression. We also analysed the expression of TLR2 
and TLR4, two of the key receptors in the sensing of bacterial cell wall components. 
Treatment with PGN from WT C. difficile led to significant up-regulation of TLR4 
(P=0.03) (Figure 4.6), again mediated by lipoproteins rather than the PGN itself, as WT 
and lgt PGN preparations showed no difference.  
As C. difficile PGN did not have an effect on its own, we were eager to examine its 
ability to modulate LPS-induced monocytic maturation. Previously, others have 
reported the capacity of MDP to modulate LPS-mediated surface marker expression in 
DCs(69). As expected, stimulation of monocytes with LPS led to significant up-
regulation of HLA-DR (P=0.026) as well as the co-stimulatory factors CD40 (P=0.04) 
and CD80 (P=0.032) (Figure 4.7). However, we found no evidence that co-stimulation 
with lgt PGN had a significant impact on the LPS-induced expression of these proteins.  
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Figure 4.5. MHC class II and co-stimulatory molecule expression in monocytes in 
response to C. difficile PGN is lipoprotein-mediated.  
2.5×105 CD14+ monocytes were stimulated with 1μg/ml C. difficile WT or C. difficile lgt 
PGN. 24h post-stimulation the expression of MHC class II receptor HLA-DR and co-
stimulatory proteins CD80, CD86 and CD40 was analysed by flow cytometry. Data is 
presented as M.F.I and values represent mean ± SEM from four individuals. Statistical 
analysis by paired t-test (*P<0.03).   
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Figure 4.6. TLR4 up-regulation in the monocytic response to C. difficile PGN is 
lipoprotein-mediated.  
2.5×105 CD14+ monocytes were stimulated with 1μg/ml C. difficile WT or C. difficile lgt 
PGN. 24h post-stimulation TLR2 and TLR4 expression was assessed by flow 
cytometry. Data presented as M.F.I and values represent mean ± SEM from four 
individuals. Statistical analysis by paired t-test (*P<0.05).  
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Figure 4.7. Potential modulatory effect of C. difficile PGN on monocytic 
activation.  
2.5×105 CD14+ monocytes were stimulated with 1μg/ml C. difficile lgt PGN, 10ng/ml 
LPS or both. 24h post-stimulation, expression of co-stimulatory proteins was analysed 
by flow cytometry. Data presented as M.F.I and values represent mean ± SEM from 
four individuals. Statistical analysis by paired t-test (*P<0.05, **P<0.01). 
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Likewise, TLR2 expression was significantly higher (P=0.04) following treatment with 
LPS, yet was not modulated in the presence of C. difficile PGN (Figure 4.8). While we 
did not observe any affect of C. difficile PGN on TLR4-mediated surface molecule 
expression, we went on to analyse the cytokine response of monocytes co-stimulated 
with PGN and LPS based on previous studies underlining the synergistic role of NOD 
receptors in the TLR-driven cytokine production of monocytes and lymphocytes(326). 
C. difficile PGN appeared to enhance the TNFα (P=0.044) and IL-6 (P=0.046), a 
cytokine closely related to TNFα, response to LPS (Figure 4.9). However, no significant 
change in IL-10 secretion was observed. These data suggested that, although the 
expression of surface markers was unchanged, PGN from C. difficile can modulate 
TLR-mediated pro-inflammatory signaling. 
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Figure 4.8. Co-stimulation with C. difficile PGN does not modulate TLR 
expression.  
2.5×105 CD14+ monocytes were stimulated with 1μg/ml C. difficile lgt PGN, 10ng/ml 
LPS or both. 24h post-stimulation, expression of TLR2 and TLR 4 was analysed by 
flow cytometry. Data is presented as M.F.I and values represent mean ± SEM from four 
individuals. Statistical analysis by paired t-test (*P<0.05).   
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We then went on to test the capacity of C. difficile PGN to modulate the cytokine 
response to other TLR agonists. Interestingly, the TNFα cytokine response to all TLR 
agonists was enhanced in the presence of C. difficile PGN (TLR2; P=0.024, TLR3; 
P=0.035, TLR5; P=0,039) (Figure 4.10). There was also a significant increase in the 
expression of IL-6 following co-stimulation with S. aureus PGN (TLR2; P=0.012) and 
flagellin (TLR5; P=0.45), but not polyI:C (TLR3; P=0.263). C. difficile PGN significantly 
enhanced the IL-10 response to polyI:C (TLR3; P=0.042) and flagellin (TLR5; 
P=0.034), but not TLR2; despite an increase in IL-10 production from ~400 to 550pg/ml. 
To further assess the contribution of C. difficile PGN to TLR-mediated signaling and 
look for evidence of synergy, the ELISA results were expressed as ratio of the median 
value induced by lgt PGN and the corresponding TLR ligand combined versus the sum 
value of their independent effect, as previously described (327). Our analysis indicates 
that co-stimulation with lgt PGN had a synergistic effect in LPS-induced TLR4 signalling 
for all three cytokines since the value of the ratio was equal or greater to 1.5 (Figure 
4.11). 
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Figure 4.9. C. difficile PGN plays a synergistic role in TLR4-mediated cytokine 
induction in human monocytes.  
5×105 CD14+ monocytes were stimulated with 10ng/ml E. coli LPS alone or in the 
presence of 1μg/ml C. difficile lgt PGN (+) for 24h. TNFα, IL-6 and IL-10 cytokine levels 
were measured in the supernatant by ELISA. Values represent mean ± SEM (n>=3) 
analysed in duplicate. Statistical analysis by paired t-test (*P<0.05).   
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Figure 4.10. C. difficile PGN plays a synergistic role in TLR-mediated cytokine 
induction in human monocytes.  
5×105 CD14+ monocytes were stimulated with (A) 1μg/ml PGN from S. aureus (TLR2), 
(B) 50ng/ml polyI:C, (TLR3), (C) 5ng/ml Salmonella typhimurium flagellin (TLR5) alone 
or in the presence of 1μg/ml C. difficile lgt PGN (+) for 24h. TNFα, IL-6 and IL-10 
cytokine levels were measured in the supernatant by ELISA. Values represent mean ± 
SEM (n>=3) analysed in duplicate. Statistical analysis by paired t-test (*P<0.05). 
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Figure 4.11. C. difficile PGN plays a synergistic role in TLR-mediated cytokine 
induction in human monocytes.  
5×105 CD14+ monocytes were stimulated with (A) 1μg/ml PGN from S. aureus (TLR2), 
(B) 50ng/ml polyI:C (TLR3), (C) 50ng/ml Salmonella typhimurium flagellin (TLR5) alone 
or in the presence of 1μg/ml C. difficile lgt PGN for 24h. TNFα, IL-6 and IL-10 cytokine 
levels were measured in the supernatant by ELISA. Data shown as ratio of the median 
value of secreted cytokine following stimulation with both a specific TLR agonist and C. 
difficile lgt PGN over the sum value resulting from stimulation with each agonist alone. 
Values represent mean ± SEM (n>=3) analysed in duplicate.  
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4.2.3 Chronic stimulation with C. difficile PGN mediates tolerance to LPS 
So far, our work has focused on the outcome of acute, rather than chronic, PGN 
stimulation. We became interested in the effect of chronic PGN stimulation on MDMs 
and particularly the immune outcome to sequential stimulation with LPS. For this study, 
primary monocytes were treated with 1μg/ml lgt C. difficile PGN for 24h, followed by 
culture in fresh media containing 10% autologous serum for 5d. At day 6, MDMs were 
stimulated with LPS for 24h prior to analysis of TNFα and IL-10 cytokines in the 
supernatant. Remarkably, chronic stimulation with PGN led to a significant reduction in 
the TNFα response to LPS (P=0.0013) (Figure 4.12). Likewise, we observed a 
statistically significant, yet less pronounced, decrease in induction of IL-10 (P=0.0315). 
It is worth noting that pre-treatment with PGN did not lead to spontaneous cytokine 
induction. This evidence suggests that PGN from C. difficile can induce differentiating 
monocytes to adopt a tolerogenic profile as mature APCs. 
To gain more evidence of how chronic stimulation with PGN could alter the functional 
fate of MDMs, we treated monocytes with C. difficile PGN prior to their in vitro 
differentiation into MDMs. We then analysed the expression of various surface 
molecules in response to LPS. First, we looked at the expression of co-stimulatory 
proteins. CD54, a marker of macrophage activation (328), was included along with the 
markers studied earlier (see Figure 4.5). Importantly, we did not detect any significant 
difference in surface protein expression between untreated and PGN-pre-treated 
MDMs (Figure 4.13). LPS-treated MDMs expressed > 5 times more CD54 and CD86 
on their surface. CD80 levels were also higher but only by ~ 2-fold. Remarkably, CD54 
and CD86 up-regulation was significantly enhanced in cells that had been pre-treated 
with PGN by nearly 2-fold. 
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Figure 4.12. C. difficile PGN is an effector of trained immunity in human MDMs. 
5x105 CD14+ monocytes were left untreated or stimulated with 1μg/ml C. difficile lgt 
PGN for 24h in RPMI with 10% autologous serum. After 24h, cells were cultured in 
fresh media with 10% autologous serum for another 72h, prior to stimulation with 
10ng/ml LPS. 24h post-stimulation, TNFα cytokine was measured in the supernatant 
by ELISA. Values represent means ± SEM from a minimum of three donors. Statistical 
analysis by paired t-test (*P<0.05, **P<0.01).  
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Figure 4.13. C. difficile PGN pretreatment affects the LPS-mediated co-
stimulatory protein expression in human macrophages.  
2x105 MDMs were left untreated or stimulated with 1μg/ml C. difficile PGN for 24h in 
media containing 10% autologous serum. After 24h, cells were cultured in fresh media 
with 10% autologous serum for another 72h, prior to stimulation with 10ng/ml LPS. 24h 
post-stimulation, expression of various co-stimulatory proteins was analysed by flow 
cytometry. Values represent means ± SEM from four donors. Statistical analysis by 
paired t-test (*P<0.05).  
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Subsequently, we analysed the effect of chronic C. difficile PGN stimulation on the 
expression of immune receptors in response to LPS. Our panel was expanded to 
include CD14, a co-receptor of TLR2 and TLR4 (21), and CD16, an Fc receptor 
involved in antibody-dependent cytotoxicity (329). CD14 is highly expressed in 
monocytes but not macrophages, while the opposite is true for CD16; allowing us to 
assess the extent of differentiation the cells have undergone. We also analysed the 
expression of the pan-macrophage marker CD11, a component of integrin receptors 
involved in various immune phenomena (330). Furthermore, the chemokine receptors 
CCR4, prominent in M2-type macrophages(331) and CCR7, expressed in M1-type 
macrophages were also studied. Macrophages may undergo classical M1 activation or 
alternative M2 activation into states that mirror the Th1–Th2 polarization of T cells 
(332). Again, we did not detect any significant difference in surface protein expression 
between untreated and PGN-pre-treated MDMs (Figure 4.14). LPS treatment induced 
up-regulation of TLR2 and CD14, although C. difficile PGN had no effect on TLR2 
expression, similar to our findings in monocytes (see Figure 4.8). Pre-treatment with C. 
difficile PGN enhanced the up-regulation of CD14 from nearly 6-fold to 9-fold, despite 
the results not being statistically significant, possibly due to inter-donor variation. CCR4 
expression was ~ 5x higher in untreated and ~ 9x higher in C. difficile PGN pre-treated 
cells after LPS stimulation, suggesting that PGN enhances the expression of the 
receptor. Yet, similar to CD14, the effect was not statistically significant. CCR7 was up-
regulated by ~ 3-fold in both untreated and PGN-pre-treated cells. CD16 also became 
up-regulated in LPS-treated MDMs, yet we observed significant down-regulation of 
LPS-induced CD16 expression in PGN pre-treated cells. Overall, receptor up-regulation 
following treatment with LPS is consistent with the maturation on naïve immune cells to 
APCs. Pre-treatment with C. difficile PGN had a significant effect on proteins that 
showed high inducibility by LPS. CD16 was the only exception, as chronic stimulation 
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Figure 4.14. C. difficile PGN pretreatment affects the LPS-mediated receptor up-
regulation in human macrophages.  
2x105 MDMs were left untreated or stimulated with 1μg/ml C. difficile PGN for 24h in 
media containing 10% autologous serum. After 24h, cells were cultured in fresh media 
with 10% autologous serum for another 72h, prior to stimulation with 10ng/ml LPS. 24h 
post-stimulation, expression of various markers was analysed by flow cytometry. 
Values represent means ± SEM from four donors. Statistical analysis by paired t-test 
(*P<0.05, n.s P>0.15). 
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with C. difficile PGN led to a decrease in the LPS-mediated induction of the receptor. 
 
4.5 Discussion 
In this chapter, the immunogenicity of C. difficile PGN with regard to the cytokine 
response and phenotypic changes elicited in monocytes and MDMs was examined. 
Compared to the PGN of S. aureus, C. difficile PGN induced higher levels of IL-8 
(Figure 4.1), indicating a propensity for inflammatory induction. Whether the difference 
in IL-8 is the result of different PGN isolation methods or lipoprotein content remains 
unknown. On the other hand, only low levels of TNFα or IL-10 were detected (Figure 
4.1), suggesting that C. difficile PGN does not activate the TNFα/IL-10 signalling axis. 
This may further contribute to the inflammatory response to PGN, as the TNFα/IL-10 
signalling axis is known to regulate mucosal immunity (333) and limit intestinal 
inflammation. TNFα, an early-response cytokine, was only detected at significant levels 
after 24h. This discrepancy may be explained by the requirement for internalisation and 
lysozyme digestion of the PGN prior to sensing by the NODs (286). IL-1β and IL-10 
secretion in C. difficile PGN-treated cells was not significantly different from that of 
resting cells. Similarly, treatment of PBMCs with low dose DAP or MDP does not 
induce IL-1β or IL-10 in PBMCs (334),(307). Reports have shown that treatment of 
monocytes with S. aureus PGN results in high levels of IL-1β transcription, but not in 
secretion of the mature cytokine (324). Accordingly, we detected minimal levels of IL-
1β from C. difficile PGN-treated cells (Figure 4.1). The low levels of secreted IL-1β 
reaffirm the lack of inflammasome activation reported in previous experiments (see 
Figure 3.13 in Chapter 3). Interestingly, the levels of secreted IL-8, IL-1β and TNFα 
were similar to those reported for Bacillus anthracis PGN (318). The effect of S. aureus 
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PGN on cytokine production by PBMCs was similar to that reported elsewhere 
(35),(335). 
B. anthracis PGN is a potent stimulator of monocytes, neutrophils and B lymphocytes 
(286). Likewise, all three cell types were able to mount a response to C. difficile PGN in 
our experiments. Previous reports identified monocytes and neutrophils as the major 
sources of pro-inflammatory signalling in response to bacterial cell wall components 
(172). In our study, monocytes were the major contributors of IL-8 and TNFα amongst 
PBMCs (Figure 4.2 and 4.3), which is not surprising given that their TLR2 expression is 
many-fold higher compared to other blood cells (336),(337). Neutrophils were the 
second biggest contributors towards the cytokine response to PGN. It is worth noting 
that while NOD2 is expressed in both monocytes and neutrophils, NOD1 is only 
present in monocytes (69), which may lead to differential outcomes in response to 
PGN. Overall, TNFα levels were higher in comparison to other cytokines, reaffirming 
the role of TNFα as the major cytokine in the monocytic response to C. difficile PGN 
(318). As expected, the pro-inflammatory immune response was greatly affected by the 
lack of lipoproteins and, therefore, TLR2 signalling (Figure 4.2 and 4.3) (see Chapter 
3). Studies on the PGN of other bacteria have reported a similar reduction in the pro-
inflammatory immune response in the absence of lipoproteins (35),(320). On the other 
hand, induction of the anti-inflammatory cytokine IL-10 was not significantly different 
between WT and lgt PGN (Figure 4.4), contradictory to the central role of TLR2 in IL-10 
expression (338). Yet, along with TLR2, PGN also activates NOD2 (62) which is also a 
key mediator of IL-10 expression (53). 
Next, we looked at changes in the expression of both co-stimulatory molecules and 
receptors in response to C. difficile PGN. We found that up-regulation of differentiation 
markers in monocytes was lipoprotein-mediated and only affected the expression of 
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CD86 (Figure 4.5) and TLR2 (Figure 4.6). Lipoprotein-mediated up-regulation of TLR2 
in monocytes has been reported previously (284). Although others have reported the 
PGN-mediated up-regulation of CD40 and CD80 expression in THP-1 cells (339), we 
did not observe a similar effect in monocytes. The expression of other markers 
traditionally associated with monocyte maturation was unaffected, suggesting that 
treatment with C. difficile PGN does not induce monocyte differentiation. Likewise, PGN 
from S. aureus failed to induce monocyte differentiation in a previous study (340).  
We also looked at whether C. difficile PGN could modulate the expression of co-
stimulatory molecules and receptors in response to LPS. Studies on MDP have shown 
it can enhance LPS-mediated up regulation of CD80, CD86 and CD40 in DCs (60),(69). 
However, we found no evidence to suggest modulation of molecule expression in the 
presence of C. difficile PGN (Figure 4.7 and 4.8). One explanation may be that the 
proteins analysed are predominantly expressed in mature APCs, such as macrophages 
and DCs (11), rather than monocytes. As such, the investigation could be repeated 
using a more appropriate set of markers. Additionally, since LPS is a strong inducer of 
monocyte maturation, any subtle effect may have gone undetected. As discussed 
earlier, mature APCs, such as macrophages, up-regulate PRR expression (341),(301) 
and may provide a better model for the study of PGN-mediated induction in receptor 
expression. 
Since the study of cell surface factors did not provide any evidence of modulation of 
LPS signaling by C. difficile PGN, we examined the effect of the latter on the outcome 
of TLR4-mediated cytokine induction. Co-stimulation with PGN potentiated the 
production of TNFα in response to LPS (Figure 4.9) as well as other TLR ligands 
(Figure 4.10). Overall, the most significant contribution was towards TLR4 signalling, 
where we found evidence of synergistic activity between C. difficile PGN- and LPS-
 159 
mediated signaling (Figure 4.11). Accordingly, studies using MDP have found NOD2 
signalling to potentiate TLR2, TLR3 and TLR4-mediated TNFα induction but not TLR5 
(342), although a follow up study suggested the outcome was variable (327). Similar 
results were obtained for the induction of IL-6, with the exception of TLR3 where no 
modulation was detected (Figure 4.10). TLR3 and NOD ligands are weak inducers of 
IL-6 in monocytes (343) and any weak effect may have gone undetected. Finally, while 
PGN did not enhance IL-10 secretion in response to LPS (Figure 4.9), which could be 
explained by saturation of IL-10 induction by LPS alone, the IL-10 response to all other 
TLR ligands was enhanced (Figure 4.10). Notably, IL-10 enhancement was more 
prominent in the presence of the TLR5 ligand flagellin (Figure 4.11), similar to a 
previous study with MDP (327). There are contradictory reports regarding the IL-10 
response to flagellin (344) as it has been reported elsewhere that flagellin does not 
induce IL-10 production in murine cells (345). Isolated and purified flagellin was used in 
those studies; therefore it is possible that the commercially available preparation used 
may contain contaminants.  
To assess whether the detected modulation of cytokine induction was due to a 
synergistic effect of C. difficile PGN with TLR ligands, the cytokine production after 
stimulation with both ligands was compared to the outcome of stimulation with each 
ligand alone. Synergy between NOD2 and TLR2 (307),(342),(320) or TLR4 
(346),(69),(61) signalling has been reported in multiple studies. While C. difficile PGN 
was able to modulate TLR2-mediated cytokine induction, we did not detect evidence of 
synergy. The use of another TLR2 agonist with no NOD-stimulating activity, such as 
Pam3CSK4 may have been more appropriate. Finally, the study could be extended to 
other cytokines and chemokines, such as IL-8. For example MDP- and DAP-containing 
desmuramylpeptides in combination with chemically synthesized TLR agonists can 
synergistically induce IL-8 production in a NOD2- and NOD1-dependent manner, 
 160 
respectively (307). Further research into the complex crosstalk amongst these 
receptors is needed to understand their role in orchestrating the maintenance of a 
balanced pro-/anti-inflammatory axis. 
The long-term effects of PGN stimulation on innate immune cells were also 
investigated. Presently, two opposing narratives exist on the outcome of chronic NOD 
stimulation. On the one hand, studies have shown that long-term NOD2 stimulation in 
macrophages leads in tolerance to LPS re-stimulation and a diminished cytokine 
response (81). On the other, NOD ligands are reported as effectors of trained immunity 
which offers a protective effect to macrophages by enhancing their cytokine response 
to sequential LPS stimulation (84). We found evidence of cross-tolerance to LPS upon 
chronic stimulation with C. difficile PGN (Figure 4.12). Hedl et al. first reported that 
prolonged exposure of primary MDMs to MDP inhibited both the NOD2- and TLR4-
mediated pro-inflammatory response (81). Intriguingly, the same study reported that 
intestinal macrophages exhibit tolerance to MDP and the TLR4 agonist lipidA. The 
same group later demonstrated that NOD2-mediated induction of IL-10 led to the 
suppression of MAPKs and transcription factors controlling the expression of pro-
inflammatory cytokines (347). It would be interesting to study the effect of C. difficile 
PGN on MAPK signalling, as, others have shown that the pathway plays a key role on 
the inflammatory response to B. anthracis PGN (318). We also examined the 
production of IL-10, where Hedl et al. have reported that chronic NOD2 stimulation 
down-regulated IL-10 secretion upon TLR4 activation (82); mirroring our own findings 
(Figure 4.12). Finally, although we did not find evidence of “trained immunity” in PGN-
treated MDMs, it is worth noting that the outcome of a previous study (322) was highly 
dependent on the concentration of agonist used and would require use of PGN at  
significantly higher concentration. 
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In an attempt to characterise the functional reprogramming of MDMs following chronic 
stimulation with C. difficile PGN, we analysed the expression of various surface 
molecules by flow-cytometry. Treatment of monocytes with PGN did not affect the 
expression of co-stimulatory factors or receptors in the differentiated MDMs (Figure 
4.13 and 4.14) and we are not aware of any studies that have shown differential marker 
up regulation in macrophages in response to chronic stimulation with PGN. As 
expected, we observed up-regulation of a range of factors involved in immune 
surveillance following LPS stimulation. The most predominant increase was in the 
levels of the co-stimulatory molecules CD54, CD80 and CD86 (Figure 4.13), and the 
receptors CD14 and CCR4 (Figure 4.14). Previous studies have reported on the up-
regulation of CD54 (348), CD80 and CD86 (349), as well as CD14 (350) and CCR4 
(351) in response to LPS.  
In cells pre-treated with C. difficile PGN, we observed significant enhancement of both 
CD54 and CD86 expression (Figure 4.13). A previous study also reported enhanced 
expression of CD54 and CD86 after co-stimulation with LPS and the NOD1 agonist 
DAP (69). While little is currently known on the function of CD54 in macrophages (352), 
it plays a role in the macrophage-mediated Th2 polarisation of T cells (353). Likewise, 
CD86 mediates T cell activation by macrophages to induce a Th2 response (354). The 
Th2-type response induces the production of anti-inflammatory cytokines, such as IL-
10, and is considered tolerogenic. There was also an increase in the levels of CD14 
and CCR4 expression after LPS in PGN-pre-treated cells compared to untreated 
(Figure 4.14). CD14, although considered a monocytic marker, is also expressed in 
macrophages (355). Monocytes expressing both CD14 and CD16 are considered pro-
inflammatory, as opposed to those that express CD14 alone (356). In our study, while 
the expression of CD14 was enhanced, CD16 expression was lower in cells pre-treated 
with C. difficile PGN. Following the paradigm of monocytes, this may concur with the 
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adoption of a more tolerogenic profile. Finally, CCR4 is recognised as a key receptor in 
Th2-associated processes (331). Furthermore, it has been involved in the activation of 
PI3K signalling, one of the key pathways driving IL-10 transcription (357).  
Therefore, a pattern of more tolerogenic, Th2-like response to LPS in MDMs pre-
exposed to C. difficile PGN is emerging. These findings complement our work showing 
a reduced pro-inflammatory cytokine response in these MDMs, which more closely 
resembles M2-type macrophages (Figure 4.12). In future work, M2-type polarisation 
would have to be assessed by a separate set of markers such as CX3CR1, CD163 and 
CD206 (358). Furthermore, since M2-type polarisation does not lead to down-
regulation of M1-type factors (359), further analysis of markers in this category is 
required. It may be worth noting, however, that a recent evaluation of the features of 
macrophage activation in response to bacterial infection concluded that the use of the 
polarisation concept has been mostly unsuccessful (360). In the greater scheme, 
studies of this nature are important for the development of vaccine adjuvants and 
recently, peptide mimics of PGN have been identified as vaccine candidates (361). 
Studying the signalling pathways activated by C. difficile PGN and how they modulate 
control of cytokine expression at the promoter level could help unravel the mechanism 
of PGN-mediated torerance. 
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Chapter 5 
Immunomodulation by 
Campylobacter jejuni flagellum
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5.1 Introduction 
Published work from our group recently identified C. jejuni strain 11168H as a potent 
inducer of IL-10 and described the role of flagellum in the IL-10 response to this 
pathogen (218). Enhancement of IL-10 was flagellum-specific, as the use of a secretion 
positive (∆flaA) and secretion negative (∆rpoN) flagella mutant strains revealed that 
proteins secreted from C. jejuni flagella played no role in IL-10 induction. Furthermore, 
pseudaminic acid (Pse) residues attached to the flagellum appeared to modulate IL-10 
induction in human DCs. According to the study, Pse residues are recognised by the 
Siglec10 receptor, which was shown to mediate flagellum- specific enhancement of the 
IL-10 response to C. jejuni. IL-10 response to the pathogen was MAPK-dependent and 
the increase in IL-10 expression was driven by hyper-activation of the MAPK signalling 
pathway, specifically of ERK and p38 kinase activation. Focusing on the IL-10 
response to C. jejuni, we wanted to study the signalling events that mediate flagellum-
dependent enhancement of IL-10 production. 
 
5.1.2 Regulation of IL-10 expression 
In vivo expression of IL-10 following infection has been reported in macrophages, DCs 
and neutrophils (338). Both macrophages and DCs can express IL-10 in vitro following 
PRR activation by microbes, although the response is much higher in macrophages. 
TLR2 ligands are considered as specialised IL-10 inducers (362), although significant 
amounts of IL-10 are produced following TLR4 and TLR9 activation (363). On the other 
hand, TLR5 signalling is a negative regulator of IL-10 expression (345). TLR-
independent induction of IL-10 mediated by NOD2 has also been reported (53). Finally, 
C-type lectin or Fc receptor (FcR) ligands can also mediate TLR-independent IL-10 
induction (364). 
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Following TLR ligation, Toll/IL-1 receptor (TIR)-domain-containing adaptors, such as 
myeloid differentiation primary response protein 88 (MyD88) and TIR-domain- 
containing adaptor protein inducing IFNβ (TRIF), mediate signalling cellular activation. 
MyD88 and TRIF dual activation leads to optimal IL-10 induction by LPS. MyD88 
activation leads to phosphorylation of MAPKs and NF-κB (32). The MAPK cascade is 
composed of three major groups of kinases: extracellular signal-regulated kinases 
(ERKs) comprising ERK1 and ERK2; JuN N-terminal kinases (JNKs) comprising JNK1 
and JNK2; and p38 (272). ERK activation is key to the modulation of IL-10 expression 
(365) and differences in IL-10 production between macrophages and DCs correlate 
with the strength of ERK activation in each cell type (366). Following TLR stimulation, 
ERK is most highly activated in macrophages, with lower activation in DCs. IL-10 
expression is also dependent on p38 signalling in macrophages, primary DCs and 
human peripheral blood monocytes (367). ERK and p38 signalling consolidate in the 
activation of the MSK1 and MSK2 kinases, which in turn activate transcription factors 
that bind the IL-10 promoter. The transcription factors cAMP-responsive-element-
binding protein (CREB) and activating transcription factor 1 (ATF1) have been shown 
to be activated by MSKs in LPS-stimulated mouse macrophages (278). In addition, IL-
10 production is regulated by the phosphoinositide 3-kinase (PI3K)–AKT pathway, 
which antagonises the activation of glycogen synthase kinase 3 (GSK3), a negative 
regulator of IL-10 (Figure 5.1). 
Downstream of these cascades, IL10 expression depends on multiple transcription 
factors, including specific protein 1 (SP1) and SP3, IFN-regulatory factor 1 (IRF1) and 
STAT3 (338). Although no evidence of direct binding of the various STATs to the IL10 
locus currently exists, STAT proteins are increasingly being implicated in regulating the 
induction of IL-10 expression in both primary macrophages and T cells. Along with 
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these distal regulatory elements, transcription factors that bind regions of the locus 
outside the IL-10 promoter region and become activated via ERK signalling have also 
been discovered (362).  
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Figure 5.1. Induction of IL-10 expression in innate immune cells.  
(A) TLR-dependent and TLR-independent IL-10 induction in myeloid DCs and 
macrophages. (B) Positive and negative feedback loops in IL-10 induction in 
macrophages 
 
!
A 
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5.2 Results 
5.2.1 C. jejuni flagellum-mediated enhancement of IL-10 production 
Our group was the first to identify pathogenic strains of C. jejuni as potent inducers of 
the anti-inflammatory cytokine IL-10 and the role of flagella in that response (218). The 
work was carried out primarily in mouse bone marrow-derived DCs (BMDCs), and we 
have since wanted to examine whether the findings are also true in human cells. 
Human monocyte-derived DCs (mDCs) were co-cultured with two pathogenic strains of 
C. jejuni (11168H and 81-176) to study the cytokine response to the pathogen. Co-
culture with C. jejuni 11168H at two different MOIs (10 and 100) led to induction of IL-
10 with a median ~ 700 and 2100pg/ml respectively after 24h (Figure 5.2). A similar 
dose-dependent increase in TNFα was observed with cytokine levels at a median ~ 30 
and 58 ng/ml. C. jejuni 81-176 appeared to induce less IL-10 and TΝFα at MOI 100, 
with a median ~1300pg/ml and 45 ng/ml respectively, however the dose-dependent 
increase in cytokine levels was comparable between the two strains. We also 
examined the timing of cytokine induction by co-culturing mDCs with C. jejuni for 8 and 
24h. IL-10 levels of only ~ 280pg/ml were detected at 8h, but were much higher with a 
median ~ 1900pg/ml by 24h (Figure 5.3). High TNFα levels were detected both after 8h 
and 24h of co-culture with C. jejuni, with a median ~ 17 and 54 ng/ml respectively. A 
similar time-dependent effect on cytokine induction was observed in cells co-cultured 
with C. jejuni 81-176. Based on these findings, a model for C. jejuni co-culture with 
human APCs using bacteria at MOI 100 for 24h was established. 
Subsequently, we set out to investigate the role of flagellum in C. jejuni-mediated 
cytokine induction. It has been reported that some ε-proteobacteria, including C. jejuni, 
have evolved to evade TLR5 recognition (217). To confirm that the flagellum of C. jejuni 
strain 11168H does not activate TLR5, WT and TLR5-transfected HEK293 cells were 
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co-cultured with WT and ΔFlaA C. jejuni strain 11168H for 24h. S. aureus, which also 
belongs to the proteobacteria taxa and does not activate TLR5, was used as a control. 
WT and flagellum-negative FliC Salmonella typhimurium, as well as flagellin derived 
from the pathogen, were used to confirm flagellum-specific TLR5 activation. Induction 
of IL-8 was minimal in WT HEK293 cells across all treatments (Figure 5.4). Activation 
was only detected in Salmonella typhimurium-infected and flagellin-treated TLR5 
HEK293 cells, while infection with C. jejuni or ΔFliC Salmonella typhimurium did not 
induce IL-8 expression, confirming that C. jejuni flagellum is TLR5 insensitive.  
Our lab had previously demonstrated that the IL-10 response to C. jejuni is modulated 
in the presence of the flagella (218). The critical role of flagella in the induction of IL-10 
in human APCs was confirmed by co-culturing mDCs as well as M1- and M2-type 
macrophages with WT or ΔFlaA C. jejuni 1168H. While the TNFα response was 
unaffected by the lack of flagella, IL-10 levels were significantly lower in cells co-
cultured with the ΔFlaA mutant; both DCs (Figure 5.5; P=0.037) and M1-type (P=0.039) 
or M2-type (P<0.001) macrophages (Figure 5.6). Notably, the difference in IL-10 
induction was more pronounced in M2-type macrophages, which are considered anti-
inflammatory.  
The lack of a model cell line for human DCs led as to utilise pre-monocytic THP-1 cells 
which were PMA-treated to achieve macrophage-like differentiation into dTHP-1 cells, 
as discussed in Chapter 3. We also considered macrophages to be a more appropriate 
model as they produce significantly higher levels of the cytokine compared to DCs. The 
contribution of flagella in the cytokine response of these cells to C. jejuni was analysed 
to assess whether the cell line would offer an appropriate model for our investigation. 
IL-10 gene expression was analysed from 1h following co-culture with C. jejuni 11168H 
and up to 24h (Figure 5.7). IL-10 and TNFα cytokine levels were also measured at 8h  
	  	  170 
  
Figure 5.2. Dose-dependent effect of C. jejuni on monocyte-derived dendritic cell 
(mDC) IL-10 and TNFα production.  
5x105 human monocyte-derived dendritic cells (mDCs) were co-cultured with wild-type 
(WT) C. jejuni strains 11168H or 81-176 at MOI 10 or 100 for 24h. IL-10 and TNFα 
cytokines were analysed in the supernatants by ELISA. Values represent means ± 
SEM from four donors measured in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<001). 
  
0
500
1000
1500
2000
2500
11168H
Control 10 100
81-176
10 100
IL
-1
0 
[p
g/
m
L]
** **
0
20000
40000
60000
80000
11168H
Control 10 100
81-176
10 100
TN
Fα
 [p
g/
m
L]
** *
	  	  171 
Figure 5.3. Time-dependent effect of C. jejuni on mDC IL-10 and TNFα production.  
5x105 human mDCs were co-cultured with C. jejuni strain 11168H or 81-176 at MOI 
100 for 8 and 24h. IL-10 and TNFα cytokines were analysed in the supernatants by 
ELISA. Values represent means ± SEM from four donors measured in duplicate. 
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Figure 5.4. C. jejuni flagellum is not recognised by TLR5.  
1x106 WT or TLR5-transfected HEK cells were co-cultured with clinical isolates of 
various enteropathogens; WT or ΔflaA C. jejuni strain 11168H (MOI 100), S. aureus 
(MOI 5) and WT or ΔFliC Salmonella typhimurium (MOI 1). 5μg/ml flagellin from 
Salmonella typhimurium was used as a positive control of TLR5 activation. After 6h, IL-
8 was analysed in the supernatants by ELISA. Values are means ± SEM from three 
independent experiments performed in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<0.01). 
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Figure 5.5. C. jejuni flagellum is required for optimal IL-10 induction in human 
monocyte-derived DCs.   
5x105 human mDCs were co-cultured with WT or ΔFlaA C. jejuni strain 11168H MOI 
100. After 16h, IL-10 and TNFα cytokines were analysed in the supernatants by ELISA. 
Values represent means ± SEM from four donors measured in duplicate. Statistical 
analysis by paired t-test (*P=0.0127).  
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Figure 5.6. C. jejuni flagellum is required for optimal IL-10 induction in human 
MDMs.  
5x105 human monocyte-derived M1- and M2-type macrophages were co-cultured with 
WT or ΔflaA C. jejuni strain 11168H MOI 100. After 16h, IL-10 and TNFα cytokines 
were analysed in the supernatants by ELISA. Values represent means ± SEM from four 
healthy donors analysed in duplicate. Statistical analysis by paired t-test (*P=0.045,  
***P=0.0001).  
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Figure 5.7. C. jejuni flagellum is required for optimal IL-10 induction in dTHP-1 
cells.  
5x105 dTHP-1s were co-cultured with WT or ΔFlaA C. jejuni strain 11168H MOI 100 for 
8 and 24h. (A) At the indicated times, IL-10 gene transcription was analysed by 
quantitative real-time PCR. Values are expressed as mean ± SEM from three 
independent experiments (*P=0.05). (B) IL-10 and TNFα cytokines were analysed in 
the supernatant by ELISA. Values are means ± SEM from three independent 
experiments analysed in duplicate. Statistical analysis by paired t-test (*P=0.0338, 
**P=0.0056). 
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and 24h post-infection. Differential induction of IL-10 transcription in dTHP-1 cells co-
cultured with WT and ΔFlaA C. jejuni was observed consistently from 1h and up to 8h 
following infection (Figure 5.7A) with the difference becoming statistically significant at 
4h (P=0.047). Correspondingly, a statistically significant difference in IL-10 protein 
levels was observed at both 8 (P=0.034) and 24h (P=0.006) (Figure 5.7B). Similar to 
primary APCs, no difference was observed in TNFα protein levels (Figure 5.7C). 
To study the early-stage interactions of C. jejuni with macrophages, the rate of bacterial 
phagocytosis following adherence was also examined by quenching extracellular 
fluorescence from FITC-labelled bacteria, thus detecting only cells where intracellular 
bacteria were present. As Figure 5.8 shows, bacteria adhered to ~ 20% of cells after 
15mins of co-culture but only became internalised by ~ 3% of those cells. After 30mins, 
however, intracellular bacteria were detected in over 19% of cells from a total of ~ 30% 
positive for C. jejuni. And after 60mins of co-culture, that number had risen to ~ 33% of 
cells from a total of 40% of cells with bacteria present. Therefore, C. jejuni is rapidly 
internalised by dTHP-1 cells and comes early in contact with the cellular immune 
apparatus. After 90mins the numbers of total and intracellular bacteria did not change 
significantly. This information is important for the study of C. jejuni survival within 
macrophages. 
We also argued that lack of flagella could affect the motility and hence the interaction of 
the ΔFlaA C. jejuni mutant with macrophages. In addition to comparing WT and ΔFlaA 
C. jejuni, immotile heat-inactivated C. jejuni were compared to the live, motile bacteria. 
Live or heat-inactivated, WT or ΔFlaA C. jejuni was FITC-labelled prior to co-culture 
with dTHP-1s. The experiment was performed either at 4°C to prevent bacterial 
internalisation or at room temperature where phagocytosis could take place. No 
significant difference in the adherence of WT and ΔFlaA C. jejuni, live or heat- 
	  	  177 
 
Figure 5.8. Time-dependent phagocytosis of C. jejuni by dTHP-1 cells.  
5x105 dTHP-1 cells were co-cultured with FITC-labelled WT C. jejuni strain 11168H 
MOI 100 for the indicated times. After the presence of bacteria was analysed by flow 
cytometry, trypan blue was used to assess the presence of intracellular bacteria. 
Values are means ± SEM from at least three independent experiments performed in 
duplicate. Statistical analysis by paired t-test (***P< 0.0001). 
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inactivated was detected (Figure 5.9). Heat-inactivated bacteria appeared to adhere 
slightly better than live, with ~ 61 compared to 58% FITC-positive cells, perhaps due to 
the lack of a capsule which may reveal structures recognised by dTHP-1 cells.  
Likewise, we did not observe a significant difference in the internalisation of WT and 
ΔFlaA C. jejuni (Figure 5.10). Additionally, the survival assay performed showed no 
difference in C. jejuni survival between the WT and ΔFlaA mutant (Figure 5.11), 
indicating that flagellum and motility do not affect the intracellular life of the 
microorganism. 
	  	  179 
 
Figure 5.9. Flagella do not affect C. jejuni adherence to dTHP-1 cells. 5x105 dTHP-
1s were co-cultured with FITC-labelled live or heat-inactivated WT or ΔFlaA C. jejuni 
strain 11168H MOI 100 at 4°C to prevent bacteria internalisation. After 1h, bacterial 
adherence was analysed by flow cytometry. Values are means ± SEM from at least 
three independent experiments performed in duplicate. Statistical analysis by paired t-
test. 
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Figure 5.10. Flagella do not affect C. jejuni phagocytosis by dTHP-1 cells.  
5x105 dTHP-1 cells were co-cultured with FITC-labelled live or heat-inactivated WT or 
ΔFlaA C. jejuni strain 11168H MOI 100 for 1h. Intracellular bacterial presence was 
assessed using trypan blue dye and flow cytometry. Values are means ± SEM from at 
least three independent experiments performed in duplicate. Statistical analysis by 
paired t-test. 
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Figure 5.11. Flagella do not affect C. jejuni survival in dTHP-1 cells.  
5x105 dTHP-1s were co-cultured with WT or ΔFlaA C. jejuni strain 11168H MOI 100 for 
2h, followed by gentamycin treatment (100μg/ml; to kill extracellular bacteria) for an 
additional 2h. 4h post-infection, cells were lysed and intracellular bacteria plated and 
colonies counted after 48h. Values are mean ± SEM from at least three independent 
experiments performed in duplicate. 
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5.2.2 Differential signalling in the presence of C. jejuni flagella 
Once the role of the flagella in the C. jejuni-mediated IL-10 response had been 
established; we set out to characterise the signalling mechanisms underlying the 
differential cytokine induction. Previous work based in BMDCs established that 
flagellum-mediated signalling is NF-κB independent (218). We confirmed these findings 
in a model of human macrophages by transducing dTHP-1 cells with a reporter 
construct for NF-κB activation; no difference was observed between WT and ΔFlaA C. 
jejuni-induced signalling (Figure 5.12). Instead, differential induction of IL-10 in the 
presence of flagella was attributed to hyper-activation of MAPK signalling; more 
specifically ERK and p38 kinases, which in turn induced IL-10 over-expression (218). 
To study signalling pathway activation and modulation in the presence of C. jejuni 
flagella, a phosphokinase array kit was used. Protein phosphorylation is a post-
translational modification, which, in principle, triggers activation of the modified target. 
The array contains antibodies against a range of kinases embedded in the membrane. 
Following incubation of the membrane with the cell lysates, an anti-phospho-tyrosine 
antibody is used to detect the phosphorylation levels of these kinases. Levels of bound 
phosphoproteins can then be quantified by autoradiography. dTHP-1 cells were co-
cultured with C. jejuni for 1h prior to cell lysis and analysis of kinase phosphorylation on 
radiography film (Figure 5.13A). 
	  	  183 
 
Figure 5.12. WT and ΔflaA C. jejuni mediate similar levels of NF-κB induction. 
 5x105 dTHP-1s transduced with a NF-κB-luciferase reporter plasmid were co-cultured 
with WT or ΔFlaA C. jejuni strain 11168H MOI 100 for 4h (white bar) or 8h (black bar). 
Luciferase activity was determined by spectrophotometry (450 nm). Values represent 
mean ± SEM from three independent experiments performed in duplicate. Statistical 
analysis by paired t-test (**P<0.01, ***P<0.001).  
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Figure 5.13A. WT and ΔFlaA C. jejuni induce differential dTHP-1 signalling as 
determined by phosphokinase array.  
5x106 dTHP-1s were co-cultured with WT or ΔFlaA C. jejuni strain 11168H MOI 100. 
1h post-infection, kinase phosphorylation was analysed using a Phospho-kinase Array 
kit by R&D. Image shown is a representative of three independent experiments 
analysed in duplicate. 
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The film was digitalised and signal intensity analysed by imaging software. Initially, 
data were ordered by pixel density to identify the most abundant phosphokinases in the 
dTHP-1 cell response to C. jejuni (Figure 5.13B; Mean Pixel Density). MAPKs were 
amongst the highest ranking, with p38 being the most abundant and ERK1/2 and JNK 
in the following ten places amongst 45 other proteins. High levels of phosphorylated 
Akt, RSK, c-Jun, GSK-3α/β, MSK-1 and CREB, all linked to MAPK-induced signalling 
were also detected. Other highly abundant phosphoproteins were HSP27, WNK1, 
STAT2, HSP60, PRAS40 and AMPKα2. To identify flagella-specific kinase activation, 
pixel density values between dTHP-1 cells co-cultured with WT and ΔFlaA C. jejuni 
were compared. Data was plotted as fold change in signal intensity between the two 
samples (Figure 5.13B; Fold Change). Strong differential induction in the presence of 
flagella was observed for ERK and JNK and less so for p38. Members of the STAT 
family of kinases, predominantly STAT3, also became significantly more 
phosphorylated. Finally, both Akt and GSK3-α/β appeared more phosphorylated in the 
presence of flagella. While each of the above metrics can be informative in terms of 
absolute values, we wanted to assess how the flagella of C. jejuni modulate kinase 
activation relative to the microorganism. Therefore, mean pixel density values were 
multiplied by fold change to identify flagella-specific protein hyper-activation relative to 
total protein activation (Figure 5.13B; Relative Change). With regards to MAPKs, our 
analysis revealed that ERK1/2 and p38, rather than JNK, become hyper-induced in the 
presence of C. jejuni flagella. Differential phosphorylation of Akt and GSK3-α/β was the 
next most significant in ranking, re-enforcing our earlier findings. Amongst other 
kinases that appear significantly more phosphorylated in the presence of flagella are 
RSK-1/2/3, CREB, HSP27, AMPK, WNK1 and c-Jun. Finally, we confirmed that the 
presence of C. jejuni flagella leads to AKT and MAPK hyper-activation by Western 
blotting (Figure 5.14). 
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Figure 5.13B. WT and ΔFlaA C. jejuni induce differential dTHP-1 signalling as 
determined by phosphokinase array.  
Pixel density analysis was performed using Gimp 2.8 software. Data shown is ordered 
by signal value (Mean Pixel Density) in WT C. jejuni-infected cells, signal value 
difference (Fold Change) in WT vs. ΔflaA C. jejuni-infected cells, or the product of their 
multiplication (Relative Change). Values are mean from three independent experiments 
analysed in duplicate. 
Mean Pixel Density
0 2000 4000 6000 8000 10000
p38α
HSP27
Akt 1/2/3 (S473)
WNK1
RSK-1/2/3
c-Jun
GSK-3α/β
ERK1/2
CREB
STAT2
JNK
HSP60
PRAS40
AMPKα2
MSK1/2
Stat5a/b
CHk-2
EGF R
STAT5α
STAT6
STAT5b
Lyn
p70 S6 Kinase (T421/S424)
STAT3 (S727)
p53 (S15)
TOR
p53 (S46)
Src
p27
Akt 1/2/3 (T308)
β-Catenin
Fyn
Yes
Lck
Fgr
Hck
p53 (S392)
eNOS
STAT3 (Y705)
AMPKa1
PLC-γ1
PDGF Rβ
FAK
PYK2
p70 S6 Kinase (T389)
	  	  187 
Figure 5.13B. WT and ΔFlaA C. jejuni induce differential dTHP-1 signalling as 
determined by phosphokinase array (continued).  
Pixel density analysis was performed using Gimp 2.8 software. Data shown is ordered 
by signal value (Mean Pixel Density) in WT C. jejuni-infected cells, signal value 
difference (Fold Change) in WT vs. ΔflaA C. jejuni-infected cells, or the product of their 
multiplication (Relative Change). Values are mean from three independent experiments 
analysed in duplicate. 
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Figure 5.13B. WT and ΔFlaA C. jejuni induce differential dTHP-1 signalling as 
determined by phosphokinase array (continued).  
Pixel density analysis was performed using Gimp 2.8 software. Data shown is ordered 
by signal value (Mean Pixel Density) in WT C. jejuni-infected cells, signal value 
difference (Fold Change) in WT vs. ΔflaA C. jejuni-infected cells, or the product of their 
multiplication (Relative Change). Values are mean from three independent experiments 
analysed in duplicate. 
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Figure 5.14. C. jejuni flagella lead to hyper-activation of AKT and MAPK 
signalling in dTHP-1 cells.  
1x106 dTHP-1s were co-cultured with WT or ΔFlaA C. jejuni strain 11168H MOI 100. 
1h post-infection, kinase phosphorylation was analysed at the indicated times by 
Western blot. Total p38 levels were used as loading control. Representative blot from 
two independent experiments is shown. 
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Our analysis of phosphokinase array data revealed four major signalling targets that 
become hyper-phosphorylated in the presence of C. jejuni flagella; MAPKs, AKT, 
STAT3 and GSK3. Importantly, all of these kinases are involved in the regulation of IL-
10 expression, while both AKT and MAPKs have been linked to the immune response 
to C. jejuni  (282), (368), (218). The role of these kinases in C. jejuni-mediated IL-10 
induction was further assessed by the use of functional inhibitors. dTHP-1 cells were 
treated with ERK1/2-, JNK- and p38-specific inhibitors at increasing dosage prior to co-
culture with C. jejuni strain 11168H. After 24h, IL-10 and TNFα protein levels were 
measured in the supernatant. Treatment with a low dose of ERK1/2 inhibitors led to a 
significant reduction in IL-10 (UO126; P=0.0013) but not TNFα cytokine levels (Figure 
5.15). At a higher dose, we detected a decrease in the levels of both proteins, yet this 
was statistically more significant for IL-10 (UO126; p<0.0001, PD90859; p<0.0001) 
compared to TNFα (UO126; P=0.0033, PD90859; P=0.054). Inhibition of JNK only 
affected cytokine induction when a high dosage of the inhibitor was used. The effect 
appeared to have similar statistical significance for IL-10 (SP60025; P=0.0004) and 
TNFα (SP60025; P=0.0002). Again, both cytokines were affected by inhibition of p38 
signalling with a low dose of inhibitors, although the reduction in secreted IL-10 
(SB203580; P=0.0005, SB239023; p<0.0001) was statistically more significant 
compared to that of TNFα (SB203580; P=0.0149, SB239023; P=0.0069). The 
difference in cytokine production persisted when a high dosage of inhibitor was used, 
where again the decrease in IL-10 (SB203580; p<0.0001, SB239023; p<0.0001) was 
more pronounced than in TNFα (SB203580; P=0.0077, SB239023; P=0.0080). These 
findings reinforce the key role of MAPK signalling in the IL-10 to C. jejuni infection.  
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In a similar fashion, the role of AKT signalling in the IL-10 response to C. jejuni was 
investigated by treating dTHP-1 cells with inhibitors for AKT at a low and a high dose. 
Using low dose inhibitors, we observed decreased IL-10 and TNFα production after 
24h, however reduction in secreted IL-10 (LY294002; P=0.0247, Wort; P=0.0026) was 
statistically more significant than in TNFα (LY294002; P=0.0132, Wort; P=0.0855) 
(Figure 5.16). Similarly, at a high dose, the reduction in IL-10 (LY294002; P=0.0021, 
Wort; P=0.0028) was again more significant in comparison to the reduction in TNFα 
signaling (LY294002; P=0.0025, Wort; P=0.0211). Next, using the Stat3 inhibitor stattic, 
we found both the IL-10 and TNFα response to C. jejuni to be Stat3-dependent, yet the 
reduction in IL-10 (Stattic; P=0.0011) was statistically more significant than in TNFα 
(Stattic; P=0.0023). 
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Figure 5.15. MAPKs play a critical role in C. jejuni-mediated IL-10 induction.  
5x105 dTHP-1s were pre-treated with inhibitors of MAPK signalling; targeting MEK1/2 
(U0126 & PD5090859), JNK (SP600125) or p38 (SB203580 & SB239063) at a 
concentration of 1μM (light bar) or 10μM (dark bar) (5μM and 50μM for PD5090859). 
1h after treatment, cells were co-cultured with C. jejuni MOI 100 for 24h in the 
presence of inhibitors and the supernatants analysed for IL-10 and TNFα cytokines by 
ELISA. Values are mean ± SEM from three independent experiments performed and 
analysed in duplicate. Statistical analysis by paired t-test (*P<0.05, **P<0.01, 
***P<0.001). 
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Figure 5.16. AKT and STAT3 signalling are important for C. jejuni-mediated IL-10 
induction.  
5x105 dTHP-1s were pre-treated with the AKT inhibitors LY294002 and wortmannin at 
a concentration of 10μM (light bar) or 50μM (dark bar) and the STAT3 inhibitor stattin 
(10μM). 1h after treatment, cells were co-cultured with C. jejuni MOI 100 for 24h in the 
presence of inhibitors and the supernatants analysed for IL-10 and TNFα cytokines by 
ELISA. Values are mean ± SEM from three independent experiments performed and 
analysed in duplicate. Statistical analysis by paired t-test (*P<0.05, **P<0.01). 
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The final kinase identified by our phosphokinase study was GSK-3. This protein 
consists of an α and β subunit (GSK3-α/β) and acts as a negative regulator of IL-10 
expression when de-phosphorylated. Phosphorylation of the β subunit leads to the 
inactivation of GSK3 and subsequent removal of IL-10 expression blockage. LiCl was 
used to inhibit the phosphorylation of GSK-3β in dTHP-1 cells co-cultured with C. jejuni 
and IL-10 cytokine levels were assessed after 24h. While treatment with LiCl alone, 
triggered induction of IL-10, this was not statistically significant (Figure 5.17). A similar 
enhancement of the IL-10 response was observed in cells co-cultured with WT C. jejuni 
strain 11168H, which did not reach statistical significance. However, in dTHP-1 cells 
co-cultured with ΔFlaA C. jejuni strain 11168H, IL-10 production was significantly 
higher in the presence of LiCl (P=0.0374). Therefore, flagella-induced phosphorylation 
of GSK3-β is a critical step in the differential induction of IL-10 by WT C. jejuni, as it 
deactivates suppression of the cytokine. In conclusion, we have been able to verify the 
involvement of those kinases identified through our phosphokinase array study (MAPK, 
AKT, Stat3 and GSK3) (see Figure 5.11A) in the immune response to C. jejuni and 
exhibit their importance in the pathogen-driven induction of IL-10. 
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Figure 5.17. Inhibition of GSK-3β phosphorylation restores IL-10 secretion in C. 
jejuni FlaA mutant.  
5x105 dTHP-1s were pre-treated with 1mM LiCl to inhibit GSK-3β phosphorylation. 1h 
after treatment, cells were co-cultured with C. jejuni MOI 100 for 24h in the presence of 
LiCl and the supernatants analysed for IL-10 cytokine by ELISA. Values are mean ± 
SEM from three independent experiments analysed in duplicate. Statistical analysis by 
paired t-test (*P<0.05). 
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5.2.3 C. jejuni flagella induce EGFR activation 
Our work this far has outlined the differential activation of signalling cascades leading 
to induction of IL-10 in cells co-cultured with WT vs. the aflagellate ΔFlaA mutant of C. 
jejuni strain 11168H. In order to investigate the effects of C. jejuni flagella in greater 
detail, flagella were isolated and coupled to carboxyl-modified beads. Based on our 
findings of TLR-independent enhancement of AKT and MAPK signalling by C. jejuni 
flagella, we identified EGFR, a signalling factor upstream of both these cascades, as a 
likely mediator of flagellum-induced signalling. Phosphorylation of EGFR was 1.7x 
higher in the presence of flagella in dTHP-1 cells co-cultured with C. jejuni strain 
11168H (Figure 5.13B). Therefore, we hypothesised that the flagellum of C. jejuni 
would activate EGFR. dTHP-1 cells were treated with WT and ΔFlaA C. jejuni strain 
11168H, as well as flagella coupled to beads. Treatment with uncoupled beads and C. 
jejuni LOS were used as experimental controls. EGF-R phosphorylation was analysed 
by flow cytometry using an APC-conjugated anti-human phospho-EGF-R antibody 
(Figure 5.18A). According to our results, WT but not ΔFlaA C. jejuni was able to induce 
EGFR phosphorylation at statistically significant levels (P=0.0394) (Figure 5.18B). 
Interestingly, flagella alone were able to activate EGF-R in treated dTHP-1 cells 
(P=0.0101). Although an increase in the number of phospho-EGFR-positive cells was 
observed following treatment with LOS (Figure 5.18A), that shift was not statistically 
significant (Figure 5.18B). 
To test whether C. jejuni flagella-induced activation of EGFR would sufficiently 
compensate for the diminished IL-10 response to the aflagellate pathogen, dTHP-1 
cells were co-cultured with WT and ΔFlaA of C. jejuni 11168 alone or in the presence 
of flagella-coupled beads. Isolated C. jejuni flagella were not able to induce IL-10 
production or rescue IL-10 induction in response to ΔFlaA C. jejuni (Figure 5.19). We 
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reasoned that the plurality of virulence factors in the pathogen might confound any 
signalling driven by the isolated flagella and used purified LOS of C. jejuni to gain more 
insight. While LOS-mediated induction of IL-10 was marginally enhanced in the 
presence of isolated flagella, the difference was not statistically significant. Therefore, 
while treatment of dTHP-1 cells with C. jejuni flagella led to EGF-R activation, it cannot 
induce or enhance production of IL-10 on its own. 
 
5.5 Discussion 
Expanding on previous work from our group, we investigated the signalling 
mechanisms involved in flagellum-mediated enhancement of the host IL-10 response 
to C. jejuni. While previous work had been carried out in murine cells, we focused on 
innate immune cells of human origin where C. jejuni is an opportunistic pathogen. First, 
a C. jejuni infection model was established based on the co-culture of the pathogen 
with monocyte-derived DCs (Figures 5.2). As IL-10 is a late response gene (338), 
significant cytokine levels were only detected after 24h (Figure 5.3). The cytokine 
response of primary DCs to C. jejuni was comparable to that of Stephenson et al. (218) 
and similar to BMDCs findings from previous studies (231). Subsequently, we 
employed the flagellate ΔFlaA mutant of C. jejuni to investigate the mechanisms of 
flagellum-mediated IL-10 induction. As we show in Figure 5.4, the flagellum of C. jejuni, 
amongst other proteobacteria, has evolved to evade TLR5 recognition (217), which 
may contribute to host evasion by avoiding activation of APCs (369). In conjunction 
with the ability of C. jejuni flagella to enhance IL-10 production in these cells (218), a 
rather fetching hypothesis forms around the tolerogenic role of the flagella structure. 
Similar to our earlier findings in BMDCs (218), the absence of flagella led to a 
diminished IL-10 response, while TNFα levels were unaffected (Figure 5.5).   
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Figure 5.18. C. jejuni flagellum induces EGFR phosphorylation.  
5x105 dTHP-1s were co-cultured with (A) WT or ΔFlaA C. jejuni (left panel), beads or 
flagella-coated beads (10μl/ml) and C. jejuni LOS (1ng/ml) (right panel). 1h post-
stimulation, phosphorylated EGFR was detected by intracellular staining and analysed 
by flow cytometry. Histograms shown are representative of three independent 
experiments performed in duplicate. (B) Chart of mean fluorescence intensity (M.F.I) 
values expressed as Mean ± SEM from three independent experiments performed in 
duplicate. Statistical analysis by paired t-test (WT C. jejuni; P=0.0394 , Flagellum 
P=0.0101). 
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Figure 5.19. Effect of isolated flagellum on the IL-10 response to C. jejuni.  
5x105 dTHP-1s were co-cultured with WT or ΔFlaA C. jejuni MOI 100 and 1ng/ml LOS 
alone or in the presence of 10μl/ml C. jejuni flagellum-coated beads. 24h post-
stimulation, IL-10 cytokine was analysed in the supernatants by ELISA. Values are 
mean ± SEM from three independent experiments analysed in duplicate. Statistical 
analysis by paired t-test (**P=0.0037). 
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This was consistent in monocyte-derived DCs and macrophages; with both M1- and 
M2-type macrophages exhibiting flagella-dependent enhancement of IL-10 production. 
The effect was significantly more pronounced in tolerogenic M2-type macrophages 
where IL-10 transcription is enhanced via epigenetic changes during differentiation 
(370), yet evident in all three cell types. Differential IL-10 induction in the absence of 
flagella was also observed in dTHP-1 cells (Figure 5.6). The effect was independent of 
bacterial motility as bacterial adherence (Figure 5.7) and survival (Figure 5.9) were 
unaffected in the absence of flagella. Whereas the flagella are required for the invasion 
of intestinal immune cells (371), dTHP-1 cells phagocytose bacteria rapidly (within 
30min) (Figure 5.8). It is worth noting that the FlaA gene contains a variable region and 
such variability may affect the interaction of the flagella with the Siglec-10 receptor as 
well as the induction of IL-10. A comparison between strains with different FlaA 
variants would contribute greatly to our study. 
The phosphokinase array employed to delineate signalling events upstream of IL-10 
transcription, revealed the activation of two main pathways by C. jejuni; the MAPK and 
the PI3K signalling pathways (Figure 5.11B). All three members of the MAPK family 
were activated by C. jejuni, as others have previously reported (245). Akt, a kinase of 
the PI3K signalling cascade, was also highly phosphorylated. PI3K signalling was 
recently found to contribute to C. jejuni-induced colitis in mice (282). Both ERK and p38 
signalling pathways have been implicated in the induction of IL-10 (367) and ERK 
activation is required for optimal IL-10 induction in macrophages and DCs (338). As 
expected, downstream members of these two pathways also became phosphorylated. 
In the MAPK pathway, the chaperone protein HSP27 undergoes ERK-dependent 
phosphorylation (372) and the transcription factor c-Jun is a target of JNK (273). In the 
PI3K cascade, WNK1 mediates Akt-dependent signalling (373). Interestingly, some of 
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these kinases are known regulators of IL-10 expression; as discussed earlier GSK3-β 
acts as a repressor of IL-10 and the transcription factor CREB controls IL-10 
expression in macrophages (338). Downstream of both ERK and p38, the RSK-1/2/3 
complex drives epigenetic modifications in the IL-10 promoter by phosphorylating H3 
(S10) to facilitate transcription (374). Overall, the strong activation of ERK, p38 and Akt 
reinforces our hypothesis that C. jejuni induces IL-10 production in macrophages as an 
immune evasion mechanism. Finally, C.jejuni induced phosphorylation of AMPK-2α, a 
member of the AMP-activated protein kinase (AMPK) signalling pathway, which 
becomes activated when intracellular ATP levels fall (375). ATP production decreases 
as cells switch from metabolic processes to defence functions. 
By comparing WT to ΔFlaA C. jejuni, we detected differential activation of signalling 
pathways in co-cultured cells in the presence of the flagella. Phosphorylation of STAT3 
and STAT5, two ERK-dependent transcription factors that bind the IL-10 locus (376), 
was more than 2-fold higher. Both MAPK and PI3K signalling was enhanced in cells 
co-cultured with flagellated WT C. jejuni. While ERK and JNK showed higher 
differential activation compared to p38, relative induction was higher for ERK and p38 
(Figure 5.11B). When activation of MAPKs was analysed by western blotting, ERK and 
p38 rather than JNK, appeared to become hyper-activated in the presence of flagella 
(Figure 5.12). The importance of both signalling pathways in C. jejuni-mediated IL-10 
induction was confirmed by inhibitor studies (Figure 5.13, Figure 5.14 and Figure 5.15). 
MAPK activation by C. jejuni is TLR-mediated (250), (368) and drives the induction of 
IL-10 as well as pro-inflammatory mediators (377), (378). Nevertheless, inhibition of 
either ERK or p38 activation leads to a reduction, but not abrogation, of IL-10 
expression (367), which suggests that these two pathways might cooperate in TLR-
induced IL-10 production. Likewise, TLR signalling leads to activation of Akt (379), 
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although the mechanism of C. jejuni-mediated PI3K activation has not been studied in 
detail. 
In the case of C. jejuni, however, hyper-induction of MAPK and Akt signalling by the 
flagella is TLR5-independent. Using isolated flagella coupled to beads we were able to 
show that C. jejuni flagella alone is able to activate EGFR (Figure 5.16). Due to study 
limitations, the purity of the flagella preparation was not assessed for the presence of 
contaminants such as LOS. As the receptor sits upstream of both signalling cascades 
(273), we propose that flagella-mediated EGFR activation enhances MAPK and Akt 
signalling. In support of our hypothesis, Pi3K activation by Pseudomonas aeruginosa is 
dependent on EGFR activation and, furthermore, isolated flagella were shown to 
activate EGFR (380). Yet, amalgamation of more signals may be required for IL-10 
hyper-induction, as co-stimulation with flagella-coupled beads was not sufficient to 
restore cytokine levels. IL-10 gene expression requires rapid transient modifications of 
the promoter augmented by transcription factor recruitment in a remarkably time-limited 
sequence (381), therefore the addition of isolated flagella may not replicate the kinetics 
of WT C. jejuni interaction with the cells. In work published by our group and discussed 
in detail in Chapter 6, we showed that C. jejuni flagella-specific binding to the Siglec10 
receptor led to an increase in IL-10 production (218). To our knowledge, this is one of 
the first TLR5-independent flagellum interactions reported, so the involvement of other 
receptors in flagellum recognition will need to be investigated in more depth. 
While the role of IL-10 in the interaction of C. jejuni with host immunity remains unclear, 
another interesting link between C. jejuni and IL-10 expression has emerged. In 2006, 
Manfield et al. demonstrated C. jejuni-induced colitis in IL-10-/- mice at a higher rate 
than the lack of other immune elements such as TLRs and NODs (382). These 
gnobiotic IL-10 deficient mice lack the anti-inflammatory signalling to counter-act the 
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onset of colitis and have since been used in a number of studies of C. jejuni-induced 
enteritis (71), (383). Yet, while the role of intestinal IL-10 is pivotal for the onset of C. 
jejuni-induced enteritis, its role in C. jejuni pathogenesis is not yet fully understood.
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Chapter 6 
Campylobacter jejuni interaction 
with Siglec receptors
6.1 Introduction 
As shown in Chapter 5 the flagellum of C. jejuni modulates the IL-10 response to the 
pathogen. We therefore went on to investigate possible receptors involved in flagellum 
recognition. We have shown that glycosylated flagellum was able to modulate IL-10 
expression, suggesting that host glycan receptors may play a role. An emerging 
paradigm suggests that microbes can modulate host IL-10 expression via engagement 
of glycan receptors, for example Mycobacterium tuberculosis and Candida albicans 
engage DC-SIGN on DCs (384),(385). Studies have previously reported that strains of 
C. jejuni are recognised by members of the Siglec receptor family (262). More recently, 
our group showed that Siglec-10 specifically binds to the flagellum of C. jejuni (218). 
Siglecs have emerged as important players in the regulation of many cellular 
processes including endocytosis, apoptosis, cellular activation, and proliferation (253). 
Siglecs bind sialylated structures via a terminal V-set Ig domain. They exhibit varying 
specificities for the linkage of the sialic acid (SA) and the underlying glycan structure 
which can be present on both the host cell and on microbes, thus promoting both cis- 
and trans-interactions (386). 
In general, Siglecs show low affinity for the SA N-acetylneuraminic acid (Neu5Ac) α2,3 
and α2,6 linkages to galactose (Neu5Acα2–3Gal and Neu5Acα2–6Gal) that are 
commonly found as terminal sequences on glycans of glycoproteins and glycolipids of 
most mammalian cells (387). Yet some pathogenic microorganisms, including C. jejuni, 
have evolved the ability to synthesise SAs that serve as molecular mimics of the host 
cell surface in order to evade immune activation (388). C. jejuni can express 
monosialylated and disialylated LOS with a2,3- or a2,3/2,8-linked SA residues, 
respectively. LOS sialylation can affect phagocytosis and the cytokine response to C. 
jejuni (389). It has also been associated with increased severity of gastroenteritis(390), 
as well as with the development of Guillain-Barré syndrome (391). 
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For the largest part, research on the interaction of C. jejuni with Siglecs has focused on 
deciphering the link between C. jejuni infection and the onset of Guillain-Barré. 
Molecular mimicry between C. jejuni sialylated LOS and human nerve gangliosides can 
trigger the production of cross-reactive antibodies leading to induction of Guillain-
Barré(392). Strains of C. jejuni associated with Guillain-Barré contain disialylated LOS 
that is recognised by Siglec-7 (262),(393) and monosialylated LOS recognized by 
sialoadhesin (Sn; also known as Siglec-1) (263),(394). Our interest lies in the enteric 
pathology of C. jejuni and, hence, the reference C. jejuni strain 11168, a clinical isolate 
associated with enteritis, was used. C. jejuni 11168 presents GM1a and GM2 
ganglioside mimicry and therefore contains monosialylated α2,3-linked Neu5Ac on its 
surface. Enteritis-associated strains of C. jejuni with sialylated LOS are recognised by 
Sn (263), although no link to disease onset exists. The 11168 strain used in this study 
can bind to Sn (395), but not Siglec-7 (393). Despite the extensive use of C. jejuni 
11168 in research, very little is known regarding its interaction with other members of 
the Siglec family.  
 
6.1.2 Siglec-10 binding to C. jejuni flagellum 
A novel interaction between C. jejuni and a member of the Siglec family was recently 
uncovered by our team. The Siglec-10 receptor was shown to bind to structures on the 
flagellum of C. jejuni 11168 (218). While the surface of C. jejuni contains SA structures, 
the flagellum proteins of C. jejuni are O-linked glycosylated with Sia-like structures, 
derivatives of pseudaminic acid (Pse), and sometimes legionaminic acid (Leg), 
moieties. These moieties are important for flagellum assembly and colonisation in 
chickens (216),(213). In particular, the Pse5Ac7Am moiety, which is structurally related 
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to Neu5Ac, appeared to be critical. Furthermore, the interaction between C. jejuni and 
Siglec-10 receptor was independent of the Neu5Ac. In Chapter 5, we reported on the 
capacity of the flagellum to modulate IL-10 production in response to C. jejuni. 
Therefore, we became interested in the functional implications of flagellum recognition 
by Siglec-10 and, more specifically, in whether flagellum binding to Siglec-10 could 
affect IL-10 induction by C. jejuni 11168.  
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6.2 Results 
6.2.1 Role of Siglec-10 in C. jejuni flagellum-mediated IL-10 induction 
As discussed in Chapter 5, C. jejuni flagellum led to enhancement of IL-10 production 
in DCs and macrophages. Siglec-10 expression has only previously been reported in 
human monocytes and DCs, but not macrophages(256). We therefore differentiated 
primary human monocytes into both M1- and M2-type macrophages and analysed 
them for expression of Siglec-10. Both cell types were positive for Siglec-10 expression 
(Figure 6.1) although levels amongst donors were variable. Furthermore, pre-monocytic 
THP-1 cells and PMA-differentiated THP-1 (dTHP-1) cells expressed Siglec-10 (Figure 
6.2). We observed increased Siglec-10 expression following PMA maturation of THP-1 
cells, indicating induction of the receptor in mature macrophages. 
To study the potential link between Siglec-10 and C. jejuni flagellum-mediated IL-10 
induction, we over-expressed the receptor in the THP-1 cell line. Cells were transduced 
at two different MOIs (MOI 1 and MOI 10) and sorted according to Siglec-10 
expression to yield two distinct cell lines: Siglec-10-Low and Siglec-10-High, expressing 
lower and higher levels of the receptor respectively (Figure 6.3). Following PMA 
treatment, the cells were co-cultured with WT and ΔFlaA C. jejuni MOI 100 for 24h 
(Figure 6.4). Besides IL-10, we analysed the production of TNFα, which is unaffected 
by the flagellum (see Chapter 5), and IL-12 which shares regulatory pathways with and 
is inhibited by IL-10(396). GFP-transduced cells were also used as a control for the 
effects of transduction in cytokine production. We observed an increase in the 
flagellum-mediated enhancement of IL-10 in low (P=0.021) or high (p<0.0001) Siglec-
10 over-expressing cells compared to WT THP-1 cells (P=0.032) (Figure 6.4). The 
effect was flagellum-specific as there was no difference in IL-10 production amongst  
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Figure 6.1. Siglec-10 expression on human MDMs.  
5x105 primary MDMs from four donors were cultured in media with 20ng/ml GM-CSF 
for M1-type or 20ng/ml M-CSF for M2-type differentiation for 5d, followed by 24h in 
fresh media. On day 6, cells were immunostained with a conjugated anti-Siglec-10 
antibody (blue line) or IgG control (red line) and analysed by flow cytometry 
(representative histograms from two individual donors shown). 
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Figure 6.2. Siglec-10 is expressed on monocytic THP-1 and dTHP-1 cells.  
Siglec-10 expression on THP-1 and dTHP-1 cells was assessed before (solid grey line)  
or after (black line) treatment with 10ng/ml PMA for 24h by flow cytometry. IgG1 
isotype staining (dashed line) served as control. Histogram is representative of three 
independent experiments. 
  
R
el
at
iv
e 
ce
ll 
nu
m
be
r 
Siglec-10 
	  	  211 
Figure 6.3. Siglec-10 receptor overexpression in THP-1 cells.  
(A) THP-1 cells were left untransduced (dashed line) or transduced with eGFP MOI 10 
(dotted line), Siglec-10-GFP MOI 1 (solid gray line) or MOI 10 (black line) vectors. After 
72h, GFP-positive cells were quantified by flow-cytometry to assess transduction 
efficiency. (B) Cell populations were sorted by FACS based on GFP expression 
(representative dotplot from Siglec-10-High selection is shown). (C) Siglec-10 
expression was analysed by flow cytometry. Histogram is representative of two 
independent experiments.  
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Figure 6.4. Siglec-10 receptor over-expression promotes IL-10 expression in 
response to C. jejuni flagella.  
Untransduced, eGFP-transduced, Siglec-10-Low or Siglec-10-High dTHP-1 cells were 
co-cultured with WT or ΔFlaA C. jejuni MOI 100. 10ng/ml LPS stimulation was used as 
a control. 24h post-infection, (A) TNFα, (B) IL-10 and (C) IL-12 cytokines were 
analysed in the supernatants by ELISA. Values are means ± SEM from three 
independent experiments analysed in duplicate. Statistical analysis by paired t-test 
(**P<0.01, ***P<0.001). 
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cells co-cultured with ΔFlaA C. jejuni. TNFα and IL-12 levels were not significantly 
different between WT and transduced cells and remained unaltered in the absence of 
C. jejuni flagellum. Overall, our findings suggest that Siglec-10 can mediate flagellum-
specific enhancement of the macrophage IL-10 response to C. jejuni. 
 
6.2.2 Immune receptor activation by C. jejuni 
Based on the interaction of C. jejuni and Siglec-10, we went on to determine potential 
interactions of the pathogen with other members of the Siglec family. Siglec-7, Siglec-9 
and Siglec-10 have been shown to bind C. jejuni serostrain HS:19 (262), although only 
the interaction with Siglec-7 was studied in depth. We used an Immunoreceptor 
Phosphorylation Array kit by R&D to detect phosphorylation of multiple 
immunoreceptors, including Siglecs, in dTHP-1 cells co-cultured with WT C. jejuni 
11168 (Figure 6.5). Our analysis revealed phosphorylation of multiple Siglec receptors 
in the presence of C. jejuni: Siglec-3 (also known as CD33), Siglec-5 and Siglec-9 
(Figure 6.5B). Both Siglec-5 and Siglec-9 are thought to possess immunoinhibitory 
functions (386). Furthermore, their activation has recently been linked to IL-10 
expression in murine macrophages (397). We also detected phosphorylation of SH2 
domain-containing tyrosine phosphatase (SHP-2), a signalling factor recruited by the 
immunoreceptor tyrosine-based inhibitory motif (ITIM) cytoplasmic domains of Siglec 
receptors, which mediates immunosuppressive signalling (251). Two other 
immunoinhibitory receptors became phosphorylated in the presence of WT C. jejuni; 
platelet endothelial cell adhesion molecule (PECAM) (also known as CD31), which is 
known to inhibit pro-inflammatory signalling though recruitment of SHP-2 (398), and 
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Figure 6.5. C. jejuni induces phosphorylation of Siglec-5 and Siglec-9.   
dTHP-1 cells were co-cultured with WT C. jejuni 1168H MOI 100 for 60min. (A) 
Receptor activation was analysed using an Immunoreceptor Phosphorylation Array kit 
by R&D. Image shown is representative of three independent experiments. (B) Pixel 
density analysis of data (60min) shown as values ± SEM. Pixel density values between 
images were normalized using the reference point readings. 
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FcγRIIA, a molecule that can also recruit SHP-2 via its ITIM domain, leading to 
inhibition of phagocytosis (399). Since only low levels of phospho-SHP-2 were 
detected, induction of SHP-2 phosphorylation in response to C. jejuni infection was 
confirmed by flow-cytometry (Figure 6.6). Following 1h co-culture of dTHP-1 cells with 
C. jejuni, increased expression of phosphorylated SHP-2 was observed Our data 
suggests that C. jejuni infection activates Siglec-5 and Siglec-9, as well as the 
inhibitory receptors PECAM and FcγRIIA, followed by recruitment of SHP-2 to mediate 
downstream immunosuppressive functions. 
 
6.2.3 Siglec-5 receptor engagement by C. jejuni 
Naturally, we wanted to decipher the physical interaction that led to the strong 
activation of Siglec-5 and Siglec-9 by C. jejuni. An immunoabsorbance-based 
technique similar to traditional ELISA was used to analyse binding affinity between the 
bacteria and recombinant Siglec proteins. To study SA, a low affinity ligand for Siglecs, 
involvement in Siglec binding the SA-negative NeuB C. jejuni was used. in addition, 
bacteria were treated with sialidase from Arthrobacter ureafaciens which hydrolyses SA 
α2,3-, α,2,6- or α,2,8-linked to Neu5Ac. The capsule-negative kpsm mutant of C. jejuni 
was also used based on the hypothesis that the lack of a capsule would further expose 
SA ligands. Increased binding of Siglec 5 was only observed in the capsule deficient 
mutant compared to all others tested (P=0.032), Moreover, an absence of SA did not 
affect Siglec-5 binding to the pathogen as similar OD readings were observed for the 
SA-negative and WT stain (Figure 6.7). This was further confirmed by no difference 
following sialidase treatment suggesting that this interaction is SA independent. 
Therefore, Siglec-5 appears to recognise C. jejuni motifs concealed by the bacterial 
capsule.  
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Figure 6.6. C. jejuni induces phosphorylation of SHP-2 kinase.  
dTHP-1 cells were co-cultured with WT C. jejuni 1168H MOI 100 for 60min. SHP-2 
phosphorylation in uninfected (grey solid line) and infected (black line) was analysed by 
flow cytometry. IgG isotype staining (dashed line) was used as control. Representative 
histogram from three independent experiments is shown. 
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Figure 6.7. Siglec-5 recognises motifs concealed by the capsule of C. jejuni.  
Untreated or sialidase-treated (S-treated) WT or kpsm, or NeuB C. jejuni strain 11168H 
were coated onto the wells of ELISA plates and direct binding of hSiglec-5-Fc was 
assayed by incubation with 2μg/ml recombinant protein. Bound protein was detected 
using avidin-HRP and analysed in a photometric reader (450nM). Values are means ± 
SEM from at least three independent experiments in duplicate (*P=0.032).
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To explore these interactions further, we over-expressed the Siglec-5 and Siglec-9 
receptors on the human kidney CHO cell line. Transduction at MOI 100 led to ~50% of 
the cells being positive for Siglec-5 (Figure 6.8). Siglec-9 transduction efficiency was 
comparable to Siglec-5 at ~48% (Figure 6.9). Siglec-10 CHO cells were used as a 
positive control since they have been shown to specifically bind C. jejuni (218). When 
co-cultured with FITC-labelled bacteria, Siglec-5 CHO cells had more C. jejuni adhere 
to them, with ~23% FITC positive compared to only ~14% FITC positive of WT CHO 
cells (Figure 6.10). However, it is worth noting that the Siglec-10 CHO cell population is 
uniform as opposed to the Siglec-5 population were only half of them were positive for 
Siglec-5. Therefore we would expect a higher number of FITC-positive cells in both cell 
lines had uniform populations been used. Unfortunately, the plasmids used in 
transductions did not contain any “tag” proteins (e.g GFP) and we were therefore 
unable to sort these cells into pure populations. The specificity of C. jejuni binding to 
Siglec-5 CHO cells was confirmed using a neutralising/blocking (N/B) antibody against 
the receptor. The cells were treated with anti-Siglec-5 N/B antibody prior to co-culture 
with FITC-labelled C. jejuni carried out at 4οC to avoid endocytosis of the receptors. 
Blocking of Siglec-5 led to a decrease in Siglec-5-mediated binding of C. jejuni from 
~23% to ~10% of cells, but had no effect on the binding to Siglec-9 CHO cells (Figure 
6.11). These data further support the specificity of C. jejuni binding to Siglec-5. 
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Figure 6.8. Siglec-5 receptor overexpression in CHO cells.  
CHO cells were transduced with empty and Siglec-5 (MOI 10 and 100) vectors. After 
72h, cells were stained with anti-hSiglec-5 antibody conjugated to FITC anti-human IgG 
(which isotype?) antibody and analysed by flow cytometry. Representative histogram of 
one experiment performed in duplicate is shown.  
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Figure 6.9. Siglec-9 receptor overexpression in CHO cells.  
CHO cells were transduced with empty and Siglec-9 (MOI 10 and 100) vectors. After 
72h, cells were stained with anti-hSiglec-9 antibody conjugated to FITC anti-human IgG 
antibody and analysed by flow cytometry. Representative histogram of one experiment 
performed in duplicate is shown.  
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Figure 6.10. C. jejuni binds specifically to Siglec-5-overexpressing CHO cells.  
WT and Siglec-5-overexpressing CHO cells were mixed with FITC-labelled WT C. 
jejuni strain 11168H MOI 100 at 4°C to prevent internalisation. Siglec-10 CHO cells 
were used as a control for C. jejuni binding. (A) After 2h, FITC-positive cells were 
analysed by flow cytometry (representative histogram shown). (B) Data shown as 
percentage of FITC-positive cells. Values are means ± SEM from three independent 
experiments performed in duplicate. Statistical analysis by paired t-test (*P<0.05).  
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Figure 6.11. Siglec-5 blocking antibody specifically inhibits C. jejuni binding to 
the receptor.  
Siglec-5-overexpressing CHO cells were pre-treated with anti-hSiglec-5 blocking 
antibody for 1h prior to mixing with FITC-labelled WT C. jejuni strain 11168H MOI 100 
at 4°C. Anti-hSiglec-9 blocking antibody served as non-specific control. (A) After 2h, 
FITC-positive cells were analysed by flow cytometry (representative histograms 
shown). (B) Data shown as percentage of FITC-positive cells. Values are means ± 
SEM from three independent experiments performed in duplicate. Statistical analysis 
by paired t-test (P<0.05).  
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Next, the Siglec-5 CHO cell lines were used to confirm our earlier evidence of 
structure-specific recognition of C. jejuni by the two receptors. Again, the capsule 
negative kpsm and SA negative NeuB mutants of C. jejuni were utilised to test for 
capsule and SA-dependent interactions respectively. We observed significantly 
increased binding of the kpsm mutant to Siglec-5 CHO cells (P=0.03), while adherence 
of NeuB C. jejuni was not significantly different to the WT strain (Figure 6.12). This 
finding reinforces previous evidence of capsule-independent binding of C. jejuni to 
Siglec-5 (see Figure 6.7).  
Next, we wanted to delineate the functional aspects of Siglec-5 engagement by C. 
jejuni. Studies have shown that engagement of Siglecs by a pathogen can lead to 
suppression of phagocytosis in human APCs (264),(265). We used dTHP-1 cells to 
investigate the effects of C. jejuni-mediated Siglec engagement on bacterial adherence 
to and internalisation by human macrophages. The cells were pre-treated with N/B 
antibody for Siglec-5 prior to co-culture with C. jejuni strain 11168. Blocking of Siglec-5 
led to a significant decrease in bacterial binding (P=0.0249) (Figure 6.13A), indicating 
the importance of Siglec-5 for the adherence of C. jejuni to dTHP-1 cells; similar to the 
results of our binding assay (see Figure 6.12). Blocking of Siglec-5 also led to a 
significant reduction in kpsm C. jejuni binding (P=0.0309) (Figure 6.13B); suggests the 
interaction is independent of the capsule. Finally, the kpsm mutant exhibited increased 
binding to dTHP-1 cells (~75% FITC-positive cells) compared to WT C. jejuni (~67% 
FITC-positive cells), reflecting the increased affinity of Siglecs for kpsm C. jejuni 
demonstrated in our ELISA experiment (Figure 6.7).  
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Figure 6.12. C. jejuni binding to Siglec-5 is capsule-independent. 
 Siglec-5-overexpressing CHO cells were mixed with FITC-labelled WT, kpsm or NeuB 
C. jejuni strain 11168H MOI 100 at 4°C. After 2h, FITC-positive cells were analysed by 
flow cytometry. Values are means ± SEM from three independent experiments 
performed in duplicate. Statistical analysis by paired t-test (P<0.05). 
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Figure 6.13. Siglec-5 is important for capsule-independent C. jejuni adherence to 
dTHP-1 cells.  
dTHP-1 cells were pre-incubated with 5μg/ml anti-hSiglec-5 N/B antibody for 1h prior to 
co-culture with FITC-labelled (A) WT or (B) kpsm C. jejuni strain 11168H MOI 100 at 
4°C to prevent bacteria internalisation. After 1h, FITC-positive cells were analysed by 
flow cytometry. Values are means ± SEM from three independent experiments 
performed in duplicate. Statistical analysis by paired t-test (*P<0.05).  
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With the primary function of a number of Siglecs being the recognition of ‘self’ (253), we 
hypothesised that engagement of Siglec-5 by the cell’s own sialylated ligands may 
disrupt the engagement of the receptor to C. jejuni. Therefore, dTHP-1 cells were 
treated with sialidase from Clostridium perfingens which preferentially cleaves α2,3-
linked SAs from Neu5Ac in order to disengage glycan receptors bound to SA. 
Subsequently, cells were incubated with N/B antibody against Siglec-5 prior to co-
culture with WT C. jejuni strain 11168. As Figure 6.14 shows, blocking of Siglec-5 led 
to a more significant reduction in C. jejuni adherence to sialidase-treated (P=0.008) 
compared to untreated (P=0.025) dTHP-1 cells.  
To further explore the dynamics of this interaction, C. jejuni and dTHP-1 cells were co-
cultured at room temperature where the phagocytic as well as signalling processes are 
active. Here, blocking of Siglec-5 led to a statistically significant reduction in the total 
number of bacteria associated with dTHP-1 cells (P=0.003) (Figure 6.15A). A similar 
reduction was observed using kpsm C. jejuni (P=0.006), mirroring our earlier 
observation of a capsule-independent interaction between bacteria and cells (see 
Figure 6.13). On the other hand, numbers of intracellular bacteria, for both WT and 
kpsm mutant C. jejuni, were unaffected by blocking of the receptor (Figure 6.15B), 
although a small, but not significant, reduction was recorded. Therefore, interaction 
with Siglec-5 appears to be more important in C. jejuni adherence to rather than 
internalisation by macrophages. 
 
6.2.4 Siglec-9 receptor engagement by C. jejuni 
A similar experimental approach to the one detailed above (see Paragraph 6.4) was 
used to identify potential interactions between C. jejuni and Siglec-9. Employing the  
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Figure 6.14. Sialidase treatment affects Siglec-5-mediated C. jejuni adherence in 
dTHP-1 cells.  
Untreated or sialidase-treated dTHP-1 cells were pre-incubated with 5μg/ml anti-
hSiglec-5 N/B for 1h prior to co-culture with FITC-labelled WT C. jejuni strain 11168H 
MOI 100 at 4°C to prevent bacteria internalisation. After 1h, the presence of bacteria on 
cells was analysed by flow cytometry. Values are means ± SEM from three 
independent experiments performed in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<0.01).  
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Figure 6.15. Engagement of Siglec-5 alters the interaction of C. jejuni with dTHP-
1 cells. 
 dTHP-1 cells were pre-incubated with 5μg/ml anti-hSiglec-5 N/B antibody for 1h prior 
to co-culture with FITC-labelled  WT or kpsm C. jejuni strain 11168H MOI 100 at 4°C to 
prevent bacteria internalisation. After 1h, (A) total and (B) intracellular bacterial 
presence was analysed by flow cytometry. Values are means ± SEM from three 
independent experiments performed in duplicate. Statistical analysis by paired t-test 
(**P<0.01).  
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ELISA assay discussed in Figure 6.7, we were able to demonstrate binding of 
recombinant Siglec-9 to C. jejuni strain 11168. Binding was SA-dependent as there 
was a statistically significant reduction in Siglec-9 binding in the absence of SA; either 
following sialidase treatment (P=0.012) or against the NeuB mutant (P=0.011) (Figure 
6.16). Similar to Siglec-5, lack of a capsule led to a statistically significant increase in 
Siglec-9 binding (P=0.044), although this interaction was SA-mediated as it was 
sialidase-sensitive. Therefore, Siglec-9 appears to recognise SA structures on the 
pathogen. 
In binding assays using transduced CHO cells, Siglec-9 CHO cells had more C. jejuni 
adhere to them, with ~36% FITC-positive cells compared to only ~14% of WT CHO 
cells (Figure 6.17); a nearly three-fold increase. Although binding appears to be equal 
between Siglec-9 and Siglec-10 CHO cells, with ~36% and ~34% FITC positive 
respectively, only the Siglec-10 CHO cell population is uniform as discussed earlier. 
The specificity of C. jejuni binding to Siglec-9 overexpressing CHO cells was confirmed 
using blocking antibodies against the receptors. Blocking of Siglec-9 reduced C. jejuni 
binding to Siglec-9 CHO cells, from ~36% to ~14% without altering adherence to 
Siglec-5 CHO cells (Figure 6.18). In Siglec-9 CHO cells, lack of SA led to a significant 
reduction in bacterial binding (P=0.0148) (Figure 6.19); confirming that the interaction 
between the receptor and C. jejuni is SA-dependent. Binding was unaffected by the 
lack of a capsule, although we would expect an increase based on our ELISA data (see 
Figure 6.16). A likely explanation for this discrepancy is that bacterial binding becomes 
saturated by WT C. jejuni and therefore our analysis does not reflect increased affinity 
for the kpsm mutant. We confirmed that SA is the C. jejuni ligand recognised by Siglec-
9 though a competitive binding assay using  
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Figure 6.16. Siglec-9 recognises sialic acid structures on C. jejuni.  
Untreated or sialidase-treated (S-treated) WT or kpsm, or NeuB C. jejuni strain 11168H 
were coated onto the wells of ELISA plates and direct binding of hSiglec-9-Fc was 
assayed by incubation with 2μg/ml recombinant protein. Bound protein was detected 
using avidin-HRP and analysed in a photometric reader (450nM). Values are means ± 
SEM from at least three independent experiments performed in duplicate. Statistical 
analysis by paired t-test (*P<0.05). 
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Figure 6.17. C. jejuni binds specifically to Siglec-9-overexpressing CHO cells. 
 WT and Siglec-9-overexpressing CHO cells were mixed with FITC-labelled WT C. 
jejuni strain 11168H MOI 100 at 4°C to prevent internalisation. Siglec-10 CHO cells 
were used as a control for C. jejuni binding. (A) After 2h, FITC-positive cells were 
analysed by flow cytometry (representative histogram shown). (B) Data shown as 
percentage of FITC-positive cells. Values are means ± SEM from three independent 
experiments performed in duplicate. Statistical analysis by paired t-test (*P<0.05).  
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Figure 6.18. Siglec-9 blocking antibody specifically inhibits C. jejuni binding to 
the receptor.  
Siglec-9-overexpressing CHO cells were pre-treated with anti-hSiglec-9 blocking 
antibody for 1h prior to mixing with FITC-labelled WT C. jejuni strain 11168H MOI 100 
at 4°C. Anti-hSiglec-5 blocking antibody served as non-specific control. (A) After 2h, 
FITC-positive cells were analysed by flow cytometry (representative histograms 
shown). (B) Data shown as percentage of FITC-positive cells. Values are means ± 
SEM from three independent experiments performed in duplicate. Statistical analysis 
by paired t-test (**P<0.01). 
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Figure 6.19. C. jejuni binding to Siglec-9 is sialic-acid-dependent.  
Siglec-9-overexpressing CHO cells were mixed with FITC-labelled WT, kpsm or NeuB 
C. jejuni strain 11168H MOI 100 at 4°C. After 2h, FITC-positive cells were analysed by 
flow cytometry. Values are means ± SEM from three independent experiments 
performed in duplicate. Statistical analysis by paired t-test (*P<0.05). 
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isolated LOS of C. jejuni. Since C. jejuni 11168 LOS is monosialylated it should ligate 
to Siglec-9 and compete with C. jejuni for binding to CHO cells. Indeed, pre-treatment 
of Siglec-9 CHO cells with 0.1μg/ml LOS led to a significant reduction in C. jejuni 
binding (P=0.0148), nearly 50% less compared to untreated cells (Figure 6.20). We 
therefore conclude that Siglec-9 binds to the SA structures on C. jejuni LOS. 
Whereas Siglec-9 was involved in C. jejuni adherence to CHO cells (Figure 6.19), it 
played no role in binding to macrophages, since pre-treatment of dTHP-1 cells with N/B 
antibody for Siglec-9 prior to co-culture with WT or kpsm C. jejuni strain 11168 had no 
significant effect (Figure 6.21). Nevertheless, in sialidase-treated cells, Siglec-9 
appears to play a part in the pathogen’s interaction with dTHP-1 cells, as a significant 
reduction in bacterial binding (P=0.02) was observed following Siglec-9 blocking 
(Figure 6.22). Overall, in contrast to untreated dTHP-1 cells, both Siglec receptors were 
important for C. jejuni adherence to sialidase treated cells. When the experiment was 
carried out at room temperature, Siglec-9 blocking led to a significant reduction in the 
number of total bacteria, either WT (P=0.031) or kpsm (0.012) C. jejuni, associated with 
dTHP-1 cells (Figure 6.23). Similar to the blocking of Siglec-5, there was not effect on 
the number of internalised bacteria. This may come as a surprise given that Siglec-5 
and Siglec-9 act to inhibit phagocytosis and we could, therefore, expect an increase in 
the number of internalised bacteria after blocking these receptors. However, at this 
stage, it is not known how these blocking antibodies may affect the functions of these 
receptors. 
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Figure 6.20. C. jejuni binding to Siglec-9 is LOS-dependent.  
Siglec-9-overexpressing CHO cells were left untreated or treated with 100ng/ml LOS 
from C. jejuni strain 11168H at 4°C to prevent ligand internalisation. After 1h, cells were 
mixed with FITC-labelled C. jejuni strain 11168H MOI 100 at 4°C for 1h and FITC-
positive cells analysed by flow cytometry. Values are means ± SEM from three 
independent experiments performed in duplicate. Statistical analysis by paired t-test 
(*P<0.05). 
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Figure 6.21. Siglec-9 is not involved in C. jejuni adherence to dTHP-1 cells.  
dTHP-1 cells were pre-incubated with 5μg/ml anti-hSiglec-5 N/B or anti-hSiglec-9 N/B 
antibody for 1h prior to co-culture with FITC-labelled (A) WT or (B) kpsm C. jejuni strain 
11168H MOI 100 at 4°C to prevent bacteria internalisation. After 1h, FITC-positive cells 
were analysed by flow cytometry. Values are means ± SEM from three independent 
experiments performed in duplicate. Statistical analysis by paired t-test (*P<0.05).  
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Figure 6.22. Sialidase treatment affects Siglec-9-mediated C. jejuni adherence in 
dTHP-1 cells.  
Untreated or sialidase-treated dTHP-1 cells were pre-incubated with 5μg/ml anti-
hSiglec-5 N/B for 1h prior to co-culture with FITC-labelled WT C. jejuni strain 11168H 
MOI 100 at 4°C to prevent bacteria internalisation. After 1h, the presence of bacteria on 
cells was analysed by flow cytometry. Values are means ± SEM from three 
independent experiments performed in duplicate. Statistical analysis by paired t-test 
(*P<0.05, **P<0.01).  
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Figure 6.23. Engagement of Siglec-9 alters the interaction of C. jejuni with dTHP-
1 cells. 
 dTHP-1 cells were pre-incubated with 5μg/ml anti-hSiglec-9 N/B antibody for 1h prior 
to co-culture with FITC-labelled  WT or kpsm C. jejuni strain 11168H MOI 100. After 1h, 
(A) total and (B) intracellular bacterial presence was analysed by flow cytometry. 
Values are means ± SEM from three independent experiments performed in duplicate. 
Statistical analysis by paired t-test (*P<0.05).  
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6.6 Discussion 
Although we initially set out to characterise the role of Siglec-10 in the cytokine 
response to C. jejuni strain 11168, our study revealed the involvement of multiple other 
Siglec receptors in sensing the pathogen. C. jejuni strain 11168 triggered the 
phosphorylation of Siglec-3, Siglec-5 and Siglec-9 in dTHP-1 macrophage-like cells 
(Figure 6.5). Crocker and colleagues first demonstrated engagement of Siglec 
receptors by C. jejuni - predominantly Siglec-7 - although weak binding by Siglec-5, 
Siglec-9 and Siglec-10 was also detected (262). Siglecs are considered as 
immunomodulatory receptors thought to be important in distinguishing “danger-
associated” versus “pathogen-associated” signals (261). The capacity of pathogens to 
sialylate their surface and engage Siglecs offers them an evolutionary advantage by 
dampening the immune response. This is the first report of Siglec-3 activation by C. 
jejuni, although that was weak compared to Siglec-5 and Siglec-9 and was not 
investigated further. Group B streptococcus (GBS) and Pseudomonas aeruginosa are 
known to engage Siglec-9 on neutrophils and reduce their oxidative burst and 
extracellular trap formation (265),(400). GBS also binds to Siglec-5 leading to 
suppression of phagocytosis in human leukocytes and neutrophils (264). Furthermore, 
both receptors have been linked to the production of the anti-inflammatory cytokine IL-
10. Siglec-9 and Siglec-5 overexpression in the macrophage cell-lines RAW264 and 
THP-1, followed by TLR stimulation led to an increase in IL-10 production with a 
parallel decrease in TNFα (401). Siglec-9-mediated stimulation of IL-10 is mediated by 
tyrosine-based motifs (401) and is partly due to an increase in intracellular C/EPβ 
levels (397). Activation of Siglec-5 and Siglec-9 may account for the strong induction of 
IL-10 by C. jejuni compared to other enteropathogens (218). 
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The other ITIM-containing Siglec receptors did not become phosphorylated. Previous 
studies have demonstrated Siglec-7 preference for disialylated a2,3/2,8 motifs 
(262),(393), therefore we did not expect C. jejuni 11168 to activate the receptor. 
Surprisingly, neither Siglec-10 or its associated SHP-1 phosphatase (402) were 
phosphorylated despite evidence of C. jejuni binding to Siglec-10 (262),(218). 
However, Siglec-10 ligation may lead to activation of alternative domains as discussed 
below. 
GBS engagement of ITIM-bearing Siglec-5 or Siglec-9 activates inhibitory SHP2-
dependent signals that interfere with cellular activation. In cells co-cultured with C. 
jejuni we detected phosphorylation of SHP-2 but not SHP-1 (Figure 6.5 and Figure 6.6). 
SHP-2 has a dual role in immune cell regulation. While SHP-2 recruited by ITIM-
bearing receptors can inhibit immune cell activation (403),(404), it is also a positive 
regulator of cytokine and growth factor receptor signalling, mediating Ras/MAPK and 
ERK activation (405). ITIMs differ in their affinity for SHP-1 and SHP-2, and specific 
recruitment may contribute to inhibitory capacity. Helicobacter pylori, a pathogen 
closely related to C. jejuni, also activates SHP-2 by injecting cytotoxin-associated 
antigen A (cagA) protein into host cells to suppress INF-γ signalling (406),(407). Others 
have demonstrated the capacity of H. pylori to induce crosstalk between TLRs and the 
C-type lectin DC-SIGN that leads to high levels of IL-10 production by DCs (270). 
Intriguingly, SHP-2 is an oncoprotein and CagA-mediated deregulation of SHP-2 is 
associated with severe gastritis and gastric carcinoma (408). It is compelling to 
hypothesise that activation of immunosuppressive mediators such as SHP-2 by certain 
pathogens can lead to a persistent imbalance in host cell signalling that may lead to 
pathogenesis. 
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Two more immunosuppressive factors became phosphorylated; PECAM-1 and 
FcγRIIA. PECAM-1 is a negative regulator of TLR4 signalling, suppressing the TNFα 
and IL-6 response to LPS (409). Phosphorylated FcγRIIA is able to recruit SHP-1 and 
SHP-2 (399) and, like Siglec-5, can inhibit Fc receptor-mediated phagocytosis (410). 
This is the first report of C. jejuni-mediated activation of these factors and further work 
is required to decipher their contribution in the macrophage response to the pathogen. 
We went on to identify the C. jejuni structures involved in Siglec-5 and Siglec-9 
engagement. By over-expressing each receptor (Figure 6.8 and Figure 6.9), we 
detected increased binding of WT C. jejuni to Siglec-5 (Figure 6.10) and Siglec-9 
(Figure 6.17) over-expressing CHO cells. Binding to Siglec-9 was more prominent 
compared to Siglec-5, similar to findings in other C. jejuni strains (262), although we 
aim to repeat these studies in uniform cell populations in the future. Critically, using 
neutralising/blocking antibodies to block the receptor’s binding site we were able to 
demonstrate Siglec-5 and Siglec-9-specific binding to C. jejuni 11168 (Figure 6.10 and 
Figure 6.18).  
Studies on GBS have reported Siglec receptor binding to sialylated capsular and LOS 
structures on pathogens (258),(265). We found increased interaction of Siglec-5-Fc 
chimera to the acapsular kpsm mutant compared to WT C. jejuni (Figure 6.7). 
Importantly, the binding affinity was unaffected by the removal of SA or use of the SA-
negative NeuB mutant, indicating that Siglec-5 interaction with C. jejuni is independent 
of SA moieties. Accordingly, we observed increased binding of kpsm C. jejuni to Siglec-
5 (Figure 6.12) but not Siglec-9 overexpressing cells (Figure 6.19), leading us to 
hypothesise that Siglec-5 ligands are concealed by the bacterial capsule. Recent 
studies suggest that in addition to SA, Siglecs can also ligate to non-sialylated ligands. 
For example, Siglec-5 recognizes Group B Streptococcus β-protein (265), and Siglec-
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10 can interact with vascular adhesion protein-1 (259). It would be interesting to identify 
the Siglec-5 ligand(s) by utilising various C. jejuni mutants in similar binding assays. 
On the other hand, C. jejuni engagement to Silgec-9 was SA-dependent, as lack of SA 
led to a reduction in Siglec-9-Fc chimera binding (Figure 6.16). Furthermore, we 
observed decreased binding of the SA-negative NeuB C. jejuni to Siglec-9 over-
expressing CHO cells compared to the WT strain (Figure 6.19), indicating that 
sialylated LOS may act as a ligand for the receptor. This was confirmed by showing 
that C. jejuni LOS competes with the pathogen for Siglec-9 binding (Figure 6.20). This 
first report of Siglec-9 binding to GM1 or GM2-like epitopes is intriguing and may help 
explain why although Siglec-9 exhibits binding preference for GD1a-like motifs (411), it 
cannot recognise GD1a LOS (262). Sn is the only other Siglec reported to bind GM1α-
like structures on C. jejuni (263),(394). Siglec-9 binds to the capsular polysaccharide of 
GBS which also presents terminal sialylated α2,3-Galβ1-4GlcNAc units (265). The 
weak affinity for C. jejuni can likely be attributed to the presence of less accessible 
“internal”, rather than terminal, SA residues in GM1- and GM2-like epitopes (394). 
Using purified C. jejuni LOS treated with sialidase enzymes of different affinities in 
competitive binding assays as the above (see Figure 6.20) should reveal the SA 
recognised by Siglec-9. Similar to Siglec-5, we observed an increase in Siglec-9 
binding to kpsm C. jejuni (Figure 6.16); likely a result of sialylated ligands located 
beneath the capsule. Others have reported on the negative effect of the capsule on the 
interaction of C. jejuni with host cell receptors (412) and in our hands it interfered with 
bacterial ligation to both Siglec-5 and Siglec-9.  
We also looked at the role of these two receptors in the interaction of C. jejuni with a 
model of human macrophages. Although expression of Siglecs has not been reported 
in macrophages (256), high levels of phosphorylated Siglec-5 and Siglec-9 were 
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detected in dTHP-1 cells(Figure 6.5). Siglec receptor expression in this cell line 
requires further study. Alternatively, neutrophils may offer a more relevant model for the 
study of C. jejuni – Siglec interactions as they are known to express both receptors 
(413),(414). Furthermore, bacteria such as Group B Streptococcus, E. coli and P. 
aeruginosa and are thought to interact with Siglec-5 and Siglec-9 on neutrophils to 
inhibit phagocytosis (415),(400),(416). 
Surprisingly, only Siglec-5 ligation appeared to be important for C. jejuni adherence to 
dTHP-1 cells (Figure 6.13 and Figure 6.21), despite the affinity exhibited by Siglec-9 in 
our ELISA experiment (Figure 6.16). Studies have demonstrated that Siglec receptors 
engage in cis interactions with endogenous ligands and as a result binding may be 
blocked or “masked” (134),(417). Treatment with sialidase led to an increase in both 
Siglec-5 and Siglec-9-mediated adherence of C. jejuni (Figure 6.14 and Figure 6.22) 
and therefore, we consider both to be important in the pathogen’s interaction with 
macrophages. It would be worth undertaking these experiments again using different 
blocking antibodies or even silencing of Siglec genes by RNA interference. 
Bacterial sialylation is thought to affect phagocytosis of microorganisms, such as GBS 
(264) and C. jejuni; with sialylated C. jejuni being phagocytosed more efficiently in vitro 
by bone-marrow macrophages (389). Furthermore, CD33-related Siglecs are thought to 
be involved in the uptake and processing of soluble and particulate ligands (418) and in 
Siglec-9, the endocytotic function was shown to be ITIM-dependent (419). Whereas the 
number of total bacteria present in dTHP-1 cells was reduced, we did not detect a 
difference in the number of intracellular pathogens (Figure 6.15 and Figure 6.23). This 
was somewhat unexpected since others have reported Siglec-5- and Siglec-9-mediated 
suppression of phagocytosis in leukocytes infected with GBS (264),(415). However, it 
may be worth noting that the immunosuppressive effects of Siglec-9 are mediated by 
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SHP-1, not SHP-2 (415). Since only the later became activated (Figure 6.5), it is 
possible that Siglec-9 engagement did not induce any endocytotic functions. On the 
other hand Siglec-5 ITIM phosphorylation is independent of inhibitory signalling (254).  
It is worth noting that binding of C. jejuni 11168 to Sn would have an opposing effect on 
phagocytosis as Sn activation enhances the phagocytosis of C. jejuni in macrophages 
(394),(395). Furthermore, human Siglecs are expressed in pairs of two, where 
receptors share nearly identical extracellular ligand-binding regions, yet have divergent 
trans-membrane and cytoplasmic regions. The inhibitory ITIM-containing Siglec-5 is 
paired with the activating ITAM-containing Siglec-14 (420) to counter pathogen 
exploitation of inhibitory signalling by providing the host with additional activatory 
pathways as research on GBS has recently shown (416). It is currently unknown 
whether C. jejuni 11168 can activate Siglec-14 and potentially modulate host immune 
response through this interaction. These reports outline the complex signalling 
properties of Siglec activation and further studies are required to decipher the interplay 
of downstream mediators triggered by C. jejuni infection. 
Prior work from Dr Holly Stephenson had demonstrated the capacity of C. jejuni 11168 
to bind another Siglec receptor; Siglec-10 (218). Using CHO cells overexpressing the 
Siglec-10 receptor, the study demonstrated a significant increase in binding of WT C. 
jejuni to Siglec-10 expressing CHO cells. Importantly, this increase was not noted in 
response to the ∆flaA or the Pse-negative ∆Cj1316 isogenic mutant strains, indicating 
that binding is mediated by Pse structures on the flagellum surface (218). As detailed in 
Chapter 5, Pse structures on the flagellum were able to modulate the IL-10 response of 
dTHP-1 cells to C. jejuni 11168. Here, we have identified a link between the 
engagement of Siglec-10 and the enhancement of IL-10 production by the flagellum. 
Firstly, we established the presence of Siglec-10 in human M1- and M2-macrophages 
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(Figure 6.1) and observed up-regulation of Siglec-10 expression following 
differentiation of THP-1 cells (Figure 6.2), similar to reports that Siglec-9 becomes up-
regulated during the development of monocytes into immature DCs (421). Critically, 
over-expression of the receptor in THP-1 cells led to an increase in flagellum-mediated 
enhancement of IL-10 (Figure 6.4). It is important to note that C. jejuni-mediated IL-10 
induction is predominantly TLR/MyD88-dependent (218) and Siglec-10 engagement 
modulates this TLR-signalling to enhance the production of IL-10. While this is the first 
report of Siglec-10 mediated modulation of IL-10, both Siglec-5 and Siglec-9 have been 
linked to host IL-10 immunity as discussed earlier. In a similar approach, receptor over-
expression in THP-1 cells led to 2.5 - 4 times higher IL-10 production upon stimulation 
with LPS or PGN (401). 
As mentioned above, we did not detect phosphorylation of the Siglec-10 ITIM domain in 
dTHP-1 cells co-cultured with C. jejuni (Figure 6.5). However, ITIM activation would 
lead to modulation of pro-inflammatory signalling (260), which is unaffected by the 
flagellum (see Chapter 5). Despite ITIMs being the best characterised intracellular 
signalling Siglec domains, Siglec-10 also contains a putative growth factor receptor 
binding protein-2 (Grb2) binding motif (422). Grb2-mediated signalling is known to alter 
p38 signalling (423), one of the main pathways involved in C. jejuni-mediated IL-10 
production (see Chapter 5). Future studies must identify how Siglec-10 engagement 
may modulate activation of p38. Sotomayer and colleagues have previously reported 
that the flagellin moiety of Salmonella typhmurium is a negative regulator of LPS-
mediated IL-10 expression; and this cellular process is TLR5-dependent (345). Our 
findings highlight an opposing paradigm whereby the flagellum of C. jejuni engages 
with the host in a TLR5-independent, Siglec-10-mediated manner leading to positive 
regulation of IL-10. In conjunction with the evidence of Siglec-5 and Siglec-9 activation, 
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our work has identified C. jejuni as a pathogen “geared” towards induction of anti-
inflammatory signaling. 
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Chapter 7 
Discussion
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There is a host of evidence to suggest commensal, nonpathogenic and pathogenic 
microorganisms have evolved mechanisms to modulate host immunity. Commensals 
generally lack the virulence factors found in pathogenic species and therefore do not 
trigger an inflammatory response (4). Bacterial pathogens, particularly those invading 
tissues after mucosal colonization, disrupt the intestinal balance and cause overt 
inflammation involving massive activation of humoral and cellular immune effectors. 
Naturally, bacterial pathogens have evolved sophisticated mechanisms to suppress 
inflammation in order to gain advantage and enhance their chances of survival (12). 
While disruption of tolerance by these organisms has been extensively studied, little is 
currently known about how they evade or subvert the immune response (7). Some of 
the most common strategies shared by many pathogens is modulation of their surface 
and antigenic hypervariability in order to avoid recognition or activate inhibitory 
receptors in immune cells. 
In this work we have identified the role of microbial motifs from the two most 
predominant gastrointestinal pathogens in the evasion on host immunity. We 
hypothesised that the structural components of C. difficile and C. jejuni facilitate 
immune evasion by engaging inhibitory receptors on innate immune cells. Firstly, we 
showed that PGN from C. difficile activates the tolerogenic receptors NOD1 and NOD2, 
without triggering activation of the inflammasome. PGN was also able to modulate TLR 
signaling in response to other MAMPs, altering the cytokine response of human 
monocytes. Furthermore, while the acute cytokine response to LPS was enhanced in 
the presence of PGN, chronic stimulation with PGN was able to alter the fate of MDMs 
and diminish their response to LPS stimulation. Naïve immune cells exposed to PGN 
adopted a more tolerogenic profile during maturation as evidenced by the expression of 
surface molecules and secretion of cytokines. Given the prevalence of Clostridiales in 
the gut, we can expect PGN fragments released in the environment to inform the 
development of APCs. A recent study showed in vivo immunomodulation by NOD1 
ligands could affect neutrophil function in mice by priming the innate immune system 
(311). More in vivo experiments are needed to verify the physiological relevance of 
these findings as the majority of current evidence are drawn from in vitro studies. 
Finally, it was interesting to observe the difference in TLR activation by and cytokine 
response to PGN polymers from C. difficile and S. aureus, suggesting the bacteria may 
have adapted their surface antigens to suit their colonisation strategy.  
We then concentrated on C. jejuni, which has evolved mutations in its flagellum such 
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that it no longer interacts with TLR5 (217). Instead, C. jejuni flagella activate the 
immunoinhibitory Siglec-10 receptor to induce production of IL-10 (203). We studied 
the mechanism by which selective enhancement takes place and showed that flagella 
can specifically activate signaling mediators that control IL-10 expression. Although, 
the anti-inflammatory properties of IL-10, including its ability to prevent C. jejuni-
mediated colitis, have been described elsewhere (382), we have demonstrated that C. 
jejuni has evolved surface motifs that will engage receptors linked IL-10 induction. It will 
be interesting to study whether other proteobacteria have evolved to exploit similar 
cellular mechanisms.  
Interestingly, we were able to demonstrate the novel interaction of C. jejuni with two 
further Siglec receptors; Siglec-5 and Siglec-9. Both have been involved in the 
inhibition of phagocytosis, dampening of TLR signaling and blocking of pro-
inflammatory cytokine secretion. The interaction of C. jejuni to Siglec-9 was dependent 
on the Neu5Ac SA of LOS, which exhibits molecular mimicry to host gangliosides 
(196). Neu5Ac is the predominant SA found on mammalian cells and many human 
pathogens, including C. jejuni, coat their surface with it.  Presumably, mimicry of host 
glycans is a potential immune evasion strategy, as immune cells with specificities for 
these glycans will be deleted leading to increased peripheral tolerance. A similar 
mechanism of bacterial immune evasion was reported for GBS, which can impair 
neutrophil defense functions by coopting a host inhibitory receptor via sialoglycan 
molecular mimicry (264). The functional outcome of C. jejuni engagement with the two 
receptors has yet to be determined. 
Furthermore, it is thought that epitopes shared by bacteria and host tissues may 
contribute to autoimmunity, such as the development of Guillain-Barré syndrome by 
patients with campylobacteriosis. Therefore, the study of these interactions may not 
only contribute to the fight of acute infections but also chronic diseases. Overall, we 
have presented evidence that pathogenic bacteria have evolved surface motifs which 
can engage immunoinhibitory receptors in order to dampen inflammation. This 
suggests that survival, and not just pathogenesis, has been an important part in the 
evolution of the most successful pathogens. The study of immune manipulation by 
bacteria is an emerging field that offers a promising new interface in microbiology and 
immunology. 
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